



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

09 August 2021  
EMA/CHMP/442451/2021  
Human Medicines Division

## Committee for medicinal products for human use (CHMP)

Minutes for the meeting 21-24 June 2021

Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

### Disclaimers

Some of the information contained in this set of minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the [CHMP meeting highlights](#) once the procedures are finalised and start of referrals will also be available.

Of note, the minutes is a working document primarily designed for CHMP members and the work the Committee undertakes.

### Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



## Table of contents

<b>1.</b>	<b>Introduction</b>	<b>8</b>
1.1.	Welcome and declarations of interest of members, alternates and experts.....	8
1.2.	Adoption of agenda .....	8
1.3.	Adoption of the minutes .....	8
<b>2.</b>	<b>Oral Explanations</b>	<b>9</b>
2.1.	Pre-authorisation procedure oral explanations.....	9
2.1.1.	zanubrutinib - Orphan - EMEA/H/C/004978 .....	9
2.1.2.	istradefylline - EMEA/H/C/005308 .....	9
2.1.3.	Voxzogo - vosoritide - Orphan - EMEA/H/C/005475 .....	9
2.2.	Re-examination procedure oral explanations .....	9
2.3.	Post-authorisation procedure oral explanations .....	10
2.3.1.	Tecentriq - atezolizumab - EMEA/H/C/004143/II/0052 .....	10
2.4.	Referral procedure oral explanations .....	10
<b>3.</b>	<b>Initial applications</b>	<b>10</b>
3.1.	Initial applications; Opinions .....	10
3.1.1.	Abecma - idecabtagene vicleucel - Orphan - ATMP - EMEA/H/C/004662 .....	10
3.1.2.	Abiraterone Mylan - abiraterone acetate - EMEA/H/C/005368.....	11
3.1.3.	Bimzelx - bimekizumab - EMEA/H/C/005316.....	11
3.1.4.	Byooviz - ranibizumab - EMEA/H/C/005545 .....	12
3.1.5.	Evrenzo - roxadustat - EMEA/H/C/004871 .....	12
3.1.6.	Fingolimod Mylan - fingolimod - EMEA/H/C/005661 .....	13
3.1.7.	Flynpovi - eflornithine / sulindac - Orphan - EMEA/H/C/005043 .....	13
3.1.8.	Minjuvi - tafasitamab - Orphan - EMEA/H/C/005436 .....	13
3.1.9.	Voxzogo - vosoritide - Orphan - EMEA/H/C/005475 .....	14
3.2.	Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) .....	15
3.2.1.	zanubrutinib - Orphan - EMEA/H/C/004978 .....	15
3.2.2.	abrocitinib - EMEA/H/C/005452 .....	15
3.2.3.	artesanate - Orphan - EMEA/H/C/005550.....	15
3.2.4.	pralsetinib - EMEA/H/C/005413 .....	16
3.2.5.	lonapegsomatropin - Orphan - EMEA/H/C/005367 .....	16
3.2.6.	imatinib - EMEA/H/C/005595.....	16
3.2.7.	sodium thiosulfate - PUMA - EMEA/H/C/005130 .....	17
3.2.8.	pegcetacoplan - Orphan - EMEA/H/C/005553.....	17
3.2.9.	ripretinib - Orphan - EMEA/H/C/005614 .....	17
3.2.10.	glucarpidase - Orphan - EMEA/H/C/005467 .....	17

<b>3.3.</b>	<b>Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable) .....</b>	<b>18</b>
3.3.1.	dengue tetravalent vaccine (live, attenuated) - Article 58 - EMEA/H/W/005362 .....	18
3.3.2.	ertapenem - EMEA/H/C/005815 .....	18
3.3.3.	gefapixant - EMEA/H/C/005476 .....	18
3.3.4.	gefapixant - EMEA/H/C/005884 .....	18
3.3.5.	somatrogon - Orphan - EMEA/H/C/005633 .....	19
3.3.6.	enfortumab vedotin - EMEA/H/C/005392 .....	19
3.3.7.	dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/005155 .....	19
3.3.8.	eptacog beta (activated) - EMEA/H/C/005655 .....	19
3.3.9.	sacituzumab govitecan - EMEA/H/C/005182 .....	20
3.3.10.	rimegepant - EMEA/H/C/005725 .....	20
3.3.11.	retifanlimab - Orphan - EMEA/H/C/005632 .....	20
<b>3.4.</b>	<b>Update on on-going initial applications for Centralised procedure.....</b>	<b>20</b>
3.4.1.	lisocabtagene maraleucel / lisocabtagene maraleucel - Orphan - ATMP - EMEA/H/C/00473120 .....	
3.4.2.	dabigatran etexilate - EMEA/H/C/005639 .....	21
3.4.3.	adrenaline - EMEA/H/C/005584 .....	21
3.4.4.	pegfilgrastim - EMEA/H/C/004780 .....	21
<b>3.5.</b>	<b>Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004 .....</b>	<b>21</b>
<b>3.6.</b>	<b>Initial applications in the decision-making phase.....</b>	<b>22</b>
3.6.1.	Lextemy - bevacizumab - EMEA/H/C/005611 .....	22
<b>3.7.</b>	<b>Withdrawals of initial marketing authorisation application .....</b>	<b>22</b>
<b>4.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 .....</b>	<b>22</b>
<b>4.1.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion .....</b>	<b>22</b>
4.1.1.	Rinvoq - upadacitinib - EMEA/H/C/004760/X/0006/G .....	22
4.1.2.	Xeljanz - tofacitinib - EMEA/H/C/004214/X/0024/G .....	23
<b>4.2.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues .....</b>	<b>23</b>
4.2.1.	Akynzeo - fosnetupitant / netupitant / palonosetron - EMEA/H/C/003728/X/0031 .....	23
4.2.2.	Feriprox - deferiprone - EMEA/H/C/000236/X/0145 .....	24
<b>4.3.</b>	<b>Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question .....</b>	<b>24</b>
4.3.1.	Ayvakyt - avapritinib - Orphan - EMEA/H/C/005208/X/0004/G .....	24
4.3.2.	Nuwiq - simoctocog alfa - EMEA/H/C/002813/X/0042 .....	24
<b>4.4.</b>	<b>Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 .....</b>	<b>25</b>
<b>4.5.</b>	<b>Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 .....</b>	<b>25</b>

## 5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008 25

<b>5.1.</b>	<b>Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information.....</b>	<b>25</b>
5.1.1.	Brilique - ticagrelor - EMEA/H/C/001241/II/0049.....	25
5.1.2.	Briviact - brivaracetam - EMEA/H/C/003898/II/0032/G .....	26
5.1.3.	Comirnaty - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0030 .....	26
5.1.4.	Galafold - migalastat - Orphan - EMEA/H/C/004059/II/0029 .....	27
5.1.5.	Jakavi - ruxolitinib - EMEA/H/C/002464/II/0053.....	27
5.1.6.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0099 .....	27
5.1.7.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0104 .....	28
5.1.8.	Keytruda - pembrolizumab - EMEA/H/C/003820/II/0105 .....	28
5.1.9.	Kispilix - lenvatinib - EMEA/H/C/004224/II/0045.....	28
5.1.10.	Lenvima - lenvatinib - EMEA/H/C/003727/II/0042 .....	29
5.1.11.	Nucala - mepolizumab - EMEA/H/C/003860/II/0035 .....	29
5.1.12.	Nucala - mepolizumab - EMEA/H/C/003860/II/0036/G .....	30
5.1.13.	Nucala - mepolizumab - EMEA/H/C/003860/II/0037 .....	30
5.1.14.	Opdivo - nivolumab - EMEA/H/C/003985/II/0095 .....	30
5.1.15.	Opdivo - nivolumab - EMEA/H/C/003985/II/0100 .....	31
5.1.16.	Repatha - evolocumab - EMEA/H/C/003766/II/0049/G.....	31
5.1.17.	Tecentriq - atezolizumab - EMEA/H/C/004143/II/0052 .....	32
5.1.18.	Verzenio - abemaciclib - EMEA/H/C/004302/II/0013 .....	32
5.1.19.	Zepatier - elbasvir / grazoprevir - EMEA/H/C/004126/II/0029 .....	33
5.1.20.	WS1941 Edistride - dapagliflozin - EMEA/H/C/004161/WS1941/0043 Forxiga - dapagliflozin - EMEA/H/C/002322/WS1941/0062 .....	33
5.1.21.	WS1953 Segluromet - ertugliflozin / metformin hydrochloride - EMEA/H/C/004314/WS1953/0012 Steglatro - ertugliflozin - EMEA/H/C/004315/WS1953/0013 .....	34
5.1.22.	WS2049/G Lacosamide UCB - lacosamide - EMEA/H/C/005243/WS2049/0009/G Vimpat - lacosamide - EMEA/H/C/000863/WS2049/0091/G .....	34
<b>5.2.</b>	<b>Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .....</b>	<b>35</b>
<b>5.3.</b>	<b>Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .....</b>	<b>35</b>

## 6. Ancillary medicinal substances in medical devices 35

<b>6.1.</b>	<b>Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions .....</b>	<b>35</b>
<b>6.2.</b>	<b>Update of Ancillary medicinal substances in medical devices .....</b>	<b>35</b>

<b>7.</b>	<b>Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)</b>	<b>35</b>
<b>7.1.</b>	<b>Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)</b>	<b>35</b>
<b>8.</b>	<b>Pre-submission issues</b>	<b>35</b>
<b>8.1.</b>	<b>Pre-submission issue</b>	<b>35</b>
8.1.1.	dexmedetomidine hydrochloride – H0005811	35
8.1.2.	efgartigimod alfa – Orphan - H0005849	36
8.1.3.	lenacapavir - H0005638	36
8.1.4.	lutetium – H0005483	36
8.1.5.	tebentafusp – H0004929	36
<b>8.2.</b>	<b>Priority Medicines (PRIME)</b>	<b>37</b>
8.2.1.	List of applications received	37
8.2.2.	Recommendation for PRIME eligibility	37
<b>9.</b>	<b>Post-authorisation issues</b>	<b>37</b>
<b>9.1.</b>	<b>Post-authorisation issues</b>	<b>37</b>
9.1.1.	Caprelsa - vandetanib - EMEA/H/C/002315/II/0043	37
9.1.2.	Cometriq - cabozantinib - EMEA/H/C/002640/II/0044, Orphan	38
9.1.3.	Cosentyx - secukinumab - EMEA/H/C/003729/II/0076	38
9.1.4.	Esbriet - pirfenidone - EMEA/H/C/002154/II/0069	38
9.1.5.	Hepcludex - bulevirtide - EMEA/H/C/004854/R/0003	39
9.1.6.	Jardiance - empagliflozin - EMEA/H/C/002677/II/0057	39
9.1.7.	Natpar - parathyroid hormone - EMEA/H/C/003861/II/0029	39
9.1.8.	Nodetrip – duloxetine – EMEA/H/C/000573	40
9.1.9.	Ad-hoc assessment of the therapeutic effect of monoethyl fumarate salts within Fumaderm40	
9.1.10.	Xeljanz - tofacitinib - EMEA/H/C/004214/II/0027	40
9.1.11.	Vaxzevria – COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0021/G41	
9.1.12.	Vaxzevria – COVID 19 Vaccine (ChAdOx1 S [recombinant]) - EMEA/H/C/005675/II/0020/G41	
<b>10.</b>	<b>Referral procedures</b>	<b>42</b>
<b>10.1.</b>	<b>Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004</b>	<b>42</b>
<b>10.2.</b>	<b>Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004</b>	<b>42</b>
<b>10.3.</b>	<b>Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004</b>	<b>42</b>
<b>10.4.</b>	<b>Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC</b>	<b>42</b>
10.4.1.	Lidocain/ Prilocain IDETEC – lidocaine, prilocaine - EMEA/H/A-29(4)/1506	42
<b>10.5.</b>	<b>Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC</b>	<b>43</b>
<b>10.6.</b>	<b>Community Interests - Referral under Article 31 of Directive 2001/83/EC</b>	<b>43</b>

10.6.1.	STRESAM and generics – etifoxine (hydrochloride) - EMEA/H/A-31/1509 .....	43
<b>10.7.</b>	<b>Re-examination Procedure under Article 32(4) of Directive 2001/83/EC.....</b>	<b>43</b>
<b>10.8.</b>	<b>Procedure under Article 107(2) of Directive 2001/83/EC .....</b>	<b>43</b>
<b>10.9.</b>	<b>Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003 .....</b>	<b>44</b>
<b>10.10.</b>	<b>Procedure under Article 29 of Regulation (EC) 1901/2006.....</b>	<b>44</b>
<b>10.11.</b>	<b>Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008 .....</b>	<b>44</b>
<b>11.</b>	<b>Pharmacovigilance issue</b>	<b>44</b>
<b>11.1.</b>	<b>Early Notification System .....</b>	<b>44</b>
<b>12.</b>	<b>Inspections</b>	<b>44</b>
<b>12.1.</b>	<b>GMP inspections .....</b>	<b>44</b>
<b>12.2.</b>	<b>GCP inspections.....</b>	<b>44</b>
<b>12.3.</b>	<b>Pharmacovigilance inspections.....</b>	<b>44</b>
<b>12.4.</b>	<b>GLP inspections .....</b>	<b>45</b>
<b>13.</b>	<b>Innovation Task Force</b>	<b>45</b>
<b>13.1.</b>	<b>Minutes of Innovation Task Force.....</b>	<b>45</b>
<b>13.2.</b>	<b>Innovation Task Force briefing meetings.....</b>	<b>45</b>
<b>13.3.</b>	<b>Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004 .....</b>	<b>45</b>
<b>13.4.</b>	<b>Nanomedicines activities .....</b>	<b>45</b>
<b>14.</b>	<b>Organisational, regulatory and methodological matters</b>	<b>45</b>
<b>14.1.</b>	<b>Mandate and organisation of the CHMP .....</b>	<b>45</b>
<b>14.2.</b>	<b>Coordination with EMA Scientific Committees.....</b>	<b>45</b>
14.2.1.	Pharmacovigilance Risk Assessment Committee (PRAC) .....	45
<b>14.3.</b>	<b>Coordination with EMA Working Parties/Working Groups/Drafting Groups .....</b>	<b>46</b>
14.3.1.	Biologics Working Party (BWP).....	46
14.3.2.	Infectious Diseases Working Party (IDWP).....	46
14.3.3.	Name Review Group (NRG) .....	46
14.3.4.	Scientific Advice Working Party (SAWP) .....	46
14.3.5.	Ad-hoc Influenza Working Group.....	47
<b>14.4.</b>	<b>Cooperation within the EU regulatory network.....</b>	<b>47</b>
<b>14.5.</b>	<b>Cooperation with International Regulators.....</b>	<b>47</b>
<b>14.6.</b>	<b>Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee .....</b>	<b>47</b>
<b>14.7.</b>	<b>CHMP work plan .....</b>	<b>47</b>

<b>14.8.</b>	<b>Planning and reporting .....</b>	<b>47</b>
<b>14.9.</b>	<b>Others .....</b>	<b>47</b>
<b>15.</b>	<b>Any other business</b>	<b>48</b>
<b>15.1.</b>	<b>AOB topic.....</b>	<b>48</b>
15.1.1.	Update on COVID-19.....	48
15.1.2.	Procedural guidance for variation for variant update to covid-19 vaccines .....	48
15.1.3.	etesivimab – EMEA/H/C/005837/0000 .....	48
15.1.4.	bamlanivimab – EMEA/H/C/005836/0000.....	48
15.1.5.	COVID-19 vaccine (NVX-CoV2373) – EMEA/H/C/005808 .....	48
15.1.6.	regdanvimab – EMEA/H/C/005854 .....	49
15.1.7.	Spikevax - COVID-19 mRNA Vaccine (nucleoside-modified) – EMEA/H/C/005791/II/002149	
<b>Lists of participants</b>		<b>50</b>
<b>Explanatory notes</b>		<b>62</b>

## **1. Introduction**

### **1.1. Welcome and declarations of interest of members, alternates and experts**

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced the restricted involvement of some meeting participants in upcoming discussions as included in the pre-meeting list of participants and restrictions. See June 2021 CHMP minutes for the list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session held 21-24 June 2021.

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 17 or more members were present remotely). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

### **1.2. Adoption of agenda**

CHMP agenda for 21-24 June 2021

The CHMP adopted the agenda.

### **1.3. Adoption of the minutes**

CHMP minutes for 17-20 May 2021

Minutes from Preparatory Meeting and Organisational Matters (PROM) meeting held on 14 June 2021

The CHMP adopted the CHMP minutes for 17-20 May 2021.

The CHMP adopted the minutes from the PROM meeting held on 14 June 2021.



## 2. Oral Explanations

### 2.1. Pre-authorisation procedure oral explanations

#### 2.1.1. zanubrutinib - Orphan - EMEA/H/C/004978

---

BeiGene Ireland Ltd; treatment of Waldenström's macroglobulinaemia (WM)

Scope: Oral explanation

**Action:** Oral explanation to be held on 22 June 2021 at 14:00

List of Outstanding Issues adopted on 22.04.2021. List of Questions adopted on 15.10.2020.

An oral explanation was held on Tuesday, 22 June 2021. The presentation by the applicant focused on quality aspects.

See 3.2

#### 2.1.2. istradefylline - EMEA/H/C/005308

---

indicated as an adjunctive treatment to levodopa-based regimens in patients with Parkinson's disease

Scope: Oral explanation

**Action:** Oral explanation to be held on 23 June 2021 at 11:00

List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 30.04.2020.

An oral explanation was held on Wednesday 23 June 2021. The presentation by the applicant focused on the clinical data in support of the application.

#### 2.1.3. Voxzogo - vosoritide - Orphan - EMEA/H/C/005475

---

BioMarin International Limited; indicated for the treatment of achondroplasia.

Scope: Possible oral explanation, opinion

**Action:** Possible oral explanation to be held on 22 June 2021 at 16:00

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.04.2021. List of Questions adopted on 10.12.2020.

The CHMP agreed that an oral explanation was not needed at this time.

See 3.1

### 2.2. Re-examination procedure oral explanations

No items

## 2.3. Post-authorisation procedure oral explanations

### 2.3.1. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0052

---

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include Tecentriq in combination with nab-paclitaxel and anthracycline-based chemotherapy for the neoadjuvant treatment of adult patients with locally advanced or early Triple Negative Breast Cancer (TNBC) based on the results of the pivotal study WO39392 (IMpassion031); as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the Tecentriq 840 mg concentrate for solution for infusion SmPC and section 4.8 of the Tecentriq 1,200 mg concentrate for solution for infusion SmPC are updated. The Package Leaflet is updated in accordance. Version 18 of the RMP has also been submitted."

Oral explanation

**Action:** Oral explanation to be held on 23 June 2021 at 15:30

Request for Supplementary Information adopted on 25.02.2021.

Participation of patient representatives.

An oral explanation was held on Wednesday 23 June 2021. The presentation by the applicant focused on the clinical data in support of the application.

The CHMP noted the withdrawal of the extension of indication application.

See 5.1

## 2.4. Referral procedure oral explanations

No items

## 3. Initial applications

### 3.1. Initial applications; Opinions

#### 3.1.1. Abecma - idecabtagene vicleucel - Orphan - ATMP - EMEA/H/C/004662

---

Celgene Europe BV; treatment of multiple myeloma

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 19.02.2021, 04.12.2020. List of Questions adopted on 11.09.2020.

The Committee confirmed that all issues previously identified in this application had been

addressed.

Based on the draft opinion prepared by the CAT, the CHMP adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that idecabtagene vicleucel is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 24 June 2021.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

### 3.1.2. [Abiraterone Mylan - abiraterone acetate - EMEA/H/C/005368](#)

---

Mylan IRE Healthcare Limited; treatment of metastatic castration resistant prostate cancer

Scope: Opinion

**Action:** For adoption

Hybrid application (Article 10(3) of Directive No 2001/83/EC); Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Zytiga

List of Outstanding Issues adopted on 22.04.2021, 25.02.2021. List of Questions adopted on 23.07.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

### 3.1.3. [Bimzelx - bimekizumab - EMEA/H/C/005316](#)

---

UCB Pharma S.A.; treatment of plaque psoriasis

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.04.2021. List of Questions adopted on 10.12.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that bimekizumab is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

#### 3.1.4. Byooviz - ranibizumab - EMEA/H/C/005545

---

Samsung Bioepis NL B.V.; treatment of neovascular age-related macular degeneration (AMD)

Scope: Opinion

**Action:** For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 20.05.2021. List of Questions adopted on 28.01.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 15 June 2021.

The summary of opinion was circulated for information.

#### 3.1.5. Evrenzo - roxadustat - EMEA/H/C/004871

---

Astellas Pharma Europe B.V.; treatment of anaemia

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 20.05.2021, 25.02.2021. List of Questions adopted on 17.09.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation

timetable.

Furthermore, the CHMP considered that roxadustat is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

### 3.1.6. Fingolimod Mylan - fingolimod - EMEA/H/C/005661

---

Mylan Ireland Limited; treatment of multiple sclerosis

Scope: Opinion

**Action:** For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Gilenya

List of Questions adopted on 25.03.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

### 3.1.7. Flynpovi - eflornithine / sulindac - Orphan - EMEA/H/C/005043

---

Cancer Prevention Pharma (Ireland) Limited; treatment of adult patients with familial adenomatous polyposis (FAP)

Scope: Opinion

**Action:** For adoption

Fixed combination application (Article 10b of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 25.03.2021. List of Questions adopted on 15.10.2020.

The CHMP adopted a negative opinion by consensus, recommending the refusal of the marketing authorisation application. The CHMP adopted the assessment report.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The refusal question and answers document was circulated for information.

### 3.1.8. Minjuvi - tafasitamab - Orphan - EMEA/H/C/005436

---

Incyte Biosciences Distribution B.V.; is indicated in combination with lenalidomide followed

by tafasitamab monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from low grade lymphoma, who are not eligible for, or refuse, autologous stem cell transplant (ASCT).

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 20.05.2021. List of Questions adopted on 17.09.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that tafasitamab is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 28 June 2021.

The summary of opinion was circulated for information.

### 3.1.9. Voxzogo - vosoritide - Orphan - EMEA/H/C/005475

BioMarin International Limited; indicated for the treatment of achondroplasia

Scope: Possible oral explanation, opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Outstanding Issues adopted on 22.04.2021. List of Questions adopted on 10.12.2020.

The CHMP agreed that an oral explanation was not needed at this time.

See 2.1

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that vosoritide is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendations dated 21 June 2021.

The summary of opinion was circulated for information.

### **3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)**

#### **3.2.1. zanubrutinib - Orphan - EMEA/H/C/004978**

---

BeiGene Ireland Ltd; treatment of Waldenström's macroglobulinaemia (WM)

Scope: Possible oral explanation, list of outstanding issues

**Action:** For adoption

List of Outstanding Issues adopted on 22.04.2021. List of Questions adopted on 15.10.2020.

See 2.1

An oral explanation was held on Tuesday, 22 June 2021. The presentation by the applicant focused on quality aspects.

The Committee adopted a 2<sup>nd</sup> list of outstanding issues with a specific timetable.

#### **3.2.2. abrocitinib - EMEA/H/C/005452**

---

indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 28.01.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

#### **3.2.3. artesunate - Orphan - EMEA/H/C/005550**

---

Amivas Ireland Ltd; treatment of malaria

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 28.01.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.4. pralsetinib - EMEA/H/C/005413

---

treatment of non-small cell lung cancer (NSCLC)

Scope: List of outstanding issues

**Action:** For adoption

List of Outstanding Issues adopted on 22.04.2021, 28.01.2021. List of Questions adopted on 17.09.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 3<sup>rd</sup> list of outstanding issues with a specific timetable.

The CHMP agreed to consult the SAG-Oncology and adopted a list of questions to this group.

### 3.2.5. lonapegsomatropin - Orphan - EMEA/H/C/005367

---

Ascendis Pharma Endocrinology Division A/S; Treatment of growth hormone deficiency

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 28.01.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed to consult the SWP and NcWG of the PDCO and adopted lists of questions to these groups.

### 3.2.6. imatinib - EMEA/H/C/005595

---

treatment of Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML), Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL), myelodysplastic/myeloproliferative diseases (MDS/MPD), hypereosinophilic syndrome (HES), eosinophilic leukaemia (CEL), Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST), and unresectable dermatofibrosarcoma protuberans (DFSP)

Scope: List of outstanding issues

**Action:** For adoption

List of Outstanding Issues adopted on 22.04.2021. List of Questions adopted on 12.11.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2<sup>nd</sup> list of outstanding issues with a specific timetable.



### 3.2.7. sodium thiosulfate - PUMA - EMEA/H/C/005130

---

for the prevention of ototoxicity induced by cisplatin (CIS) chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours.

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 25.06.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP agreed to consult the SAG-oncology and adopted a list of questions to this group.

### 3.2.8. pegcetacoplan - Orphan - EMEA/H/C/005553

---

Apellis Ireland Limited; paroxysmal nocturnal haemoglobinuria (PNH)

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 28.01.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.9. ripretinib - Orphan - EMEA/H/C/005614

---

Deciphera Pharmaceuticals (Netherlands) B.V.; Treatment of patients with advanced gastrointestinal stromal tumour (GIST)

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 28.01.2021.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.10. glucarpidase - Orphan - EMEA/H/C/005467

---

Protherics Medicines Development Europe B.V.; treatment of patients at risk of methotrexate toxicity

Scope: List of outstanding issues

**Action:** For adoption

List of Questions adopted on 10.12.2020.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### **3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)**

#### **3.3.1. dengue tetravalent vaccine (live, attenuated) - Article 58 - EMEA/H/W/005362**

---

prevention of dengue disease

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### **3.3.2. ertapenem - EMEA/H/C/005815**

---

treatment of bacterial infections and prophylaxis of surgical site infection following elective colorectal surgery

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### **3.3.3. gefapixant - EMEA/H/C/005476**

---

treatment of refractory or unexplained chronic cough

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### **3.3.4. gefapixant - EMEA/H/C/005884**

---

treatment of refractory or unexplained chronic cough

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.5. somatrogon - Orphan - EMEA/H/C/005633

---

Pfizer Europe MA EEIG; indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.6. enfortumab vedotin - EMEA/H/C/005392

---

#### **Accelerated assessment**

treatment of locally advanced (LA) or metastatic urothelial cancer (mUC)

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.7. dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/005155

---

prevention of dengue disease

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.8. eptacog beta (activated) - EMEA/H/C/005655

---

treatment and for the prevention of bleeding

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.9. [sacituzumab govitecan - EMEA/H/C/005182](#)

---

#### **Accelerated assessment**

treatment of unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC)

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.10. [rimegepant - EMEA/H/C/005725](#)

---

management of migraine

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.11. [retifanlimab - Orphan - EMEA/H/C/005632](#)

---

Incyte Biosciences Distribution B.V.; Treatment of locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed on or who are intolerant of platinum-based chemotherapy

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

## 3.4. **Update on on-going initial applications for Centralised procedure**

### 3.4.1. [lisocabtagene maraleucel / lisocabtagene maraleucel - Orphan - ATMP - EMEA/H/C/004731](#)

---

Bristol-Myers Squibb Pharma EEIG; treatment of large B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B)

Scope: Letter from the applicant dated 28 May 2021 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in April 2021.

**Action:** For information

List of Outstanding Issues adopted on 16.04.2021. List of Questions adopted on 06.11.2020.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in April 2021.

#### 3.4.2. [dabigatran etexilate - EMEA/H/C/005639](#)

---

prevention of venous thromboembolic events

Scope: Letter from the applicant dated 06 May 2021 requesting an extension of clock-stop to respond to the list of questions adopted in November 2020.

**Action:** For adoption

List of Questions adopted on 12.11.2020.

The CHMP agreed to the request by the applicant for extension to the clock stop to respond to the list of questions adopted in November 2020.

#### 3.4.3. [adrenaline - EMEA/H/C/005584](#)

---

For the emergency treatment of allergic reactions, including anaphylaxis

Scope: Request by the applicant for an extension to the clock stop to respond to the list of questions adopted in March 2021.

**Action:** For adoption

List of Questions adopted on 25.03.2021.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in March 2021.

#### 3.4.4. [pegfilgrastim - EMEA/H/C/004780](#)

---

treatment of neutropenia

Scope: Request by the applicant dated 24 June 2021 for an extension to the clock stop to respond to the list of questions adopted in September 2020

**Action:** For adoption

List of Questions adopted on 17.09.2020.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in September 2020.

### 3.5. **Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004**

No items

### 3.6. Initial applications in the decision-making phase

#### 3.6.1. Lextemy - bevacizumab - EMEA/H/C/005611

---

Mylan IRE Healthcare Limited; Treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer and recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer.

First-line treatment of patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer.

First-line treatment of patients with advanced and/or metastatic renal cell cancer.

Similar biological application (Article 10(4) of Directive No 2001/83/EC), Duplicate of Abevmy

Withdrawal of marketing authorisation

**Action:** For information

The CHMP noted the withdrawal of the marketing authorisation.

### 3.7. Withdrawals of initial marketing authorisation application

No items

## 4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

### 4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion

#### 4.1.1. Rinvoq - upadacitinib - EMEA/H/C/004760/X/0006/G

---

AbbVie Deutschland GmbH & Co. KG

Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce

Scope: "Extension application to introduce a new strength (30 mg prolonged-release tablet), grouped with a type II variation (C.I.6.a) to add a new indication (treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy for Rinvoq). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2 and 5.3 of the SmPC, Annex II as well as the Package Leaflet are updated. The RMP (version 4.3) is adopted."

**Action:** For adoption

List of Outstanding Issues adopted on 20.05.2021. List of Questions adopted on 25.02.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP

---

Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### **4.1.2. [Xeljanz - tofacitinib - EMEA/H/C/004214/X/0024/G](#)**

---

Pfizer Europe MA EEIG

Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: "Extension application to introduce a new pharmaceutical form (oral solution, 1 mg/ml) grouped with a type II variation (C.I.6.a) to add a new indication (treatment of active polyarticular course juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older). The RMP (version 12.1) is updated in accordance. Additionally, the marketing authorisation holder took the opportunity to align the PI with the latest QRD template."

**Action:** For adoption

List of Outstanding Issues adopted on 25.03.2021. List of Questions adopted on 15.10.2020.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

## **4.2. [Extension of marketing authorisation according to Annex I of Commission Regulation \(EC\) No 1234/2008; Day 180 list of outstanding issues](#)**

### **4.2.1. [Akynzeo - fosnetupitant / netupitant / palonosetron - EMEA/H/C/003728/X/0031](#)**

---

Helsinn Birex Pharmaceuticals Limited

Rapporteur: Peter Kiely, PRAC Rapporteur: Ilaria Baldelli

Scope: "Extension application to introduce a new pharmaceutical form (concentrate for solution for infusion)."

**Action:** For adoption

List of Questions adopted on 28.01.2021.

The Committee discussed the issues identified in this application, relating to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

#### 4.2.2. Ferriprox - deferiprone - EMEA/H/C/000236/X/0145

---

Chiesi Farmaceutici S.p.A.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "Extension application to introduce a new pharmaceutical form (gastro-resistant tablets). The RMP (version 14.0) is updated in accordance."

**Action:** For adoption

List of Outstanding Issues adopted on 25.02.2021. List of Questions adopted on 17.09.2020.

The Committee discussed the issues identified in this application, relating to quality and clinical aspects and the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.

#### 4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

##### 4.3.1. Ayvakyt - avapritinib - Orphan - EMEA/H/C/005208/X/0004/G

---

Blueprint Medicines (Netherlands) B.V.

Rapporteur: Blanca Garcia-Ochoa, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Menno van der Elst

Scope: "Extension application to add two new strengths of film-coated tablets (25 mg and 50 mg), grouped with a type II variation (C.I.6.a) to introduce a new therapeutic indication for Ayvakyt. Extension of indication to include treatment of adult patients with advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM-AHN), and mast cell leukaemia (MCL), after at least one systemic therapy for Ayvakyt based on the results of the BLU-285-2101 and BLU-285-2202 studies. The new indication is applicable to the new and existing presentations (25 mg, 50 mg, 100 mg and 200 mg film-coated tablets). As a consequence, sections 1, 2, 3, 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2, 5.3, 6.1 and 8 of the SmPC are updated. The Labelling and Package Leaflet are updated in accordance. Version 1.1 of the RMP has also been submitted."

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to quality, non-clinical and clinical aspects as well as the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

##### 4.3.2. Nuwiq - simoctocog alfa - EMEA/H/C/002813/X/0042

---

Octapharma AB



Rapporteur: Jan Mueller-Berghaus

Scope: "Extension application to add a new strength of 1500 IU for simoctocog alfa powder and solvent for solution for injection, for Intravenous use.

The marketing authorisation holder took the opportunity to align the PI to the latest QRD template (version 10.2)."

**Action:** For adoption

The Committee discussed the issues identified in this application, related to quality aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### **4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008**

No items

#### **4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008**

No items

### **5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008**

#### **5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information**

##### **5.1.1. Brilique - ticagrelor - EMEA/H/C/001241/II/0049**

AstraZeneca AB

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Maria Concepcion Prieto Yerro, PRAC  
Rapporteur: Menno van der Elst

Scope: "Extension of indication to include, in co-administration with acetylsalicylic acid (ASA), the prevention of stroke in adult patients with acute ischaemic stroke or transient ischaemic attack (TIA), based on the final results of study D5134C00003 (THALES), a phase III, international, multicentre, randomised, double-blind, placebo-controlled study to investigate the efficacy and safety of ticagrelor and ASA compared with ASA in the prevention of stroke and death in patients with acute ischaemic stroke or transient ischaemic attack; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13 of the RMP has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 28.01.2021, 17.09.2020.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 3<sup>rd</sup> request for supplementary information with a specific timetable.

#### 5.1.2. Briviact - brivaracetam - EMEA/H/C/003898/II/0032/G

---

UCB Pharma S.A.

Rapporteur: Filip Josephson, PRAC Rapporteur: Adam Przybylkowski

Scope: "- Extension of indication to include patients from 1 month to 4 years of age for the Briviact treatment. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The RMP version 8.0 has also been submitted. Furthermore, the PI is brought in line with the latest QRD template version 10.2 and the MAH took the opportunity to implement minor editorial updates.

- (B.II.f.1.b.2)

- (B.IV.1.a.1)

The Package Leaflet and Labelling are updated in accordance."

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to quality, non-clinical and clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

The CHMP agreed to consult an ad-hoc expert group and adopted a list of questions to the experts.

#### 5.1.3. Comirnaty - COVID-19 mRNA vaccine (nucleoside-modified) - EMEA/H/C/005735/II/0030

---

BioNTech Manufacturing GmbH

Rapporteur: Filip Josephson, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of the existing indication from "individuals 16 years of age and older" to "individuals 12 years of age and older" for Comirnaty; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.0 of the RMP has also been submitted."

Opinion was adopted at an extraordinary meeting held remotely on 28 May 2021.

**Action:** For information

The CHMP discussed the application at an extraordinary CHMP held on 28 May 2021.

On 28.05.2021, the Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.4. Galafold - migalastat - Orphan - EMEA/H/C/004059/II/0029

---

Amicus Therapeutics Europe Limited

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication for Galafold (migalastat) to include long-term treatment of adolescents 12 to < 16 years with a confirmed diagnosis of Fabry disease ( $\alpha$ -galactosidase A deficiency) and who have an amenable mutation. As a consequence, sections 4.1, 4.2, 4.8 and 5.2 of the SmPC and sections 1 and 2 of the Package Leaflet are updated accordingly. A revised RMP version 4.0 has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 25.03.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.5. Jakavi - ruxolitinib - EMEA/H/C/002464/II/0053

---

Novartis Europharm Limited

Rapporteur: Filip Josephson, Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Annika Folin

Scope: "Extension of indication to include treatment of patients with GvHD aged 12 years and older who have inadequate response to corticosteroids or other systemic therapies for Jakavi; as a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives for The Netherlands in the Package Leaflet."

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.6. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0099

---

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for Keytruda to include in combination with chemotherapy, treatment of locally recurrent unresectable or metastatic triple negative breast cancer in adults whose tumours express PD L1 with a CPS  $\geq$  10 and who have not received prior

chemotherapy for metastatic disease; as a consequence, sections 4.1, 4.2 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 31.1 of the RMP has also been submitted.”

**Action:** For adoption

Request for Supplementary Information adopted on 25.03.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### **5.1.7. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0104**

---

Merck Sharp & Dohme B.V.

Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: “Extension of indication for Keytruda to include in combination with lenvatinib first line treatment of adults with advanced renal cell carcinoma (RCC); as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 32.1 of the RMP has also been submitted.”

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to non-clinical and clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### **5.1.8. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0105**

---

Merck Sharp & Dohme B.V.

Rapporteur: Armando Genazzani, PRAC Rapporteur: Menno van der Elst

Scope: “Extension of indication to include pembrolizumab in combination with lenvatinib for the treatment of advanced endometrial carcinoma in adults who have disease progression following prior systemic therapy in any setting and who are not candidates for curative surgery or radiation; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 33.1 of the RMP has also been submitted.”

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to non-clinical and clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### **5.1.9. Kisplyx - lenvatinib - EMEA/H/C/004224/II/0045**

---

Eisai GmbH

Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: David Olsen

Scope: “Extension of indication for Kisplyx to include in combination with pembrolizumab

first-line treatment of adults with advanced renal cell carcinoma (RCC); as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 13 of the RMP has also been submitted. In addition, the marketing authorisation holder took the opportunity to update the list of local representatives in the Package Leaflet.”

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to non-clinical and clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.10. Lenvima - lenvatinib - EMEA/H/C/003727/II/0042

---

Eisai GmbH

Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Annika Folin

Scope: “Extension of indication to include lenvatinib in combination with pembrolizumab for the treatment of adult patients with advanced endometrial carcinoma (EC) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 14.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to make minor editorial changes to the SmPC and update the list of local representatives in the Package Leaflet in line with the latest QRD template version 10.2.”, Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects and the request for 1 year market protection.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.11. Nucala - mepolizumab - EMEA/H/C/003860/II/0035

---

GlaxoSmithKline Trading Services Limited

Rapporteur: Peter Kiely, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: “Extension of indication to include Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) for Nucala (mepolizumab). As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7 of the RMP has also been submitted. In addition, the marketing authorisation holder took the opportunity to update the local (IT) representative in the PL.”

**Action:** For adoption

Request for Supplementary Information adopted on 28.01.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 5.1.12. Nucala - mepolizumab - EMEA/H/C/003860/II/0036/G

---

GlaxoSmithKline Trading Services Limited

Rapporteur: Peter Kiely, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include Eosinophilic Granulomatosis with Polyangiitis (EGPA) for Nucala (mepolizumab); as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7 of the RMP has also been submitted. In addition, the marketing authorisation holder took the opportunity to update the local representative (IT) in the PL.

2 Variations : Type I B.11.e.5.a.2 - To add a new pack size for pre-filled pens for Nucala, 100 mg/ml, solution for injection and another pack size for pre-filled syringes for Nucala, 100 mg/ml, solution for injection.

As a consequence, sections 6.5 and 8 of the SmPCs and section 6 of the PLs are updated accordingly. Annex IIIA is also being updated to include information relating to the new pack sizes.", Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

Request for Supplementary Information adopted on 28.01.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects, the RMP and the request for 1 year of market protection.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 5.1.13. Nucala - mepolizumab - EMEA/H/C/003860/II/0037

---

GlaxoSmithKline Trading Services Limited

Rapporteur: Peter Kiely, Co-Rapporteur: Ondřej Slanař, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include hypereosinophilic syndrome (HES) for Nucala (mepolizumab); as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 (in addition 6.6 for the powder for solution for injection ONLY) of the SmPC are updated. The Package Leaflet is updated in accordance. Version 7 of the RMP has also been submitted.

In addition, the Marketing Authorisation Holder took the opportunity to update the local representative (IT) in the PL."

**Action:** For adoption

Request for Supplementary Information adopted on 28.01.2021.

The Committee discussed the issues identified in this application, related to clinical aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 5.1.14. Opdivo - nivolumab - EMEA/H/C/003985/II/0095

---

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Blanca Garcia-Ochoa, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include adjuvant treatment of adult patients with oesophageal, or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy for Opdivo (study CA209577); as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 22.0 of the RMP has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 25.03.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

#### 5.1.15. Opdivo - nivolumab - EMEA/H/C/003985/II/0100

---

Bristol-Myers Squibb Pharma EEIG

Co-Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication for Opdivo to include adjuvant treatment of adults with muscle invasive urothelial carcinoma (MIUC) who are at high risk of recurrence after undergoing radical resection of MIUC; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 23.0 of the RMP has also been submitted."

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.16. Repatha - evolocumab - EMEA/H/C/003766/II/0049/G

---

Amgen Europe B.V.

Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Kimmo Jaakkola

Scope: "C.I.6 (EoI) Extension of indication to include one new paediatric indication in paediatric patients aged 10 years and over with heterozygous familial hypercholesterolaemia as an adjunct to diet, alone or in combination with other lipid-lowering therapy, to reduce LDL-C based on results of study 20120123 (HAUSER-RCT). It is a randomized, multicenter, placebo-controlled, double blind, parallel group, 24-week trial in 158 paediatric patients aged 10 to > 18 years with heterozygous familial hypercholesterolaemia. As a consequence, sections 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet are updated in accordance. Version 7.0 of the RMP has also been submitted."

C.I.6 (EoI) Extension of indications to modify the existing indication for treatment of adults and paediatric patients aged 10 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies based on interim results from study 20120124 (HAUSER-OLE). It was an open label, single arm, multicenter, 80-week trial to evaluate the safety, tolerability and efficacy of Repatha for LDL-C reduction in paediatric patients from aged  $\geq 10$  to  $< 18$  years of age with homozygous familial hypercholesterolaemia. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated accordingly."

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.17. Tecentriq - atezolizumab - EMEA/H/C/004143/II/0052

---

Roche Registration GmbH

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include Tecentriq in combination with nab-paclitaxel and anthracycline-based chemotherapy for the neoadjuvant treatment of adult patients with locally advanced or early Triple Negative Breast Cancer (TNBC) based on the results of the pivotal study WO39392 (IMpassion031); as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the Tecentriq 840 mg concentrate for solution for infusion SmPC and section 4.8 of the Tecentriq 1,200 mg concentrate for solution for infusion SmPC are updated. The Package Leaflet is updated in accordance. Version 18 of the RMP has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 25.02.2021.

See 2.3

Participation of patient representatives.

An oral explanation was held on Wednesday 23 June 2021. The presentation by the applicant focused on the clinical data in support of the application.

The CHMP noted the withdrawal of extension of indication application.

#### 5.1.18. Verzenios - abemaciclib - EMEA/H/C/004302/II/0013

---

Eli Lilly Nederland B.V.

Rapporteur: Filip Josephson, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva

Scope: "Extension of indication to include Verzenios in combination with endocrine therapy for adjuvant treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer at high risk of recurrence; as a consequence, sections 4.1, 4.2, 4.4, 4.6, 4.8, 5.1 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted.", Request for 1 year of market protection for a new indication (Article



14(11) of Regulation (EC) 726/2004)

**Action:** For adoption

Request for Supplementary Information adopted on 25.02.2021.

The Committee discussed the issues identified in this application, relating to non-clinical, clinical aspects and the RMP, as well as the request for 1 year market protection.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 5.1.19. [Zepatier - elbasvir / grazoprevir - EMEA/H/C/004126/II/0029](#)

---

Merck Sharp & Dohme B.V.

Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension of indication to include treatment of chronic hepatitis C (CHC) in paediatric patients 12 years of age and older who weigh at least 30 kg for Zepatier; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to quality, non-clinical and clinical aspects, as well as the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

#### 5.1.20. [WS1941](#) [Edistrade - dapagliflozin - EMEA/H/C/004161/WS1941/0043](#) [Forxiga - dapagliflozin - EMEA/H/C/002322/WS1941/0062](#)

---

AstraZeneca AB

Lead Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin

Scope: "Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC for Forxiga and Edistrade based on the results from the renal outcomes study D169AC00001 (DAPA-CKD). The Annex II.B and Package Leaflet of these products are updated accordingly. The DAPA-CKD study is a category 3, Post-Authorisation Safety Study (PASS) listed in the dapagliflozin RMP to evaluate the potential risk of lower limb amputation; it is a multicentre, event-driven, randomized, double-blind, parallel group, placebo-controlled study, evaluating the effect of dapagliflozin versus placebo, given once daily in addition to standard of care, to prevent the progression of chronic kidney disease (CKD) or cardiovascular (CV)/renal death. In addition, the Risk Management Plan for dapagliflozin (version 22) has been updated."

**Action:** For adoption

Request for Supplementary Information adopted on 25.02.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

5.1.21. [WS1953](#)  
[Segluromet - ertugliflozin / metformin hydrochloride - EMEA/H/C/004314/WS1953/0012](#)  
[Steglatro - ertugliflozin - EMEA/H/C/004315/WS1953/0013](#)

---

Merck Sharp & Dohme B.V.

Lead Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst

Scope: "Update of sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC of Steglatro and Segluromet in order to modify the indication, update posology recommendations and include efficacy and safety information based on final results from the VERTIS CV study (protocol 8835-004/B1521021) listed as a category 3 study in the RMP. This is a multi-centre, multi-national, randomised, double-blind, placebo-controlled study to evaluate the effect of ertugliflozin on cardiovascular risk in adult patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 25.02.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

5.1.22. [WS2049/G](#)  
[Lacosamide UCB - lacosamide - EMEA/H/C/005243/WS2049/0009/G](#)  
[Vimpat - lacosamide - EMEA/H/C/000863/WS2049/0091/G](#)

---

UCB Pharma S.A.

Lead Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include patients from 1 month to 4 years of age for treatment of partial-onset seizures with or without secondary generalisation as monotherapy and adjunctive therapy for Vimpat/Lacosamide USB. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. Version 16.0 of the RMP has also been submitted.

B.IV.1.a.1 - type IB

B.II.f.1.b.2 - type IB

The Package Leaflet and labelling are updated in accordance."

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to quality and clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.  
The CHMP agreed to consult an ad hoc expert group and adopted a list of questions to the experts.

**5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

No items

**5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

No items

**6. Ancillary medicinal substances in medical devices**

**6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions**

No items

**6.2. Update of Ancillary medicinal substances in medical devices**

No items

**7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)**

**7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)**

No items

**8. Pre-submission issues**

**8.1. Pre-submission issue**

**8.1.1. dexmedetomidine hydrochloride – H0005811**

Acute treatment of agitation associated with schizophrenia or bipolar disorder in adults.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

**Action:** For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

#### 8.1.2. efgartigimod alfa – Orphan - H0005849

---

argenx BV; Treatment of adult patients with generalised myasthenia gravis.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

**Action:** For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

#### 8.1.3. lenacapavir - H0005638

---

in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with multidrug resistant HIV 1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations.

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

**Action:** For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

#### 8.1.4. lutetium – H0005483

---

treatment of metastatic castration-resistant prostate cancer in adult male patients

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

**Action:** For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

#### 8.1.5. tebentafusp – H0004929

---

treatment of advanced uveal melanoma

Scope: Briefing note and the Rapporteurs' recommendation on the request for accelerated assessment.

**Action:** For adoption

The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs' recommendation on the Request for Accelerated Assessment.

## 8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at present time as these contain commercially confidential information

### 8.2.1. List of applications received

---

**Action:** For information

The CHMP noted the list of applications received.

### 8.2.2. Recommendation for PRIME eligibility

---

**Action:** For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 4 recommendations for eligibility to PRIME: 4 were denied.

The individual outcomes are listed in PRIME Monthly Report on EMA website.

## 9. Post-authorisation issues

### 9.1. Post-authorisation issues

#### 9.1.1. Caprelsa - vandetanib - EMEA/H/C/002315/II/0043

---

Genzyme Europe BV

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant

Scope: "C.I.4 Update of section 5.1 of the SmPC in order to update pharmacodynamic information based on interim results from study D4200C00104, listed as a specific obligation in the Annex II. This is an observational study (including a retrospective arm to evaluate the Benefit/Risk of vandetanib (Caprelsa) 300 mg in RET mutation negative and RET mutation positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic thyroid cancer (MTC)), to confirm the efficacy and safety of Caprelsa in RET-negative patients with the aim to fulfil SOB001 and convert Caprelsa from conditional to normal Marketing Authorisation. In addition, the MAH takes to opportunity to rectify the Dutch translation of the Caprelsa Product Information."

**Action:** For adoption

Request for Supplementary Information adopted on 28.05.2020.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

### 9.1.2. Cometriq - cabozantinib - EMEA/H/C/002640/II/0044, Orphan

---

Ipsen Pharma

Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst

Scope: "Update of the annex IIE and SmPC section 5.1 to remove the specific obligation (SOB 001) and the reference to the conditional approval based on the final results from the study XL184-401 (EXAMINER), a randomised, double-blind study to evaluate the efficacy and safety of cabozantinib (XL184) at 60 mg/day compared to a 140 mg/day in progressive, metastatic medullary thyroid cancer patients. The package leaflet is updated accordingly. The updated RMP version 5.4 has also been submitted. With this submission, the MAH is proposing to revert from conditional marketing authorisation to full marketing authorisation.

Additionally, the MAH took the opportunity to bring the Product Information in line with the latest QRD template version 10.2 Rev 1, to add the sodium content in the Summary of Product Characteristics and Package Information Leaflet in line with the guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' and update details of local representatives."

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

### 9.1.3. Cosentyx - secukinumab - EMEA/H/C/003729/II/0076

---

Novartis Europharm Limited

Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia

Scope: C.I.4 - Update of sections 4.2 and 5.1 of the SmPC in order to introduce a new posology regimen for adult plaque psoriasis patients and psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis based on the final results from study CAIN457A2324 and exposure-response modelling; this is a randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 kg or higher with moderate to severe chronic plaque-type psoriasis; the Package Leaflet is updated accordingly. The RMP version 9.0 has also been submitted.

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to clinical aspects and the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

### 9.1.4. Esbriet - pirfenidone - EMEA/H/C/002154/II/0069

---

Roche Registration GmbH

Rapporteur: Peter Kiely, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Extension of indication to include the treatment of unclassifiable interstitial lung disease (UILD) for Esbriet; as a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 11.0 of the RMP has also been submitted."

Withdrawal of extension of indication application

**Action:** For information

Request for Supplementary Information adopted on 22.04.2021

The CHMP noted the withdrawal of this variation application.

#### 9.1.5. Hepcludex - bulevirtide - EMEA/H/C/004854/R/0003

MYR GmbH

Rapporteur: Filip Josephson, PRAC Rapporteur: Adam Przybylkowski

Scope: "Annual renewal"

**Action:** For adoption

Request for Supplementary Information adopted on 22.04.2021.

The CHMP noted the update.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

#### 9.1.6. Jardiance - empagliflozin - EMEA/H/C/002677/II/0057

Boehringer Ingelheim International GmbH

Rapporteur: Johann Lodewijk Hillege

Scope: "Update of sections 4.2 and 4.4 of the SmPC to lower the renal threshold for initiation and use of empagliflozin depending on eGFR, and of the section 5.1 wording about endpoints with reference to EMPA-REG OUTCOME study. The PL is updated accordingly."

**Action:** For adoption

Request for Supplementary Information adopted on 25.03.2021.

The Committee discussed the issues identified in this application, relating to clinical aspects.

The Committee adopted a 2<sup>nd</sup> request for supplementary information with a specific timetable.

#### 9.1.7. Natpar - parathyroid hormone - EMEA/H/C/003861/II/0029

Shire Pharmaceuticals Ireland Limited

Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Rhea Fitzgerald

Scope: "Submission of the final results of study SHP634-101: An Open-Label, Randomized,

Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once-Daily and Twice-Daily Dose Regimens of recombinant human Parathyroid Hormone (rhPTH [1-84]) Administered Subcutaneously to Subjects with Hypoparathyroidism. Further clinical evaluation of an alternative dosing regimen is no longer warranted, as outlined in the current specific obligation (study SHP634-403). The conditional marketing authorisation can therefore be converted into a standard marketing authorisation (no longer subject to a specific obligation) valid for 5 years.”

**Action:** For adoption

The Committee discussed the issues identified in this application, relating to non-clinical and clinical aspects, as well as the RMP.

The Committee adopted a request for supplementary information with a specific timetable.

#### 9.1.8. [Nodetrip – duloxetine – EMEA/H/C/000573](#)

---

Esteve Pharmaceuticals S.A.; treatment of major depressive episodes and diabetic peripheral neuropathic pain

Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Filip Josephson

New active substance (Article 8(3) of Directive No 2001/83/EC)

Withdrawal of marketing authorisation

**Action:** For information

The CHMP noted the withdrawal of the marketing authorisation.

#### 9.1.9. [Ad-hoc assessment of the therapeutic effect of monoethyl fumarate salts within Fumaderm](#)

---

Implementation of the Judgment of the General Court of 5 May 2021 in Case T-611/18, *Pharmaceutical Works Polpharma v EMA*; Annulment of EMA’s non-validation decision for a generic application of Tecfidera.

For the purpose of the implementation of the Judgment, the CHMP will assess the therapeutic contribution of monoethyl fumarate (MEF) salts within the combination product Fumaderm.

Scope: Appointment of Rapporteurs, LoQ, timetable

**Action:** For adoption

The CHMP appointed a Rapporteur and a Co-Rapporteur.

The CHMP adopted a list of questions with a specific timetable.

#### 9.1.10. [Xeljanz - tofacitinib - EMEA/H/C/004214/II/0027](#)

---

Pfizer Europe MA EEIG

Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan

Scope: “Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of Xeljanz 11 mg prolonged-release tablets SmPC in order to include the treatment of active psoriatic arthritis (PsA) in



adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug therapy; as an alternative to the immediate release film-coated tablets; section 4.2 of Xeljanz film-coated tablets is also updated to include switching with the prolonged-release tablet in the treatment of PsA. The Package Leaflet is updated accordingly. The RMP version 13.1 has also been submitted.”

Request for Supplementary Information adopted on 25.03.2021, 10.12.2020.

**Action:** For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

#### 9.1.11. [Vaxzevria – COVID 19 Vaccine \(ChAdOx1 S \[recombinant\]\) - EMEA/H/C/005675/II/0021/G](#)

---

AstraZeneca AB

Rapporteur: Sol Ruiz, Co-Rapporteur: Hans Hillege, PRAC Rapporteur: Jean-Michel Dogné

Scope: Quality variation

**Action:** For discussion

The Committee discussed the issues identified in this application, relating to quality aspects.

The Committee adopted a request for supplementary information with a specific timetable.

#### 9.1.12. [Vaxzevria – COVID 19 Vaccine \(ChAdOx1 S \[recombinant\]\) - EMEA/H/C/005675/II/0020/G](#)

---

AstraZeneca AB

Rapporteur: Sol Ruiz, Co-Rapporteur: Hans Hillege, PRAC Rapporteur: Jean-Michel Dogné

Scope: Quality variation

**Action:** For adoption

Request for Supplementary Information adopted on 08.06.2021.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

## 10. Referral procedures

### 10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004

No items

### 10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

No items

### 10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004

No items

### 10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC

#### 10.4.1. Lidocain/ Prilocain IDETEC – lidocaine, prilocaine - EMEA/H/A-29(4)/1506

---

International Drug Development France

Referral Rapporteur: Kristine Moll Harboe, Co-Rapporteur: Paula Boudewina van Hennik

Scope: List of outstanding issues

**Action:** For adoption

Summary: Decentralised Procedure number: DK/H/3106/001/DC, notification by the Danish Agency notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC. The objecting MS is of the opinion that therapeutic equivalence has not been demonstrated between the test and the reference product.

List of questions adopted on 25.03.2021.

The CHMP adopted a list of outstanding issues with a specific timetable.

CHMP list of outstanding issues: 24.06.2021

Submission of responses: 26.08.2021

Re-start of the procedure: 16.09.2021

Rapporteur/co-rapporteur joint assessment report(s) circulated to CHMP: 24.09.2021

Comments: 01.10.2021

Updated Rapporteur/co-rapporteur joint assessment report(s) circulated to CHMP: 07.10.2021

CHMP opinion: October 2021 CHMP

---

## **10.5. Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC**

No items

## **10.6. Community Interests - Referral under Article 31 of Directive 2001/83/EC**

### **10.6.1. STRESAM and generics – etifoxine (hydrochloride) - EMEA/H/A-31/1509**

---

Various

Referral Rapporteur: John Joseph Borg, Co-Rapporteur: Simona Badoi

Scope: start of procedure, timetable, list of questions, appointment of rapporteurs

**Action:** For adoption

Summary: ANSM has triggered a referral under Article 31 of Directive 2011/83/EC to review the B/R balance of etifoxine containing products, in light of the new results from the AMETIS study.

The CHMP appointed John Joseph Borg as Referral Rapporteur and Simona Badoi (collaboration with Bulgaria) as Referral Co-Rapporteur.

The CHMP adopted a list of questions with a specific timetable.

Notification: 27.05.2021

Start of the procedure (CHMP): June 2021 CHMP

List of questions: 24.06.2021

Submission of responses: 26.08.2021

Re-start of the procedure: 16.09.2021

Rapporteur/co-rapporteur assessment reports circulated to CHMP: 24.09.2021

Comments: 01.10.2021

Updated Rapporteur/co-rapporteur assessment reports circulated to CHMP: 07.10.2021

CHMP list of outstanding issues/CHMP opinion: October 2021 CHMP

## **10.7. Re-examination Procedure under Article 32(4) of Directive 2001/83/EC**

No items

## **10.8. Procedure under Article 107(2) of Directive 2001/83/EC**

No items

**10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003**

No items

**10.10. Procedure under Article 29 of Regulation (EC) 1901/2006**

No items

**10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008**

No items

## **11. Pharmacovigilance issue**

**11.1. Early Notification System**

June 2021 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

**Action:** For information

The CHMP noted the information.

## **12. Inspections**

**12.1. GMP inspections**

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

**12.2. GCP inspections**

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

**12.3. Pharmacovigilance inspections**

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

#### **12.4. GLP inspections**

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

### **13. Innovation Task Force**

#### **13.1. Minutes of Innovation Task Force**

No items

#### **13.2. Innovation Task Force briefing meetings**

No items

#### **13.3. Requests for CHMP Opinion under Article 57(1)J and (1)P of Regulation (EC) No 726/2004**

No items

#### **13.4. Nanomedicines activities**

No items

### **14. Organisational, regulatory and methodological matters**

#### **14.1. Mandate and organisation of the CHMP**

No items

#### **14.2. Coordination with EMA Scientific Committees**

##### **14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)**

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for June 2021

**Action:** For adoption

The CHMP adopted the EURD list.

## 14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

### 14.3.1. Biologics Working Party (BWP)

---

Chair: Sol Ruiz/Nanna Aaby Kruse

Reports from BWP June 2021 meeting to CHMP for adoption:

- 20 reports on products in scientific advice and protocol assistance
- 14 reports on products in pre-authorisation procedures
- 5 reports on products in plasma master file

**Action:** For adoption

The CHMP adopted the BWP reports.

### 14.3.2. Infectious Diseases Working Party (IDWP)

---

Call for nominations for IDWP Chair.

The mandate of the IDWP chair Maria Jesús Fernández Cortizo expired in November 2020. Nominations should be sent by 8 July 2021. Candidates are kindly asked to submit a brief CV in support of their candidature together with a cover letter highlighting their expertise. The election is scheduled at the July CHMP Plenary meeting.

**Action:** For information

The CHMP noted the call for nominations for the IDWP chair.

### 14.3.3. Name Review Group (NRG)

---

Table of Decisions of the NRG meeting held on 26-27 May 2021.

**Action:** For adoption

The CHMP adopted the table of decisions.

### 14.3.4. Scientific Advice Working Party (SAWP)

---

Chair: Anja Schiel

Report from the SAWP meeting held on 07-10 June 2021. Table of conclusions

**Action:** For information

The CHMP noted the report.

Scientific advice letters:

Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.

#### 14.3.5. Ad-hoc Influenza Working Group

---

Scope: EU Strain selection for the Influenza Vaccines for the Season 2021/2022: Updated Report from the Ad Hoc Influenza working group to the BWP

**Action:** For adoption

The CHMP adopted the updated report.

Scope: Updated EU Recommendation for the Seasonal Influenza Vaccine Composition for the Season 2021/2022

**Action:** For adoption

The CHMP adopted the updated EU recommendation.

#### 14.4. Cooperation within the EU regulatory network

No items

#### 14.5. Cooperation with International Regulators

No items

#### 14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

No items

#### 14.7. CHMP work plan

No items

#### 14.8. Planning and reporting

No items

#### 14.9. Others

No items

## 15. Any other business

### 15.1. AOB topic

#### 15.1.1. Update on COVID-19

---

**Action:** For information

The CHMP noted the information.

#### 15.1.2. Procedural guidance for variation for variant update to covid-19 vaccines

---

Final procedural guidance for variation for variant update to covid-19 vaccines.

**Action:** For adoption

The CHMP adopted the procedural guidance.

#### 15.1.3. etesivimab – EMEA/H/C/005837/0000

---

treatment of COVID-19

Scope: Rolling review 3<sup>rd</sup> interim opinion

Rolling review 3<sup>rd</sup> interim opinion was adopted at an extraordinary meeting held remotely on 28 May 2021.

**Action:** For information

The CHMP noted the RR 3<sup>rd</sup> interim opinion, which was adopted by consensus at an extraordinary CHMP meeting held remotely on 28 May 2021.

#### 15.1.4. bamlanivimab – EMEA/H/C/005836/0000

---

treatment of COVID-19

Scope: Rolling review 3<sup>rd</sup> interim opinion

Rolling review 3<sup>rd</sup> interim opinion was adopted at an extraordinary meeting held remotely on 28 May 2021.

**Action:** For information

The CHMP noted the RR 3<sup>rd</sup> interim opinion, which was adopted by consensus at an extraordinary CHMP meeting held remotely on 28 May 2021.

#### 15.1.5. COVID-19 vaccine (NVX-CoV2373) – EMEA/H/C/005808

---

prevention of COVID-19

Scope: Interim opinion and overview for the rolling review 2 adopted via written procedure on 14 June 2021



**Action:** For information

The CHMP noted the RR interim opinion, which was adopted via written procedure.

#### 15.1.6. [regdanvimab – EMEA/H/C/005854](#)

---

treatment of COVID-19

Scope: Interim opinion adopted via written procedure on 11 June 2021

**Action:** For information

The CHMP noted the RR interim opinion, which was adopted via written procedure.

#### 15.1.7. [Spikevax - COVID-19 mRNA Vaccine \(nucleoside-modified\) – EMEA/H/C/005791/II/0021](#)

---

Moderna Biotech Spain, S.L.; extension of indication to include use in adolescents 12 to 17 years of age for COVID-19 vaccine

Scope: Timetable adopted via written procedure on 9 June 2021.

**Action:** For information

The CHMP noted the RR timetable, which was adopted via written procedure.

## Lists of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 21-24 June 2021 CHMP meeting.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphia	Alternate	Austria	No interests declared	
Christophe Focke	Member	Belgium	No restrictions applicable to this meeting	
Karin Janssen van Doorn	Alternate	Belgium	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Kirstine Moll Harboe	Alternate	Denmark	No interests declared	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähtenvuo	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantinos Markopoulos	Member	Greece	No interests declared	
Eleftheria Nikolaidi	Alternate	Greece	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Alternate	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	
Peter Kiely	Alternate	Ireland	No interests declared	
Armando Genazzani	Member	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Romaldas Mačiulaitis	Member	Lithuania	No participation in final deliberations and voting on	COVID-19 vaccines
Martine Trauffer	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Helen Vella	Alternate	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Bjorg Bolstad	Member	Norway	No restrictions applicable to this meeting	
Ingrid Wang	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Francisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No participation in discussions, final deliberations and voting on	Nuwiq - simoctocog alfa EMA/H/C/002813/X/0042  Ad-hoc assessment of the therapeutic effect of monoethyl fumarate salts within Fumaderm
Nevenka Trsinar Brodt	Alternate	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Kristina Dunder	Member	Sweden	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No restrictions applicable to this meeting	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Mark Ainsworth	Expert - via Webex *	Denmark	No interests declared	
Tina Visholm Jensen	Expert - via Webex*	Denmark	No interests declared	
Christina Højelse	Expert - via Webex*	Denmark	No restrictions applicable to this meeting	
Juha-Matti Juntunen	Expert - via Webex*	Finland	No interests declared	
Steen W Hansen	Expert - via Webex*	Denmark	No restrictions applicable to this meeting	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Bruno Delafont	Expert - via Webex*	France	no part in discussions, final deliberations and voting on	Vaxzevria – COVID 19 Vaccine (ChAdOx1 S [recombinant]) – II/20/G II/21/G  Brilique - ticagrelor - II/49  WS1941 Edistrade / Forxiga  Nucala - mepolizumab II/0035 II/0036/G II/0037
Muriel Uzzan	Expert - via Webex*	France	No interests declared	
Irene Bachmann	Expert - via Webex*	Germany	No interests declared	
Sabine Mayrhofer	Expert - via Webex*	Germany	No interests declared	
Nora Cascante Estepa	Expert - via Webex*	Germany	No interests declared	
Sandrine CHIAPPINI	Expert - via Webex*	France	No interests declared	
Sophie Teng	Expert - via Webex*	France	No interests declared	
Norontsoa Rasolondramanitra	Expert - via Webex*	France	No interests declared	
Elena Wolff-Holz	Expert - via Webex*	Germany	No interests declared	
Anna Vikerfors	Expert - via Webex*	Sweden	No interests declared	
Olga Kholmanskikh	Expert - via Webex*	Belgium	No interests declared	
Alexandru Mihail Simion	Expert - via Webex*	Belgium	No restrictions applicable to this meeting	
Edwige Haelterman Brenneisen	Expert - via Webex*	Belgium	No interests declared	
Violette Dirix	Expert - via Webex*	Belgium	No interests declared	
Valerie Lescrainier	Expert - via Webex*	Belgium	No interests declared	
Roberta Agius	Expert - via Webex*	Malta	No interests declared	
Miriam Bartolo	Expert - via Webex*	Malta	No restrictions applicable to this meeting	
Paula Cardona Xuereb	Expert - via Webex*	Malta	No interests declared	
Robert Nistico	Expert - via Webex*	Malta	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Kairi Rooma	Expert - via Webex*	Estonia	No interests declared	
Brigitte Mueller	Expert - via Webex*	Austria	No interests declared	
Harald Bernsteiner	Expert - via Webex*	Austria	No interests declared	
Elisabeth Wischnitzki	Expert - via Webex*	Austria	No interests declared	
Karl Katholnig	Expert - via Webex*	Austria	No restrictions applicable to this meeting	
Elina Asikanius	Expert - via Webex*	Finland	No restrictions applicable to this meeting	
Geraldine O'Dea	Expert - via Webex*	Ireland	No interests declared	
Larissa Higgins	Expert - via Webex*	Ireland	No interests declared	
Nicolas Lee	Expert - via Webex*	Ireland	No restrictions applicable to this meeting	
Maria Victoria Tudanca Pacios	Expert - via Webex*	Spain	No restrictions applicable to this meeting	
Conception Gimenez Rebollo	Expert - via Webex*	Spain	No part in final deliberations and voting on	Repatha - evolocumab - II/49/G WS1941 Edistrade /Forxiga
Macarena Gajardo	Expert - via Webex*	Spain	No interests declared	
Alicia Pérez González	Expert - via Webex*	Spain	No interests declared	
Maria Chamorro Somoza Díaz-Sarmiento	Expert - via Webex*	Spain	No interests declared	
Ana Sagredo	Expert - via Webex*	Spain	No interests declared	
Marcos Timón	Expert - via Webex*	Spain	No interests declared	
Carmen Susana Rojo	Expert - via Webex*	Spain	No interests declared	
Susanna Hausmann	Expert - via Webex*	Germany	No interests declared	
Julian Paesler	Expert - via Webex*	Germany	No interests declared	
Hinke Johanna Van der Woude	Expert - via Webex*	Netherlands	No interests declared	
Nynke Brouwer	Expert - via Webex*	Netherlands	No interests declared	
Louise Claessen	Expert - via Webex*	Netherlands	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Joke Dols	Expert - via Webex*	Netherlands	No interests declared	
Laura Rodwell	Expert - via Webex*	Netherlands	No interests declared	
Nienke Rodenhuis	Expert - via Webex*	Netherlands	No interests declared	
Johannes Petrus Theodorus Span	Expert - via Webex*	Netherlands	No interests declared	
Wilhelm Johan de Waard	Expert - via Webex*	Netherlands	No interests declared	
Patrick Vrijlandt	Expert - via Webex*	Netherlands	No interests declared	
Isabell Hoffmann	Expert - via Webex*	Germany	No interests declared	
Susanne Mueller-Egert	Expert - via Webex*	Germany	No interests declared	
Hilke Zander	Expert - via Webex*	Germany	No interests declared	
Annette Lommel	Expert - via Webex*	Germany	No interests declared	
Bettina Kartmann	Expert - via Webex*	Germany	No interests declared	
Mette Linnert Jensen	Expert - via Webex*	Denmark	No interests declared	
Kristin Skougaard	Expert - via Webex*	Denmark	No interests declared	
Anne-Marie Dalseg	Expert - via Webex*	Denmark	No interests declared	
Kristina Bech Jensen	Expert - via Webex*	Denmark	No interests declared	
Susanne Høpner Rasmussen	Expert - via Webex*	Denmark	No restrictions applicable to this meeting	
Nanna Borup Johansen	Expert - via Webex*	Denmark	No interests declared	
Sine Buhl Naess-Schmidt	Expert - via Webex*	Denmark	No restrictions applicable to this meeting	
Ebru Karakoc Madsen	Expert - via Webex*	Denmark	No restrictions applicable to this meeting	
Anne Hasle Buur	Expert - via Webex*	Denmark	No interests declared	
Mette Toftegaard Madsen	Expert - via Webex*	Denmark	No interests declared	
Lene Weber Vestermark	Expert - via Webex*	Denmark	No interests declared	
Maria Grazia Evandri	Expert - via Webex*	Italy	No interests declared	
Cristina Migali	Expert - via Webex*	Italy	No interests declared	
Antonella Isgrò	Expert - via Webex*	Italy	No interests declared	

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Gabriella Passacquale	Expert - via Webex*	Italy	No interests declared	
Sara Galluzzo	Expert - via Webex*	Italy	No interests declared	
Francesca Galeotti	Expert - via Webex*	Italy	No restrictions applicable to this meeting	
Svetlana Lorenzano	Expert - via Webex*	Italy	No restrictions applicable to this meeting	
Fabrice Eroukhmanoff	Expert - via Webex*	Norway	No restrictions applicable to this meeting	
Lars Peter Engeset Austdal	Expert - via Webex*	Norway	No interests declared	
Marianne Loiten Dalhus	Expert - via Webex*	Norway	No interests declared	
Emmely de Vries	Expert - via Webex*	Netherlands	No interests declared	
Esther Brandon	Expert - via Webex*	Netherlands	No interests declared	
Peter Theunissen	Expert - via Webex*	Netherlands	No interests declared	
Deirdre Mannion	Expert - via Webex*	Denmark	No restrictions applicable to this meeting	
Loes den Otter	Expert - via Webex*	Netherlands	No interests declared	
Elisabeth Johanne Rook	Expert - via Webex*	Netherlands	No interests declared	
Helen Blok	Expert - via Webex*	Netherlands	No interests declared	
Anna Mari Lone	Expert - via Webex*	Norway	No restrictions applicable to this meeting	
Martina Schuessler-Lenz	Expert - via Webex*	Germany	No interests declared	
Rune Kjeklen	Expert - via Webex*	Norway	No restrictions applicable to this meeting	
Inger Mulder-van Dam	Expert - via Webex*	Netherlands	No interests declared	
Linda Trauffler	Expert - via Webex*	Austria	No interests declared	
Jean-Michel Dogné	Expert - via Webex*	Belgium	No interests declared	



Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Louise Frederikke Swaffield Bang-Lauritsen	Expert - via Webex*	Denmark	No interests declared	
Karen Van Malderen	Expert - via Webex*	Belgium	No interests declared	
Jan Willem van der Laan	Expert - via Webex*	Netherlands	No interests declared	
Anja Schiel	Expert - via Webex*	Norway	No interests declared	
Filip Kukulski	Expert - via Webex*	Health Canada	No interests declared	
Rolando Barbaro Dominguez Morales	Expert - via Webex*	WHO	No interests declared	
Charlotte Geluk	Expert - via Webex*	Swissmedic	No interests declared	
Meeting run with the help of EMA staff				

\*Experts were evaluated against the product(s) they have been invited to talk about

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the extraordinary CHMP meeting held on 28 May 2021.

Name	Role	Member State or affiliation	Outcome restriction following evaluation of e-DoI	Topics on agenda for which restrictions apply
Harald Enzmann	Chair	Germany	No interests declared	
Andrea Laslop	Member	Austria	No interests declared	
Daniela Philadelphia	Alternate	Austria	No interests declared	
Ilko Getov	Member	Bulgaria	No interests declared	
Margareta Bego	Member	Croatia	No interests declared	
Selma Arapovic Dzakula	Alternate	Croatia	No interests declared	
Helena Panayiotopoulou	Member	Cyprus	No interests declared	
Ondřej Slanař	Member	Czechia	No restrictions applicable to this meeting	
Tomas Radimersky	Alternate	Czechia	No interests declared	
Sinan B. Sarac	Member	Denmark	No interests declared	
Kirstine Moll Harboe	Alternate	Denmark	No interests declared	
Alar Irs	Member	Estonia	No restrictions applicable to this meeting	
Edward Laane	Alternate	Estonia	No restrictions applicable to this meeting	
Outi Mäki-Ikola	Member	Finland	No restrictions applicable to this meeting	
Johanna Lähteenvuori	Alternate	Finland	No interests declared	
Alexandre Moreau	Member	France	No interests declared	
Jean-Michel Race	Alternate	France	No interests declared	
Martina Weise	Member	Germany	No restrictions applicable to this meeting	
Janet Koenig	Alternate	Germany	No interests declared	
Konstantinos Markopoulos	Member	Greece	No interests declared	
Eleftheria Nikolaidi	Alternate	Greece	No interests declared	
Agnes Gyurasics	Alternate	Hungary	No interests declared	
Hrefna Gudmundsdottir	Alternate	Iceland	No interests declared	
Jayne Crowe	Member	Ireland	No interests declared	

Armando Genazzani	Member	Italy	No interests declared	
Elita Poplavska	Member	Latvia	No interests declared	
Simona Stankeviciute	Alternate	Lithuania	No interests declared	
Martine Trauffler	Member	Luxembourg	No interests declared	
John Joseph Borg	Member	Malta	No interests declared	
Johann Lodewijk Hillege	Member	Netherlands	No interests declared	
Paula Boudewina van Hennik	Alternate	Netherlands	No interests declared	
Bjorg Bolstad	Member	Norway	No restrictions applicable to this meeting	
Ingrid Wang	Alternate	Norway	No interests declared	
Ewa Balkowiec Iskra	Member	Poland	No interests declared	
Bruno Sepodes	Member (Vice-Chair)	Portugal	No interests declared	
Fatima Ventura	Alternate	Portugal	No participation in final deliberations and voting on	COVID-19 vaccines
Simona Badoi	Member	Romania	No interests declared	
Dana Gabriela Marin	Alternate	Romania	No interests declared	
Francisek Drafi	Member	Slovakia	No interests declared	
Dorota Distlerova	Alternate	Slovakia	No restrictions applicable to this meeting	
Nevenka Trsinar Brodt	Alternate	Slovenia	No interests declared	
Maria Concepcion Prieto Yerro	Member	Spain	No interests declared	
Blanca Garcia-Ochoa	Alternate	Spain	No interests declared	
Filip Josephson	Alternate	Sweden	No interests declared	
Christian Gartner	Co-opted member	Austria	No restrictions applicable to this meeting	
Carla Torre	Co-opted member	Portugal	No interests declared	
Jan Mueller-Berghaus	Co-opted member	Germany	No interests declared	
Blanka Hirschlerova	Co-opted member	Czechia	No interests declared	
Sol Ruiz	Co-opted member	Spain	No interests declared	
Helena Faust	Expert - via Webex*	Sweden	No interests declared	
Helena Back	Expert - via Webex*	Sweden	No interests declared	
Jessica Mwinyi	Expert - via Webex*	Sweden	No interests declared	

Charlotta Bergquist	Expert - via Webex*	Sweden	No interests declared	
Brigitte Mueller	Expert - via Webex*	Austria	No interests declared	
Andreas Kirisits	Expert - via Webex*	Austria	No interests declared	
Harald Bernsteiner	Expert - via Webex*	Austria	No interests declared	
Irene Bachmann	Expert - via Webex*	Germany	No interests declared	
Jana Klimasová	Expert - via Webex*	Slovakia	No restrictions applicable to this meeting	
Maria Victoria Tudanca Pacios	Expert - via Webex*	Spain	No restrictions applicable to this meeting	
Alicia Pérez González	Expert - via Webex*	Spain	No interests declared	
Svein Rune Andersen	Expert - via Webex*	Norway	No interests declared	
Nanna Borup Johansen	Expert - via Webex*	Denmark	No interests declared	
Marianne Orholm	Expert - via Webex*	Denmark	No interests declared	
Heidi Meyer	Expert - via Webex*	Germany	No interests declared	
Annette Lommel	Expert - via Webex*	Germany	No interests declared	
Nora Cascante Estepa	Expert - via Webex*	Germany	No interests declared	
Valerie Lescrainier	Expert - via Webex*	Belgium	No interests declared	
Kairi Rooma	Expert - via Webex*	Estonia	No interests declared	
Karl Zimmermann	Expert - via Webex*	Germany	No interests declared	
Anja Schmidt	Expert - via Webex*	Germany	No interests declared	
Steffen Gross	Expert - via Webex*	Germany	No interests declared	
Katja Findeisen	Expert - via Webex*	Germany	No restrictions applicable to this meeting	
Menno van der Elst	Expert - via Webex*	Netherlands	No interests declared	
Sabine Straus	Expert - via Webex*	Germany	No interests declared	
Ulla Wändel Liminga	Expert - via Webex*	Sweden	No interests declared	
Isabelle Parent Du Chatelet	Expert - via Webex*	France	No interests declared	
Celine Chartier	Expert - via Webex*	France	No interests declared	
Alexis Jacquet	Expert - via Webex*	France	No restrictions applicable to this meeting	
Adriana Ammassari	Expert - via Webex*	Italy	No interests declared	
Anja Schiel	Expert - via Webex*	Norway	No interests declared	
Sara Galluzzo	Expert - via Webex*	Italy	No interests declared	

Rolando Barbaro Dominguez Morales	Expert - via Webex*	WHO	No interests declared	
Ting Lu	Expert - via Webex*	Health Australia	No interests declared	
Meeting run with the help of EMA staff				

\*Experts were evaluated against the product(s) they have been invited to talk about

Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.

## Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

### Oral explanations (section 2)

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

### Initial applications (section 3)

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.

### Extension of marketing authorisations according to Annex I of Reg. 1234/2008 (section 4)

Extensions of marketing authorisations are applications for the change or addition of new strengths,

formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

### **Type II variations - Extension of indication procedures** *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

### **Ancillary medicinal substances in medical devices** *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

### **Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004** *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

### **Re-examination procedures** *(section 5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

### **Withdrawal of application** *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

### **Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use)** *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

### **Pre-submission issues** *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

### **Post-authorisation issues** *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

### **Referral procedures** *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a

particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found [here](#).

#### **Pharmacovigilance issues** (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

#### **Inspections Issues** (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

#### **Innovation task force** (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found [here](#).

#### **Scientific advice working party (SAWP)** (section 14.3.1)

This section refers to the monthly report from the CHMP's Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found [here](#).

#### **Satellite groups / other committees** (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

#### **Invented name issues** (section 14.3)

This section lists issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group's main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found [here](#).

More detailed information on the above terms can be found on the EMA website: [www.ema.europa.eu/](http://www.ema.europa.eu/)





EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

09 August 2021  
EMA/CHMP/439472/2021

## Annex to 21-24 June 2021 CHMP Minutes

### Pre-submission and post-authorisations issues

<b>A. PRE-SUBMISSION ISSUES .....</b>	<b>3</b>
A.1. ELIGIBILITY REQUESTS.....	3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications .....	3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION .....	3
<b>B. POST-AUTHORISATION PROCEDURES OUTCOMES .....</b>	<b>3</b>
B.1. Annual re-assessment outcomes.....	3
B.1.1. Annual reassessment for products authorised under exceptional circumstances .....	3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES .....	3
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal .....	3
B.2.2. Renewals of Marketing Authorisations for unlimited validity .....	3
B.2.3. Renewals of Conditional Marketing Authorisations .....	6
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES .....	7
B.4. EPARs / WPARs .....	12
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES .....	13
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects .....	13
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects .....	20
B.5.3. CHMP-PRAC assessed procedures.....	34
B.5.4. PRAC assessed procedures.....	46
B.5.5. CHMP-CAT assessed procedures .....	54
B.5.6. CHMP-PRAC-CAT assessed procedures.....	54
B.5.7. PRAC assessed ATMP procedures .....	54
B.5.8. Unclassified procedures and worksharing procedures of type I variations .....	54
B.5.9. Information on withdrawn type II variation / WS procedure .....	58
B.5.10. Information on type II variation / WS procedure with revised timetable .....	58
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION .....	58
B.6.1. Start of procedure for New Applications: timetables for information .....	58
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information .....	59



B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information .....	60
B.6.4. Annual Re-assessments: timetables for adoption.....	62
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed .....	62
B.6.6. VARIATIONS – START OF THE PROCEDURE .....	64
B.6.7. Type II Variations scope of the Variations: Extension of indication .....	64
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects .....	66
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects.....	68
B.6.10. CHMP-PRAC assessed procedures.....	73
B.6.11. PRAC assessed procedures .....	76
B.6.12. CHMP-CAT assessed procedures.....	77
B.6.13. CHMP-PRAC-CAT assessed procedures .....	78
B.6.14. PRAC assessed ATMP procedures.....	78
B.6.15. Unclassified procedures and worksharing procedures of type I variations .....	78
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY .....	79
B.7.1. Yearly Line listing for Type I and II variations .....	79
B.7.2. Monthly Line listing for Type I variations .....	79
B.7.3. Opinion on Marketing Authorisation transfer (MMD only) .....	79
B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only) .....	79
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only) .....	79
B.7.6. Notifications of Type I Variations (MMD only).....	79
<b>C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled) .....</b>	<b>79</b>
<b>D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed) .....</b>	<b>79</b>
<b>E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES .....</b>	<b>79</b>
E.1. PMF Certification Dossiers .....	79
E.1.1. Annual Update .....	79
E.1.2. Variations .....	79
E.1.3. Initial PMF Certification .....	79
E.2. Time Tables – starting & ongoing procedures: For information .....	79
<b>F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver ....</b>	<b>80</b>
<b>G. ANNEX G.....</b>	<b>80</b>
G.1. Final Scientific Advice (Reports and Scientific Advice letters): .....	80
G.2. PRIME .....	80
G.2.1. List of procedures concluding at 21-24 June 2021 CHMP plenary: .....	80
G.2.2. List of procedures starting in June 2021 for July 2021 CHMP adoption of outcomes .....	80
<b>H. ANNEX H - Product Shared Mailboxes – e-mail address .....</b>	<b>80</b>

## A. PRE-SUBMISSION ISSUES

### A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for June 2021: <b>For adoption</b>	Adopted
---	---------

### A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for June 2021: <b>For adoption</b>	Adopted
---	---------

### A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

## B. POST-AUTHORISATION PROCEDURES OUTCOMES

### B.1. Annual re-assessment outcomes

#### B.1.1. Annual reassessment for products authorised under exceptional circumstances

<b>Evoltra - clofarabine -</b> <b>EMA/H/C/000613/S/0072</b> Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant	Positive Opinion adopted by consensus together with the CHMP assessment report.  The Marketing Authorisation remains under exceptional circumstances.  The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.
<b>Lamzede - velmanase alfa -</b> <b>EMA/H/C/003922/S/0019, Orphan</b> Chiesi Farmaceutici S.p.A., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jan Neuhauser	Positive Opinion adopted by consensus together with the CHMP assessment report.  The Marketing Authorisation remains under exceptional circumstances.  The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.

### B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

#### B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

#### B.2.2. Renewals of Marketing Authorisations for unlimited validity

<b>Afstyla - lonoctocog alfa -</b>	Positive Opinion adopted by consensus together
------------------------------------	--

<p><b>EMA/H/C/004075/R/0037</b>  CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Johanna Lähtenvuo, PRAC Rapporteur: Sonja Hrabcik</p>	<p>with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p><b>Darunavir Mylan - darunavir - EMA/H/C/004068/R/0014</b>  Mylan S.A.S, Generic, Generic of Prezista, Rapporteur: John Joseph Borg, PRAC Rapporteur: Liana Gross-Martirosyan  Request for Supplementary Information adopted on 24.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Emtricitabine/Tenofovir disoproxil Krka - emtricitabine / tenofovir disoproxil - EMA/H/C/004215/R/0018</b>  KRKA, d.d., Novo mesto, Generic, Generic of Truvada, Rapporteur: John Joseph Borg, PRAC Rapporteur: Ana Sofia Diniz Martins  Request for Supplementary Information adopted on 24.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Emtricitabine/Tenofovir disoproxil Mylan - emtricitabine / tenofovir disoproxil - EMA/H/C/004050/R/0016</b>  Mylan S.A.S, Generic, Generic of Truvada, Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Ana Sofia Diniz Martins  Request for Supplementary Information adopted on 24.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Fiasp - insulin aspart - EMA/H/C/004046/R/0028</b>  Novo Nordisk A/S, Rapporteur: Kristina Dunder, Co-Rapporteur: Ingrid Wang, PRAC Rapporteur: Annika Folin</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p><b>Granpidam - sildenafil - EMA/H/C/004289/R/0009</b>  Accord Healthcare S.L.U., Generic, Generic of Revatio, Rapporteur: Kolbeinn Gudmundsson, PRAC Rapporteur: Menno van der Elst</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can</p>

	<p>be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p><b>Inhixa - enoxaparin sodium - EMEA/H/C/004264/R/0076</b></p> <p>Techdow Pharma Netherlands B.V., Duplicate, Duplicate of Thorinane (EXP), Rapporteur: Andrea Laslop, Co-Rapporteur: Peter Kiely, PRAC Rapporteur: Menno van der Elst</p> <p>Request for Supplementary Information adopted on 22.04.2021.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p><b>Movymia - teriparatide - EMEA/H/C/004368/R/0024</b></p> <p>STADA Arzneimittel AG, Duplicate, Duplicate of Terrosa, Rapporteur: Daniela Philadelphia, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ronan Grimes</p> <p>Request for Supplementary Information adopted on 24.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Olumiant - baricitinib - EMEA/H/C/004085/R/0025</b></p> <p>Eli Lilly Nederland B.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Christophe Focke, PRAC Rapporteur: Adam Przybylkowski</p> <p>Request for Supplementary Information adopted on 24.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Parsabiv - etelcalcetide - EMEA/H/C/003995/R/0017</b></p> <p>Amgen Europe B.V., Rapporteur: Johann Lodewijk Hillege, Co-Rapporteur: Andrea Laslop (AT) (MNAT with AT for Non-Clinical, AT for Clinical Efficacy, AT for Coordination, AT for Clinical Safety, AT for Clinical Pharmacology, DE-BfArM for Quality), PRAC Rapporteur: Ilaria Baldelli</p> <p>Request for Supplementary Information adopted on 24.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>SomaKit TOC - edotreotide - EMEA/H/C/004140/R/0019, Orphan</b></p> <p>Advanced Accelerator Applications, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Ronan Grimes</p> <p>Request for Supplementary Information adopted on 24.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>

<p><b>Tenofovir disoproxil Mylan - tenofovir disoproxil - EMEA/H/C/004049/R/0022</b></p> <p>Mylan S.A.S, Generic, Generic of Viread, Rapporteur: Romaldas Mačiulaitis, PRAC Rapporteur: Adrien Inoubli Request for Supplementary Information adopted on 24.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Terrosa - teriparatide - EMEA/H/C/003916/R/0020</b></p> <p>Gedeon Richter Plc., Rapporteur: Daniela Philadelphy, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Ronan Grimes Request for Supplementary Information adopted on 24.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>

### B.2.3. Renewals of Conditional Marketing Authorisations

<p><b>Adakveo - crizanlizumab - EMEA/H/C/004874/R/0003, Orphan</b></p> <p>Novartis Europharm Limited, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Laurence de Fays Request for Supplementary Information adopted on 24.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Hepcludex - bulevirtide - EMEA/H/C/004854/R/0003, Orphan</b></p> <p>MYR GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Adam Przybylkowski Request for Supplementary Information adopted on 22.04.2021.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report.</p> <p>The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.</p> <p>The Marketing Authorisation remains conditional.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>
<p><b>VITRAKVI - larotrectinib - EMEA/H/C/004919/R/0014</b></p> <p>Bayer AG, Rapporteur: Filip Josephson, PRAC Rapporteur: Rugile Pilviniene Request for Supplementary Information adopted on 20.05.2021.</p>	<p>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</p> <p>The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.</p> <p>The Marketing Authorisation remains conditional.</p> <p>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</p>

### B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

---

#### Signal detection

PRAC recommendations on signals adopted at the PRAC meeting held on 07-10 June 2021  
PRAC:

---

#### Signal of capillary leak syndrome

Noted

Vaxzevria - COVID-19 Vaccine (ChAdOx1-S [recombinant])

Rapporteur: Sol Ruiz, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Jean-Michel Dogné

PRAC recommendation on a variation, DHPC, Communication plan; adopted via written procedure on Monday 14 June 2021

**Action:** For information

---

#### Signal of major adverse cardiovascular events (MACE) and malignancies excluding non-melanoma skin cancer (NMSC) from a clinical trial

Adopted

Xeljanz - tofacitinib

Rapporteur: Armando Genazzani, Co-Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Liana Gross-Martirosyan  
PRAC recommendation on a variation / DHPC

**Action:** For adoption

---

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its June 2021 meeting:

---

#### EMA/H/C/PSUSA/00002480/202010

(posaconazole)

CAPS:

**Noxafil** (EMA/H/C/000610) (posaconazole), Merck Sharp & Dohme B.V., Rapporteur: Alexandre Moreau

NAPS:

**NAPs** - EU

PRAC Rapporteur: Adrien Inoubli, "10/07/2019 To: 25/10/2020"

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance, concerning the following change(s):

Update of section 4.5 of the SmPC to add wording on the interaction between posaconazole and all-trans retinoic acid (ATRA, or tretinoin), based on literature reports of hypercalcaemia occurring when posaconazole and ATRA were combined, highlighting the importance of monitoring ATRA's side effects

---

	<p>when used in combination with drugs inhibiting the cytochrome P450 enzymes.</p> <p>The package leaflet is updated accordingly.</p> <p>The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
<p><b>EMA/H/C/PSUSA/00002652/202011</b> (rituximab) CAPS: <b>Blitzima</b> (EMA/H/C/004723) (rituximab), Celltrion Healthcare Hungary Kft., Rapporteur: Sol Ruiz <b>MabThera</b> (EMA/H/C/000165) (rituximab), Roche Registration GmbH, Rapporteur: Sinan B. Sarac <b>Ritemvia (SRD)</b> (EMA/H/C/004725) (rituximab), Celltrion Healthcare Hungary Kft., Rapporteur: Sol Ruiz <b>Rixathon</b> (EMA/H/C/003903) (rituximab), Sandoz GmbH, Rapporteur: Jan Mueller-Berghaus <b>Riximyo</b> (EMA/H/C/004729) (rituximab), Sandoz GmbH, Rapporteur: Jan Mueller-Berghaus <b>Ruxience</b> (EMA/H/C/004696) (rituximab), Pfizer Europe MA EEIG, Rapporteur: Paula Boudewina van Hennik <b>Truxima</b> (EMA/H/C/004112) (rituximab), Celltrion Healthcare Hungary Kft., Rapporteur: Sol Ruiz, PRAC Rapporteur: Anette Kirstine Stark, "17/11/2019 To: 17/11/2020"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisations for the above mentioned medicinal products, concerning the following changes:</p> <p>Update of sections 4.4 and 4.6 of the SmPC to amend the existing warning on malignancy risk and to add information on breast-feeding. The package leaflet is updated accordingly.</p> <p>The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p> <p>Note: the MAH withdrew Ritemvia and the withdrawal CD was issued on 21.06.2021. Therefore, Ritemvia was not included anymore in the final CHMP opinion.</p>
<p><b>EMA/H/C/PSUSA/00002822/202009</b> (sulfur hexafluoride) CAPS: <b>SonoVue</b> (EMA/H/C/000303) (sulphur hexafluoride), Bracco International B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "30/09/2017 To: 30/09/2020"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.4 of the SmPC to amend the current warning regarding hypersensitivity reactions. The package leaflet is updated accordingly.</p> <p>The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
<p><b>EMA/H/C/PSUSA/00010133/202009</b> (regorafenib) CAPS:</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation</p>



---

**Stivarga** (EMA/H/C/002573) (regorafenib),  
Bayer AG, Rapporteur: Paula Boudewina van  
Hennik, PRAC Rapporteur: Menno van der Elst,  
"27/09/2017 To: 26/09/2020"

and the PRAC assessment report as appended,  
recommends by consensus, the variation to the  
terms of the marketing authorisation(s) for the  
above mentioned medicinal product(s),  
concerning the following change(s):  
Update of section 4.8 of the Summary of Product  
Characteristics (SmPC) to include Severe liver  
injury (including hepatic failure) under System  
Organ Class (SOC) Hepatobiliary disorders to the  
list of adverse drug reactions (ADRs). Section  
4.4 of the SmPC is also updated to add hepatic  
failure to the existing hepatic effects. The  
package leaflet is updated accordingly.  
The Icelandic and the Norwegian CHMP  
members agree with the above-mentioned  
recommendation of the CHMP.

---

**EMA/H/C/PSUSA/00010301/202011**  
(ibrutinib)  
CAPS:  
**Imbruva** (EMA/H/C/003791) (ibrutinib),  
Janssen-Cilag International NV, Rapporteur: Filip  
Josephson, PRAC Rapporteur: Nikica Mirošević  
Skvrce, "13/11/2019 To: 12/11/2020"

The CHMP, having considered in accordance with  
Article 28 of Regulation (EC) No 726/2004 the  
PSUR on the basis of the PRAC recommendation  
and the PRAC assessment report as appended,  
recommends by consensus, the variation to the  
terms of the marketing authorisation(s) for the  
above mentioned medicinal product(s),  
concerning the following change(s):  
Update of section 4.4 of the SmPC to add a  
warning on the assessment prior to treatment  
and monitoring of the liver function and viral  
hepatitis status.  
Update of section 4.8 of the SmPC to add the  
adverse reaction Eye haemorrhage with a  
frequency uncommon and addition of the  
information that in some cases loss of vision  
occurred.  
The package leaflet is updated accordingly.  
The Icelandic and the Norwegian CHMP  
members agree with the above-mentioned  
recommendation of the CHMP.

---

**EMA/H/C/PSUSA/00010319/202010**  
(nintedanib (respiratory indication))  
CAPS:  
**OFEV** (EMA/H/C/003821) (nintedanib),  
Boehringer Ingelheim International GmbH,  
Rapporteur: Peter Kiely, PRAC Rapporteur:  
Nikica Mirošević Skvrce, "15/04/2020 To:  
15/10/2020"

The CHMP, having considered in accordance with  
Article 28 of Regulation (EC) No 726/2004 the  
PSUR on the basis of the PRAC recommendation  
and the PRAC assessment report as appended,  
recommends by consensus, the variation to the  
terms of the marketing authorisation(s) for the  
above mentioned medicinal product(s),  
concerning the following change(s):  
Update of section 4.4 of the SmPC to add a  
warning on thrombotic microangiopathy. The  
package leaflet has been amended accordingly.  
The list of local representatives was also

---

	<p>updated.</p> <p>The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
<p><b>EMA/H/C/PSUSA/00010458/202011</b> (susoctocog alpha) CAPS: <b>Obizur</b> (EMA/H/C/002792) (susoctocog alfa), Baxalta Innovations GmbH, Rapporteur: Andrea Laslop, PRAC Rapporteur: Brigitte Keller-Stanislawski, "12/05/2020 To: 11/11/2020"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.4, 4.8 and 5.1 of the SmPC to highlight that the initial dosing below the recommended dose is associated with lack of efficacy, to strengthen the existing wording on inhibitors and to recommend testing for anti-rpFVIII antibodies prior to initiation of treatment. The package leaflet is updated accordingly.</p> <p>The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
<p><b>EMA/H/C/PSUSA/00010638/202010</b> (midostaurin) CAPS: <b>Rydapt</b> (EMA/H/C/004095) (midostaurin), Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "28/10/2019 To: 27/10/2020"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.4 of the SmPC to clarify the non-infectious aetiology of pneumonitis and of section 4.8 of the SmPC to add the adverse reactions Pneumonitis, Interstitial lung disease and Electrocardiogram QT prolonged. The package leaflet is updated accordingly.</p> <p>The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
<p><b>EMA/H/C/PSUSA/00010761/202011</b> (pegvaliase) CAPS: <b>Palynziq</b> (EMA/H/C/004744) (pegvaliase), BioMarin International Limited, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Rhea Fitzgerald, "22/05/2020 To: 22/11/2020"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of section 4.8 of the SmPC to add the</p>

	<p>adverse reaction dyspnoea with a frequency of 'common', the associated footnote should be updated accordingly. The package leaflet is updated accordingly.</p> <p>The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
<p><b>EMA/H/C/PSUSA/00010819/202010</b> (fostamatinib) CAPS: <b>Tavlesse</b> (EMA/H/C/005012) (fostamatinib), Instituto Grifols, S.A., Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Menno van der Elst, "16/04/2020 To: 16/10/2020"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.8 of the SmPC to add the adverse reaction headache with a frequency common. The package leaflet is updated accordingly.</p> <p>The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
<p><b>EMA/H/C/PSUSA/00010839/202011</b> (givosiran) CAPS: <b>GIVLAARI</b> (EMA/H/C/004775) (givosiran), Alnylam Netherlands B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Martin Huber, "18/05/2020 To: 18/11/2020"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.8 of the SmPC to add the adverse reaction pancreatitis with a frequency common. The package leaflet is to be updated accordingly.</p> <p>The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.</p>
<p><b>EMA/H/C/PSUSA/00010840/202011</b> (remdesivir) CAPS: <b>Veklury</b> (EMA/H/C/005622) (remdesivir), Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, PRAC Rapporteur: Eva Jirsová, "07/05/2020 To: 06/11/2020"</p>	<p>The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):</p> <p>Update of section 4.8 of the SmPC to add the adverse reaction of sinus bradycardia with a frequency of not known. The package leaflet is updated accordingly.</p>

	The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
<b>EMA/H/C/PSUSA/00010888/202011</b> (crizanlizumab) CAPS: <b>Adakveo</b> (EMA/H/C/004874) (crizanlizumab), Novartis Europharm Limited, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Laurence de Fays, "15/11/2019 To: 14/11/2020"	The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s): Update of sections 4.2, 4.4 and 4.8 of the SmPC to add recommendations for managing infusion-related reactions, to update the warning on infusion-related reactions and to add the adverse reaction 'severe pain in various locations occurring during infusion or within 24 hours of the infusion' with frequency not known. The package leaflet is updated accordingly. The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

#### B.4. EPARs / WPARs

<b>Bylvay - odevixibat - EMA/H/C/004691, Orphan</b> Albireo, treatment of progressive familial intrahepatic cholestasis (PFIC), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
<b>Icatibant Accord - icatibant - EMA/H/C/005083</b> Accord Healthcare S.L.U., treatment of hereditary angioedema, Generic, Generic of Firazyr, Generic application (Article 10(1) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
<b>IMCIVREE - setmelanotide - EMA/H/C/005089, Orphan</b> Rhythm Pharmaceuticals Limited, Treatment of obesity and the control of hunger associated with deficiencies in the leptin-melanocortin pathway, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
<b>Klisyri - tirbanibulin - EMA/H/C/005183</b> Almirall, S.A., topical field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis, New active substance (Article 8(3) of	For information only. Comments can be sent to the PL in case necessary.

---

Directive No 2001/83/EC)

---

<b>OZAWADE - pitolisant - EMEA/H/C/005117</b> BIOPROJET PHARMA, Treatment of Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnoea (OSA), New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
--	---

---

<b>Ryeqo - relugolix / estradiol / norethisterone acetate - EMEA/H/C/005267</b> Gedeon Richter Plc., treatment of uterine fibroids, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
---	---

---

<b>Skysona - elivaldogene autotemcel - EMEA/H/C/003690, Orphan, ATMP</b> bluebird bio (Netherlands) B.V, treatment of early cerebral adrenoleukodystrophy, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
--	---

---

<b>Verquvo - vericiguat - EMEA/H/C/005319</b> Bayer AG, treatment of symptomatic chronic heart failure, New active substance (Article 8(3) of Directive No 2001/83/EC)	For information only. Comments can be sent to the PL in case necessary.
---	---

---

## **B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES**

Scopes related to Chemistry, Manufacturing and Controls cannot be released at the present time as these contain commercially confidential information.

### **B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects**

---

<b>Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0088/G, Orphan</b> Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik Opinion adopted on 24.06.2021. Request for Supplementary Information adopted on 20.05.2021.	Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
--	---

---

<b>ADYNOVI - ruriotocog alfa pegol - EMEA/H/C/004195/II/0021/G</b> Baxalta Innovations GmbH, Rapporteur: Andrea Laslop Request for Supplementary Information adopted on 17.06.2021.	Request for supplementary information adopted with a specific timetable.
---	--

---

<b>Bemfola - follitropin alfa - EMEA/H/C/002615/II/0029</b> Gedeon Richter Plc., Rapporteur: Paula	Positive Opinion adopted by consensus on 28.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP
---	---

---

Boudewina van Hennik Opinion adopted on 28.05.2021.	recommendation.
<b>Benlysta - belimumab - EMA/H/C/002015/II/0094</b> GlaxoSmithKline (Ireland) Limited, Rapporteur: Kristina Dunder Opinion adopted on 03.06.2021.	Positive Opinion adopted by consensus on 03.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>Bridion - sugammadex - EMA/H/C/000885/II/0041/G</b> Merck Sharp & Dohme B.V., Rapporteur: Outi Mäki-Ikola Opinion adopted on 28.05.2021.	Positive Opinion adopted by consensus on 28.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>Briviact - brivaracetam - EMA/H/C/003898/II/0034/G</b> UCB Pharma S.A., Rapporteur: Filip Josephson Opinion adopted on 24.06.2021.	Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>COMIRNATY - covid-19 mRNA vaccine (nucleoside-modified) - EMA/H/C/005735/II/0033/G</b> BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 25.05.2021.	Positive Opinion adopted by consensus on 25.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>COMIRNATY - covid-19 mRNA vaccine (nucleoside-modified) - EMA/H/C/005735/II/0034</b> BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 28.05.2021.	Positive Opinion adopted by consensus on 28.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>COMIRNATY - covid-19 mRNA vaccine (nucleoside-modified) - EMA/H/C/005735/II/0035/G</b> BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 01.06.2021.	Positive Opinion adopted by consensus on 01.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>COMIRNATY - covid-19 mRNA vaccine (nucleoside-modified) - EMA/H/C/005735/II/0039/G</b> BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson Opinion adopted on 08.06.2021.	Positive Opinion adopted by consensus on 08.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>COVID-19 Vaccine Janssen - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMA/H/C/005737/II/0005</b> Janssen-Cilag International N.V., Rapporteur: Christophe Focke Opinion adopted on 24.06.2021.	Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

<b>Cyramza - ramucirumab -</b> <b>EMA/H/C/002829/II/0041</b> Eli Lilly Nederland B.V., Rapporteur: Paula Boudewina van Hennik Request for Supplementary Information adopted on 24.06.2021.	Request for supplementary information adopted with a specific timetable.
<b>Darzalex - daratumumab -</b> <b>EMA/H/C/004077/II/0048/G, Orphan</b> Janssen-Cilag International NV, Rapporteur: Sinan B. Sarac Opinion adopted on 24.06.2021. Request for Supplementary Information adopted on 20.05.2021.	Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>Empliciti - elotuzumab -</b> <b>EMA/H/C/003967/II/0026</b> Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Hennik Opinion adopted on 03.06.2021. Request for Supplementary Information adopted on 15.04.2021.	Positive Opinion adopted by consensus on 03.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>Hizentra - human normal immunoglobulin -</b> <b>EMA/H/C/002127/II/0128</b> CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 17.06.2021.	Request for supplementary information adopted with a specific timetable.
<b>Increlex - mecasermin -</b> <b>EMA/H/C/000704/II/0068/G</b> Ipsen Pharma, Rapporteur: Outi Mäki-Ikola Request for Supplementary Information adopted on 17.06.2021.	Request for supplementary information adopted with a specific timetable.
<b>Keytruda - pembrolizumab -</b> <b>EMA/H/C/003820/II/0106/G</b> Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani Opinion adopted on 28.05.2021.	Positive Opinion adopted by consensus on 28.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>Keytruda - pembrolizumab -</b> <b>EMA/H/C/003820/II/0107</b> Merck Sharp & Dohme B.V., Rapporteur: Armando Genazzani Opinion adopted on 03.06.2021.	Positive Opinion adopted by consensus on 03.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>Kineret - anakinra -</b> <b>EMA/H/C/000363/II/0084</b> Swedish Orphan Biovitrum AB (publ), Rapporteur: Kirstine Moll Harboe Opinion adopted on 17.06.2021.	Positive Opinion adopted by consensus on 17.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.



<p><b>Nepexto - etanercept -</b>  <b>EMA/H/C/004711/II/0002</b>  Mylan IRE Healthcare Limited, Rapporteur:  Martina Weise  Opinion adopted on 24.06.2021.  Request for Supplementary Information adopted  on 10.09.2020.</p>	<p>Positive Opinion adopted by consensus on  24.06.2021. The Icelandic and Norwegian CHMP  Members were in agreement with the CHMP  recommendation.</p>
<p><b>Nimenrix - meningococcal group A, C,  W135 and Y conjugate vaccine -</b>  <b>EMA/H/C/002226/II/0108/G</b>  Pfizer Europe MA EEIG, Rapporteur: Bjorg  Bolstad  Request for Supplementary Information adopted  on 17.06.2021.</p>	<p>Request for supplementary information adopted  with a specific timetable.</p>
<p><b>Nyvepria - pegfilgrastim -</b>  <b>EMA/H/C/005085/II/0002/G</b>  Pfizer Europe MA EEIG, Rapporteur: Ondřej  Slanař  Opinion adopted on 24.06.2021.</p>	<p>Positive Opinion adopted by consensus on  24.06.2021. The Icelandic and Norwegian CHMP  Members were in agreement with the CHMP  recommendation.</p>
<p><b>Ontruzant - trastuzumab -</b>  <b>EMA/H/C/004323/II/0032</b>  Samsung Bioepis NL B.V., Rapporteur: Karin  Janssen van Doorn  Request for Supplementary Information adopted  on 17.06.2021.</p>	<p>Request for supplementary information adopted  with a specific timetable.</p>
<p><b>Orfadin - nitisinone -</b>  <b>EMA/H/C/000555/II/0075</b>  Swedish Orphan Biovitrum International AB,  Rapporteur: Armando Genazzani  Opinion adopted on 28.05.2021.  Request for Supplementary Information adopted  on 28.01.2021.</p>	<p>Positive Opinion adopted by consensus on  28.05.2021. The Icelandic and Norwegian CHMP  Members were in agreement with the CHMP  recommendation.</p>
<p><b>Palynziq - pegvaliase -</b>  <b>EMA/H/C/004744/II/0019, Orphan</b>  BioMarin International Limited, Rapporteur:  Johann Lodewijk Hillege  Request for Supplementary Information adopted  on 17.06.2021.</p>	<p>Request for supplementary information adopted  with a specific timetable.</p>
<p><b>Pemetrexed Sandoz - pemetrexed -</b>  <b>EMA/H/C/004011/II/0011/G</b>  Sandoz GmbH, Generic, Generic of Alimta,  Rapporteur: Bjorg Bolstad  Request for Supplementary Information adopted  on 24.06.2021.</p>	<p>Request for supplementary information adopted  with a specific timetable.</p>
<p><b>ReFacto AF - moroctocog alfa -</b>  <b>EMA/H/C/000232/II/0158/G</b>  Pfizer Europe MA EEIG, Rapporteur: Kirstine</p>	<p>Request for supplementary information adopted  with a specific timetable.</p>



Moll Harboe Request for Supplementary Information adopted on 10.06.2021, 11.03.2021.	
<b>Remsima - infliximab -</b> <b>EMA/H/C/002576/II/0101/G</b> Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola Request for Supplementary Information adopted on 03.06.2021.	Request for supplementary information adopted with a specific timetable.
<b>Replagal - agalsidase alfa -</b> <b>EMA/H/C/000369/II/0112/G</b> Shire Human Genetic Therapies AB, Rapporteur: Johann Lodewijk Hillege Request for Supplementary Information adopted on 10.06.2021.	Request for supplementary information adopted with a specific timetable.
<b>Respreeza - human alpha1-proteinase</b> <b>inhibitor - EMA/H/C/002739/II/0053/G</b> CSL Behring GmbH, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 17.06.2021.	Request for supplementary information adopted with a specific timetable.
<b>SCENESSE - afamelanotide -</b> <b>EMA/H/C/002548/II/0037, Orphan</b> Clinuvel Europe Limited, Rapporteur: Janet Koenig Request for Supplementary Information adopted on 28.05.2021.	Request for supplementary information adopted with a specific timetable.
<b>Spikevax - COVID-19 mRNA Vaccine</b> <b>(nucleoside-modified) -</b> <b>EMA/H/C/005791/II/0013/G</b> Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 25.05.2021.	Positive Opinion adopted by consensus on 25.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>Spikevax - COVID-19 mRNA Vaccine</b> <b>(nucleoside-modified) -</b> <b>EMA/H/C/005791/II/0016/G</b> Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 04.06.2021.	Positive Opinion adopted by consensus on 04.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>Spikevax - COVID-19 mRNA Vaccine</b> <b>(nucleoside-modified) -</b> <b>EMA/H/C/005791/II/0018/G</b> Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus Opinion adopted on 11.06.2021.	Positive Opinion adopted by consensus on 11.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>TAKHZYRO - lanadelumab -</b>	Request for supplementary information adopted

<b>EMEA/H/C/004806/II/0021/G, Orphan</b> Shire Pharmaceuticals Ireland Limited, Rapporteur: Kristina Dunder Request for Supplementary Information adopted on 24.06.2021.	with a specific timetable.
<b>Tremfya - guselkumab -</b> <b>EMEA/H/C/004271/II/0029/G</b> Janssen-Cilag International N.V., Rapporteur: Agnes Gyurasics Request for Supplementary Information adopted on 24.06.2021.	Request for supplementary information adopted with a specific timetable.
<b>Ultomiris - ravulizumab -</b> <b>EMEA/H/C/004954/II/0015/G</b> Alexion Europe SAS, Rapporteur: Blanca Garcia- Ochoa Opinion adopted on 24.06.2021.	Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>Vaxelis - diphtheria, tetanus, pertussis</b> <b>(acellular, component), hepatitis B (rDNA),</b> <b>poliomyelitis (inact.) and Haemophilus</b> <b>type b conjugate vaccine (adsorbed) -</b> <b>EMEA/H/C/003982/II/0077</b> MCM Vaccine B.V., Rapporteur: Christophe Focke Opinion adopted on 28.05.2021.	Positive Opinion adopted by consensus on 28.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>Vaxelis - diphtheria, tetanus, pertussis</b> <b>(acellular, component), hepatitis B (rDNA),</b> <b>poliomyelitis (inact.) and Haemophilus</b> <b>type b conjugate vaccine (adsorbed) -</b> <b>EMEA/H/C/003982/II/0079</b> MCM Vaccine B.V., Rapporteur: Christophe Focke Opinion adopted on 17.06.2021.	Positive Opinion adopted by consensus on 17.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>Vaxzevria - COVID 19 Vaccine (ChAdOx1 S</b> <b>[recombinant]) -</b> <b>EMEA/H/C/005675/II/0016</b> AstraZeneca AB, Rapporteur: Sol Ruiz Opinion adopted on 27.05.2021. Request for Supplementary Information adopted on 12.05.2021.	Positive Opinion adopted by consensus on 27.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>Vaxzevria - COVID 19 Vaccine (ChAdOx1 S</b> <b>[recombinant]) -</b> <b>EMEA/H/C/005675/II/0020/G</b> AstraZeneca AB, Rapporteur: Sol Ruiz Opinion adopted on 22.06.2021. Request for Supplementary Information adopted on 08.06.2021.	Positive Opinion adopted by consensus on 22.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.  See 9.1
<b>Vaxzevria - COVID 19 Vaccine (ChAdOx1 S</b>	Request for supplementary information adopted

<b>[recombinant]] -</b> <b>EMA/H/C/005675/II/0021/G</b> AstraZeneca AB, Rapporteur: Sol Ruiz Request for Supplementary Information adopted on 24.06.2021.	with a specific timetable.  See 9.1
<b>Verkazia - ciclosporin -</b> <b>EMA/H/C/004411/II/0013/G, Orphan</b> Santen Oy, Duplicate, Duplicate of IKERVIS, Rapporteur: Peter Kiely Request for Supplementary Information adopted on 24.06.2021, 25.03.2021.	Request for supplementary information adopted with a specific timetable.
<b>Xofigo - radium-223 -</b> <b>EMA/H/C/002653/II/0041</b> Bayer AG, Rapporteur: Janet Koenig Request for Supplementary Information adopted on 10.06.2021.	Request for supplementary information adopted with a specific timetable.
<b>Xofigo - radium-223 -</b> <b>EMA/H/C/002653/II/0042/G</b> Bayer AG, Rapporteur: Janet Koenig Request for Supplementary Information adopted on 10.06.2021.	Request for supplementary information adopted with a specific timetable.
<b>Zirabev - bevacizumab -</b> <b>EMA/H/C/004697/II/0019</b> Pfizer Europe MA EEIG, Rapporteur: Bjorg Bolstad Opinion adopted on 17.06.2021.	Positive Opinion adopted by consensus on 17.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>WS1908/G</b> <b>Hefiya-EMA/H/C/004865/WS1908/0030/G</b> <b>Hyrimoz-EMA/H/C/004320/WS1908/0030/G</b> Sandoz GmbH, Lead Rapporteur: Daniela Philadelphy Request for Supplementary Information adopted on 17.06.2021.	Request for supplementary information adopted with a specific timetable.
<b>WS2037</b> <b>Gardasil-EMA/H/C/000703/WS2037/0092</b> <b>Gardasil 9-EMA/H/C/003852/WS2037/0045</b> MSD Vaccins, Lead Rapporteur: Kristina Dunder Opinion adopted on 24.06.2021.	Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>WS2044</b> <b>Herceptin-EMA/H/C/000278/WS2044/0171</b> <b>MabThera-EMA/H/C/000165/WS2044/0184</b>	Request for supplementary information adopted with a specific timetable.

---

Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus  
Request for Supplementary Information adopted on 24.06.2021.

---

**WS2062**  
**M-M-RVAXPRO-EMA/H/C/000604/**  
**WS2062/0106**  
**ProQuad-EMA/H/C/000622/WS2062/**  
**0146**

MSD Vaccins, Lead Rapporteur: Jan Mueller-Berghaus  
Opinion adopted on 10.06.2021.

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**WS2068/G**  
**Blitzima-EMA/H/C/004723/WS2068/**  
**0042/G**  
**Ritemvia-EMA/H/C/004725/WS2068/**  
**0042/G**  
**Truxima-EMA/H/C/004112/WS2068/**  
**0045/G**

Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz  
Opinion adopted on 10.06.2021.

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**WS2074**  
**Riarify-EMA/H/C/004836/WS2074/0012**  
**Trimbow-EMA/H/C/004257/WS2074/**  
**0017**  
**Trydonis-EMA/H/C/004702/WS2074/**  
**0012**

Chiesi Farmaceutici S.p.A., Lead Rapporteur: Janet Koenig  
Opinion adopted on 24.06.2021.

Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

#### **B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects**

---

**Adcetris - brentuximab vedotin -**  
**EMA/H/C/002455/II/0089, Orphan**

Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik, "Submission of long-term follow-up data for clinical trial Echelon-2 (SGN035-014): A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphoma. The study is submitted to fulfil the post-approval-measure MEA 015.1."

Request for Supplementary Information adopted

Request for supplementary information adopted with a specific timetable.

---

on 24.06.2021.

---

**Bridion - sugammadex -  
EMA/H/C/000885/II/0039**

Merck Sharp & Dohme B.V., Rapporteur: Outi Mäki-Ikola, "Update of sections 4.8 and 5.1 of the SmPC in order to update information on the safety profile in American Society of Anesthesiologists (ASA) Class 3 or 4 patients (patients with severe systemic disease or patients with severe systemic disease that is a constant threat to life) based on final results from study 8616-P145, an interventional safety study of sugammadex for the reversal of neuromuscular blockage induced by rocuronium or vecuronium in adult ASA 3-4 participants." Opinion adopted on 03.06.2021.  
Request for Supplementary Information adopted on 09.04.2021.

Positive Opinion adopted by consensus on 03.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Calquence - acalabrutinib -  
EMA/H/C/005299/II/0005**

AstraZeneca AB, Rapporteur: Filip Josephson, "Submission of the final report from study XS-1468 to further characterise the plasma protein binding of acalabrutinib and its metabolite ACP-5862 in different species." Opinion adopted on 24.06.2021.

Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Cholib - fenofibrate / simvastatin -  
EMA/H/C/002559/II/0029/G**

Mylan IRE Healthcare Limited, Rapporteur: Alar Irs, "Update of section 4.4 of the SmPC in order to amend the existing warning on immune-mediated necrotizing myopathy (IMNM) and section 4.5 of the SmPC to add drug-drug interaction information with cobicistat, following the update of the company's core data sheet (CCDS) due to new data. Section 4.3 of the SmPC was consequently amended, also to include the necessary cross-references. Section 4.8 of the SmPC was also amended to add immune-mediated necrotizing myopathy with a rare frequency. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list the UK (Northern Ireland) local representative in the Package Leaflet." Opinion adopted on 03.06.2021.  
Request for Supplementary Information adopted on 09.04.2021.

Positive Opinion adopted by consensus on 03.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Cimzia - certolizumab pegol -  
EMA/H/C/001037/II/0098**

UCB Pharma S.A., Rapporteur: Kristina Dunder,  
"Update of sections 4.8 and 5.1 of the SmPC in order to update the safety and efficacy information on reduction of anterior uveitis flares in patients diagnosed with active axial spondyloarthritis based on the final results from study AS0007 (C-VIEW); this is a multicenter, open-label study to assess the effects of certolizumab pegol on the reduction of anterior uveitis flares in axial spondyloarthritis subjects with a history of anterior uveitis."

Request for Supplementary Information adopted on 28.05.2021.

Request for supplementary information adopted with a specific timetable.

---

**Dapivirine Vaginal Ring 25 mg - dapivirine  
- EMA/H/W/002168/II/0007**

International Partnership for Microbicides  
Belgium AISBL, Rapporteur: Paula Boudewina van Hennik, "Submission of the final report for study report no. 15760.01, conducted to evaluate the antiviral activity of dapivirine on hepatitis E virus (HEV) in vitro. In addition, the SOH took the opportunity to submit data on: antiviral activity of Dapivirine against influenza A and B viruses; the effects of a vaginal film formulation of dapivirine on various species of Lactobacilli present in the vagina; the antitumor activity of dapivirine in glioblastoma cells. With this submission, the post-authorisation measure REC 001 is addressed."

Request for Supplementary Information adopted on 28.05.2021.

Request for supplementary information adopted with a specific timetable.

---

**Dengvaxia - dengue tetravalent vaccine  
(live, attenuated) -  
EMA/H/C/004171/II/0018**

Sanofi Pasteur, Rapporteur: Christophe Focke,  
"Submission of the final report from study DNG10042, listed as a category 3 study in the RMP. This report summarises the findings on the dengue vaccine (Dengvaxia) effectiveness against virologically confirmed symptomatic infection, carried out after the mass vaccination program conducted by the Brazilian state of Paraná from 2016 to 2018."

Opinion adopted on 10.06.2021.

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Dovprela - pretomanid -  
EMA/H/C/005167/II/0004/G, Orphan**

Mylan IRE Healthcare Limited, Rapporteur: Filip

Request for supplementary information adopted with a specific timetable.

---

Josephson, "Grouped application including three type II variations under category C.I.4.

Update of sections 4.5 and 5.3 of the SmPC based on data from three non-clinical studies:

- Assessment of pretomanid as an inhibitor of human OCT2-, OATP1B3-, BCRP-, and P-gp mediated transport;
- In vitro evaluation of induction/inhibition of CYP 2C8, 2C9, and 2C19 in human hepatocytes;
- A 24-Month Oral (Gavage) Carcinogenicity Study in Rats."

Request for Supplementary Information adopted on 10.06.2021, 09.04.2021.

---

**Dupixent - dupilumab -**

**EMA/H/C/004390/II/0044**

sanofi-aventis groupe, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC based on safety follow up data up to 3 years from the open-label extension study (R668-AD-1225) of dupilumab in adult patients with moderate to severe atopic dermatitis."

Opinion adopted on 24.06.2021.

Request for Supplementary Information adopted on 20.05.2021.

Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Entyvio - vedolizumab -**

**EMA/H/C/002782/II/0059/G**

Takeda Pharma A/S, Rapporteur: Armando Genazzani, "C.I.4

Update of section 4.6 of the SmPC in order to implement information on lactation based on study Vedolizumab-4001 (An Open-Label, Multicenter and Open Enrollment Model, Postmarketing, Milk-Only Lactation Study to Assess Concentration of Vedolizumab in Breast Milk of Lactating Women With Active Ulcerative Colitis or Crohn's Disease Who Are Receiving Vedolizumab Therapeutically). The study aimed to determine the PK parameters of vedolizumab in breast milk and to estimate mean daily infant dosage over the dosing interval through breast milk, and percentage of maternal dose consumed in breast milk by the infants.

C.I.4

Update of section 5.2 of the SmPC in order to adjust the values for clearance and serum half-life of vedolizumab IV and SC in subjects with ulcerative colitis and Crohn's disease. The updated pop PK dataset consists of pooled data across 4 phase 3 studies (C13006, C13007,

Request for supplementary information adopted with a specific timetable.

---

MLN0002SC-3027, MLN0002SC-3031) and 1 open-label extension study (MLN0002SC-3030). In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet, to correct minor typographical errors and to bring the PI in line with the latest QRD template version 10.2 rev. 1.” Request for Supplementary Information adopted on 10.06.2021.

---

**Epidyolex - cannabidiol - EMEA/H/C/004675/II/0007, Orphan**  
GW Pharma (International) B.V., Rapporteur: Kirstine Moll Harboe, “Update of sections 4.2 and 6.6 of the SmPC in order to add information regarding enteral administration using nasogastric and gastrostomy tubes. The Package Leaflet is updated accordingly. In addition, the marketing authorisation holder has taken the opportunity to update the list of local representatives in the PL and implement minor editorial changes.”  
Opinion adopted on 24.06.2021.  
Request for Supplementary Information adopted on 25.02.2021, 23.07.2020.

Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Erleada - apalutamide - EMEA/H/C/004452/II/0013**  
Janssen-Cilag International N.V., Rapporteur: Blanca Garcia-Ochoa, “Update of sections 4.6 and 5.3 of the SmPC in order to update information on pregnancy and update non-clinical information following results of a developmental toxicity study in rats.”  
Opinion adopted on 10.06.2021.  
Request for Supplementary Information adopted on 06.05.2021.

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Esbriet - pirfenidone - EMEA/H/C/002154/II/0070**  
Roche Registration GmbH, Rapporteur: Peter Kiely, “Update of section 4.8 of the SmPC to revise the MedRA frequency categories for some adverse drug reactions (ADR) and to combine the ADR 'anorexia' with the preferred term 'decreased appetite' based on a safety update report previously submitted in variation EMEA/H/C/2154/II/0021. The package leaflet is updated accordingly. Minor formatting changes were introduced in Annex II, IIIA and IIIB in the list of local representatives.”  
Opinion adopted on 10.06.2021.

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---



---

Request for Supplementary Information adopted on 09.04.2021.

---

**Eylea - aflibercept -  
EMA/H/C/002392/II/0067**

Bayer AG, Rapporteur: Alexandre Moreau,  
"C.I.4 - change in the expression of Qualitative and quantitative composition."  
Opinion adopted on 24.06.2021.  
Request for Supplementary Information adopted on 25.03.2021, 14.01.2021.

Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Imfinzi - durvalumab -  
EMA/H/C/004771/II/0030/G**

AstraZeneca AB, Rapporteur: Sinan B. Sarac,  
"Update of sections 4.2 and 4.4 of the SmPC in order to change posology recommendations for management of immune-mediated adverse reactions and amend an existing warning on Immune-mediated type 1 diabetes mellitus to include diabetic ketoacidosis; these changes are based on case studies reports, updated guidelines.  
The Package Leaflet is updated accordingly.  
In addition, the MAH took the opportunity to make some minor corrections to section 4.8 of the SmPC."  
Request for Supplementary Information adopted on 24.06.2021.

Request for supplementary information adopted with a specific timetable.

---

**Jardiance - empagliflozin -  
EMA/H/C/002677/II/0057**

Boehringer Ingelheim International GmbH,  
Rapporteur: Johann Lodewijk Hillege, "Update of sections 4.2 and 4.4 of the SmPC to lower the renal threshold for initiation and use of empagliflozin depending on eGFR, and of the section 5.1 wording about endpoints with reference to EMPA-REG OUTCOME study. The PL is updated accordingly."  
Request for Supplementary Information adopted on 24.06.2021, 25.03.2021.

Request for supplementary information adopted with a specific timetable.

See 9.1

---

**Jinarc - tolvaptan -  
EMA/H/C/002788/II/0033/G**

Otsuka Pharmaceutical Netherlands B.V.,  
Rapporteur: Armando Genazzani, "Update of section 4.5 of the SmPC in order to update the safety information based on final results from study 156-201-00233 and 156-201-00234; the Package Leaflet is updated accordingly."  
Request for Supplementary Information adopted

Request for supplementary information adopted with a specific timetable.

---

on 10.06.2021.

---

**Kisqali - ribociclib -**

**EMA/H/C/004213/II/0028**

Novartis Europharm Limited, Rapporteur: Filip Josephson, "Update of section 5.3 of the SmPC in order to update non-clinical information based on results from a 2-year carcinogenicity study in rats."

Opinion adopted on 28.05.2021.

Positive Opinion adopted by consensus on 28.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Lynparza - olaparib -**

**EMA/H/C/003726/II/0047**

AstraZeneca AB, Rapporteur: Alexandre Moreau, "Update of sections 4.8 and 5.1 of the SmPC in order to update safety and efficacy information based on the final analysis of overall survival and safety update from study POLO, a Phase III, randomised, double-blind, placebo-controlled, multicentre study in gBRCAm patients with metastatic pancreatic adenocarcinoma whose disease had not progressed after receiving first-line platinum-based chemotherapy."

Request for Supplementary Information adopted on 28.05.2021.

Request for supplementary information adopted with a specific timetable.

---

**Oncaspar - pegaspargase -**

**EMA/H/C/003789/II/0038**

Les Laboratoires Servier, Rapporteur: Alexandre Moreau, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on the risk of osteonecrosis and to include it as an adverse drug reaction associated with pegaspargase use with an unknown frequency, following review of all available non-clinical, epidemiological and clinical data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.2."

Request for Supplementary Information adopted on 28.05.2021.

Request for supplementary information adopted with a specific timetable.

---

**Phesgo - pertuzumab / trastuzumab -**

**EMA/H/C/005386/II/0002**

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to support the safety of switching from intravenous to subcutaneous route of administration or vice versa, based on results from study MO40628; this is a Phase II, randomised, open-label, cross-over study to

Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

assess preference for intravenous or subcutaneous route of administration in patients with HER2-positive early breast cancer. Minor editorial changes have been introduced in the PI.”

Opinion adopted on 24.06.2021.

Request for Supplementary Information adopted on 29.04.2021.

---

**Revestive - teduglutide -  
EMA/H/C/002345/II/0053, Orphan**

Shire Pharmaceuticals Ireland Limited,  
Rapporteur: Kirstine Moll Harboe, “Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the Product information with results from two studies included in the paediatric investigation plan (PIP). Study SHP633-1 was performed to evaluate the safety, efficacy/pharmacodynamics (PD), and pharmacokinetics (PK) of teduglutide in infants 4 to 12 months gestational age with SBS and who are dependent on parenteral support. The second study is a paediatric population PK model including data from study SHP633-301. The Package Leaflet was updated accordingly. In addition, the MAH took the opportunity to make editorial changes to section 4.5 of the SmPC.”

Request for Supplementary Information adopted on 24.06.2021.

Request for supplementary information adopted with a specific timetable.

---

**SIRTURO - bedaquiline -  
EMA/H/C/002614/II/0043, Orphan**

Janssen-Cilag International NV, Rapporteur: Filip Josephson, “Update of section 4.2 of the SmPC to include reference on the use of bedaquiline as specified in the product information of other medicines used for the treatment of pulmonary tuberculosis (TB) caused by multidrug-resistant Mycobacterium tuberculosis (MDR-TB), based on recent information regarding EU approval of pretomanid, as part of a combination regimen with bedaquiline and linezolid. In addition, the MAH took the opportunity to include an editorial correction in section 5.1 of the SmPC and to update the contact details for the local representative for UK in the package leaflet, in line with QRD version 10.2.”

Request for Supplementary Information adopted on 24.06.2021.

Request for supplementary information adopted with a specific timetable.

<p><b>Taltz - ixekizumab -</b>  <b>EMA/H/C/003943/II/0040</b>  Eli Lilly Nederland B.V., Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC with long-term efficacy and safety data in axial spondyloarthritis from study RHBY - A multicenter, long-term extension study of 104 weeks, including a double-blind, placebo-controlled 40-week randomized withdrawal-retreatment period, to evaluate the maintenance of treatment effect of ixekizumab in patients with axial spondyloarthritis."  Opinion adopted on 17.06.2021.  Request for Supplementary Information adopted on 22.04.2021, 21.01.2021.</p>	<p>Positive Opinion adopted by consensus on 17.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p><b>Ultomiris - ravulizumab -</b>  <b>EMA/H/C/004954/II/0018</b>  Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa, "To update section 4.2 Posology and method of administration of the SmPC regarding the inclusion of home infusion as an alternative infusion setting for Ultomiris for approved indications (paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS))."  Request for Supplementary Information adopted on 24.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Vemlidy - tenofovir alafenamide -</b>  <b>EMA/H/C/004169/II/0032</b>  Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to add new information on efficacy and safety based on final results from study GS-US-320-4035. This was a phase 2, open-label study to evaluate the safety and efficacy of switching to tenofovir alafenamide from tenofovir disoproxil fumarate and/or other oral antiviral treatment in virologically suppressed chronic hepatitis B subjects with renal and/or hepatic impairment."  Request for Supplementary Information adopted on 10.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p><b>Votrient - pazopanib -</b>  <b>EMA/H/C/001141/II/0067/G</b>  Novartis Europharm Limited, Rapporteur: Sinan B. Sarac, "C.I.4  Update of section 4.8 of the SmPC in order to add hepatic failure to the list of adverse</p>	<p>Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>

---

reactions reported in patients with soft tissue sarcoma (STS) with the frequency not known. The Package Leaflet is updated accordingly.  
C.I.4

Update of section 4.4 of the SmPC in order to update the information on studies with pazopanib in combination with other systemic anti-cancer therapies which were terminated early due to concerns over increased toxicity and/or mortality.

Type IA A.6

Update of section 5.1 of the SmPC with the updated ATC code L01EX03 released by WHO.”  
Opinion adopted on 10.06.2021.

---

**Wakix - pitolisant -**

**EMA/H/C/002616/II/0023/G, Orphan**

Bioprojet Pharma, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Kirsti Villikka, “Update of the product information based on new clinical data from the open-label, long-term treatment of EDS (with or without cataplexy) in narcolepsy P09-10 HARMONY III study, and the randomised, double-blind, placebo-controlled, drug abuse potential study (P16-02).”

Opinion adopted on 10.06.2021.

Request for Supplementary Information adopted on 09.04.2021, 11.03.2021, 14.01.2021, 03.09.2020.

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Xarelto - rivaroxaban -**

**EMA/H/C/000944/II/0079**

Bayer AG, Rapporteur: Kristina Dunder, “Update to SmPC section 4.4 following the submission of the final report from the CASSINI study, an interventional phase III study comparing 10 mg rivaroxaban to placebo in the prevention of venous thromboembolism in ambulatory cancer patients. The package leaflet is being updated accordingly.”

Opinion adopted on 17.06.2021.

Request for Supplementary Information adopted on 18.02.2021, 03.09.2020.

Positive Opinion adopted by consensus on 17.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Xerava - eravacycline -**

**EMA/H/C/004237/II/0012**

Paion Deutschland GmbH, Rapporteur: Filip Josephson, “Update of sections 5.3 and 6.6 of the SmPC in order to update the results of the Environmental Risk Assessment studies following their completion.”

Request for Supplementary Information adopted

Request for supplementary information adopted with a specific timetable.

---

on 28.05.2021, 11.03.2021.

---

**Yondelis - trabectedin -  
EMA/H/C/000773/II/0063**

Pharma Mar, S.A., Rapporteur: Sinan B. Sarac,  
"Update of section 4.8 of the SmPC in order to  
revise the frequency of ADRs based on a pooled  
safety analysis. the Package Leaflet is updated  
accordingly.

In addition, the MAH took the opportunity to  
bring the PI in line with the latest QRD template  
version 10.2 Rev. 1"

Request for Supplementary Information adopted  
on 24.06.2021.

Request for supplementary information adopted  
with a specific timetable.

---

**ZABDENO - ebola vaccine (rDNA,  
replication-incompetent) -  
EMA/H/C/005337/II/0003**

Janssen-Cilag International N.V., Rapporteur:  
Johann Lodewijk Hillege, "Update of sections 4.4  
and 4.8 of the SmPC to add a new warning on  
febrile seizures in children and to include  
"febrile seizures" on the list of adverse drug  
reactions (ADRs) with frequency rare, based on  
the review of febrile seizures post-marketing  
cases received within the GMS Global Safety  
Database. The Package Leaflet is updated  
accordingly. In addition, the MAH took the  
opportunity to replace the local representative  
for the UK with a local representative for the  
territory of Northern Ireland as a consequence  
of the Northern Ireland Protocol."

Request for Supplementary Information adopted  
on 28.05.2021.

Request for supplementary information adopted  
with a specific timetable.

---

**Zostavax - varicella vaccine (live) -  
EMA/H/C/000674/II/0132**

MSD Vaccins, Rapporteur: Jan Mueller-  
Berghaus, Co-Rapporteur: Outi Mäki-Ikola,  
"Submission of the final study report from the  
post-licensure observational study of the long-  
term effectiveness of Zostavax (Protocol 024)  
listed as category 3 study in the RMP.

Consequently, section 5.1 of the SmPC was  
updated. With this application, the post-  
authorisation measure REC 23 is fulfilled.

In addition, the MAH took the opportunity to  
update the list of local representatives in the  
package leaflet and include editorial corrections  
in annex A."

Opinion adopted on 03.06.2021.

Request for Supplementary Information adopted

Positive Opinion adopted by consensus on  
03.06.2021. The Icelandic and Norwegian CHMP  
Members were in agreement with the CHMP  
recommendation.

---

on 09.04.2021.

---

**WS1874/G**

**Advagraf-EMA/H/C/000712/WS1874/0058/G**

**Modigraf-EMA/H/C/000954/WS1874/0036/G**

Astellas Pharma Europe B.V., Lead Rapporteur: Jayne Crowe, "C.I.4

Update of sections 4.4 and 4.5 of the SmPC on the drug-drug interaction with CYP3A4 based on a comprehensive review of available data.

Section 4.5 of the SmPC is also updated to include impact of direct acting antiviral therapy. C.I.z

Update of section 4.8 of the SmPC to add posterior reversible encephalopathy syndrome as an adverse reaction. The MAH took also the opportunity to change the SOC for febrile neutropenia from General disorders and administration site conditions to Blood and lymphatic system disorders in section 4.8 of the SmPC and to update the instruction for handling of the product in Section 6.6 of the SmPC.

The Package Leaflet is updated accordingly."

Request for Supplementary Information adopted on 24.06.2021, 25.02.2021, 17.09.2020.

Request for supplementary information adopted with a specific timetable.

---

**WS1989**

**Combivir-EMA/H/C/000190/WS1989/0100**

**Epivir-EMA/H/C/000107/WS1989/0116**

**Trizivir-EMA/H/C/000338/WS1989/0121**

ViiV Healthcare B.V., Lead Rapporteur: Jean-Michel Race, "Update of section 4.9 of the SmPC to revise the overdose information."

Opinion adopted on 24.06.2021.

Request for Supplementary Information adopted on 11.03.2021.

Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**WS2008/G**

**Mekinist-EMA/H/C/002643/WS2008/0046/G**

**Tafinlar-EMA/H/C/002604/WS2008/0051/G**

Novartis Europharm Limited, Lead Rapporteur: Paula Boudewina van Hennik, "C.I.4 Update of section 5.1 of the Mekinist (trametinib) and Tafinlar (dabrafenib) SmPC to include the 5-years efficacy results from Phase III study COMBI-AD. This is a two-arm, randomized, double-blind Phase III study of dabrafenib in

Positive Opinion adopted by consensus on 03.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

combination with trametinib versus two placebos in the adjuvant treatment of melanoma after surgical resection in adult patients with a BRAF V600 mutation. Type IA A.6 update the SmPC with the updated ATC codes released by WHO”  
Opinion adopted on 03.06.2021.

---

**WS2039**

**Genvoya-EMA/H/C/004042/WS2039/0076**

**Stribild-EMA/H/C/002574/WS2039/0116**

**Tybost-EMA/H/C/002572/WS2039/0058**

Gilead Sciences Ireland UC, Lead Rapporteur: Bruno Sepodes, “Update of section 4.5 of the SmPC to add new information about the drug-drug interactions between cobicistat containing products (Genvoya, Tybost and Stribild) and corticosteroids, based on post-marketing data. Furthermore, the MAH took the opportunity to bring the Tybost Product Information in line with version 10.2 of the QRD template and update the list of local representatives. Moreover, minor editorial updates and corrections have been introduced throughout the Product Information of all three products.”  
Request for Supplementary Information adopted on 03.06.2021.

Request for supplementary information adopted with a specific timetable.

---

**WS2048**

**Kalydeco-EMA/H/C/002494/WS2048/0101**

**Symkevi-EMA/H/C/004682/WS2048/0030**

Vertex Pharmaceuticals (Ireland) Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Rhea Fitzgerald, “Update of the Product information to provide the final clinical study report (CSR) Part A of study VX17-661-116 (A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Tezacaftor in Combination With Ivacaftor in Subjects With Cystic Fibrosis Aged 6 Years and Older, Homozygous or Heterozygous for the F508del-CFTR Mutation).  
Consequently, the SmPC sections 4.2, 4.5, 4.8 and 5.1 and the package leaflet are updated accordingly. The RMP is also updated.”  
Request for Supplementary Information adopted on 24.06.2021.

Request for supplementary information adopted with a specific timetable.

---

**WS2052/G**

Positive Opinion adopted by consensus on

---



<b>Stayveer-EMA/H/C/002644/WS2052/0034/G</b> <b>Tracleer-EMA/H/C/000401/WS2052/0099/G</b>	10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<p>Janssen-Cilag International NV, Lead Rapporteur: Alexandre Moreau, "Grouped variation application;</p> <ul style="list-style-type: none"> <li>• Type II variation C.I.4: Update of section 4.6 of the SmPC to correct the information related to male fertility based on a review of study AC-052-402 carried out by the MAH.</li> <li>• Type IA variation A.7</li> </ul> <p>In addition, the WSA took the opportunity to update the list of local representatives in the Package Leaflet. The WSA also took the opportunity to correct some errors in the national translations."</p> <p>Opinion adopted on 10.06.2021.</p>	
<b>WS2054</b> <b>Enerzair Breezhaler-EMA/H/C/005061/WS2054/0003</b> <b>Zimbus Breezhaler-EMA/H/C/005518/WS2054/0003</b>	Request for supplementary information adopted with a specific timetable.
<p>Novartis Europharm Limited, Lead Rapporteur: Peter Kiely, "Update of section 5.1. Pharmacodynamic properties, based on the final results from the ARGON study a Phase 3b, multicenter, partially-blinded, randomized, 24-week, parallel-group, non-inferiority, open-label active controlled study comparing the efficacy and safety of QVM149 with a free triple combination of salmeterol/fluticasone + tiotropium in patients with uncontrolled asthma."</p> <p>Request for Supplementary Information adopted on 28.05.2021.</p>	
<b>WS2066</b> <b>Lacosamide UCB-EMA/H/C/005243/WS2066/0010</b> <b>Vimpat-EMA/H/C/000863/WS2066/0092</b>	Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<p>UCB Pharma S.A., Lead Rapporteur: Filip Josephson, "Update of section 4.8 of the SmPC in order to add dyskinesia to the list of adverse drug reactions (ADRs) with frequency uncommon following the outcome of continuous safety signal assessments of the relevant reported clinical and post-marketing cases. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to</p>	

---

implement editorial changes in the PI, to bring it in line with the latest QRD template version 10.2 and relevant guidelines and to update the details of the UK local representative in the PL.”  
Opinion adopted on 10.06.2021.

---

**WS2085**

**Kaftrio-EMA/H/C/005269/WS2085/0014**  
**Kalydeco-EMA/H/C/002494/WS2085/0099**

Request for supplementary information adopted with a specific timetable.

Vertex Pharmaceuticals (Ireland) Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Martin Huber, “Update of SmPC sections 4.4 and 4.8 following cases of liver failure in the post- marketing setting. The PL is updated accordingly.  
The RMP version 3.1 is submitted for Kaftrio.”  
Request for Supplementary Information adopted on 24.06.2021.

---

**B.5.3. CHMP-PRAC assessed procedures**

---

**Accofil - filgrastim -**

**EMA/H/C/003956/II/0046/G**

Accord Healthcare S.L.U., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka“-  
Type II B.II.e.5.c- To introduce a new presentation, Accofil 12 MU/0.2 mL Solution for Injection or infusion in Pre-filled Syringe, to cater to low-weight patients as the clinical administration of Filgrastim is based on body weight. The same concentration in mcg/ mL as for the already approved presentation of 300 mcg/ 0.5 mL (30 MU/0.5 ml) is obtained, i.e. 600 mcg/ mL. RMP and PI are updated to include this new strength.

- Type II B.II.e.5.c- To introduce a new presentation, Accofil 70 MU/0.73 mL Solution for Injection or infusion in Pre-filled Syringe, based on the dosing regimen to avoid multiple administrations. The same concentration in mcg/ mL as for the already approved presentation of 480 mcg/ 0.5 mL (48 MU/0.5 ml) is obtained, i.e. 960 mcg/ mL. RMP and PI are updated to include this new strength.”

Opinion adopted on 10.06.2021.

Request for Supplementary Information adopted on 09.04.2021.

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Adenuric - febuxostat -**

Request for supplementary information adopted

---

---

**EMA/H/C/000777/II/0061**

Menarini International Operations Luxembourg S.A., Rapporteur: Andrea Laslop, PRAC Rapporteur: Jan Neuhauser, "C.I.4 - Update of sections 4.4, 4.8 and 5.1 of the SmPC based on the final results from study FAST (Febuxostat versus Allopurinol Streamlined Trial) listed as a category 3 study in the RMP; this is an interventional study investigating the cardiovascular safety of febuxostat in comparison with allopurinol in patients with chronic symptomatic hyperuricaemia. The Package Leaflet is updated accordingly. The RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to update the warning relevant to the content of sodium according to the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use'."

Request for Supplementary Information adopted on 24.06.2021.

with a specific timetable.

---

**BLINCYTO - blinatumomab -  
EMA/H/C/003731/II/0039, Orphan**

Amgen Europe B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Eva Jirsová, "Submission of the final report from study 20180138 classified as category 3 PASS in RMP. This is an observational clinical study to update the OS Kaplan-Meier probability estimates and the plot last reported in the randomized Phase 3 blinatumomab 00103311 study."

Opinion adopted on 24.06.2021.

Request for Supplementary Information adopted on 11.03.2021.

Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**BYETTA - exenatide -  
EMA/H/C/000698/II/0075**

AstraZeneca AB, Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin, "Update of sections 4.2 and 5.1 of the SmPC based on the results of study H8O-MC-GWBQ (assessed by CHMP as part of PAM P46 048); a 28-week, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of exenatide twice daily in 120 patients aged 10 to 17 years, and study 2993-124; a randomised, single-blind, placebo-controlled, dose-rising

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

study to evaluate the PK, PD and tolerability of exenatide in adolescent patients)."

Opinion adopted on 10.06.2021.

---

**Caprelsa - vandetanib -  
EMA/H/C/002315/II/0043**

Genzyme Europe BV, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, "C.I.4 Update of section 5.1 of the SmPC in order to update pharmacodynamic information based on interim results from study D4200C00104, listed as a specific obligation in the Annex II. This is an observational study (including a retrospective arm to evaluate the Benefit/Risk of vandetanib (Caprelsa) 300 mg in RET mutation negative and RET mutation positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic thyroid cancer (MTC)), to confirm the efficacy and safety of Caprelsa in RET-negative patients with the aim to fulfil SOB001 and convert Caprelsa from conditional to normal Marketing Authorisation. In addition, the MAH takes to opportunity to rectify the Dutch translation of the Caprelsa Product Information."

Request for Supplementary Information adopted on 24.06.2021, 28.05.2020.

Request for supplementary information adopted with a specific timetable.

See 9.1

---

**Cometriq - cabozantinib -  
EMA/H/C/002640/II/0044, Orphan**

Ipsen Pharma, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Menno van der Elst, "Update of the annex IIE and SmPC section 5.1 to remove the specific obligation (SOB 001) and the reference to the conditional approval based on the final results from the study XL184-401 (EXAMINER), a randomised, double-blind study to evaluate the efficacy and safety of cabozantinib (XL184) at 60 mg/day compared to a 140 mg/day in progressive, metastatic medullary thyroid cancer patients. The package leaflet is updated accordingly. The updated RMP version 5.4 has also been submitted. With this submission, the MAH is proposing to revert from conditional marketing authorisation to full marketing authorisation. Additionally, the MAH took the opportunity to bring the Product Information in line with the latest QRD template version 10.2 Rev 1, to add the sodium content in the Summary of product

Request for supplementary information adopted with a specific timetable.

See 9.1

---

Characteristics and Package Information Leaflet in line with the guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' and update details of local representatives."

Request for Supplementary Information adopted on 24.06.2021.

---

**Cosentyx - secukinumab -  
EMA/H/C/003729/II/0076**

Novartis Europharm Limited, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Eva A. Segovia, "C.I.4 - Update of sections 4.2 and 5.1 of the SmPC in order to introduce a new posology regimen for adult plaque psoriasis patients and psoriatic arthritis patients with concomitant moderate to severe plaque psoriasis based on the final results from study CAIN457A2324 and exposure-response modelling; this is a randomized, double-blind, multicenter study assessing short (16 weeks) and long-term efficacy (up to 1 year), safety, and tolerability of sub-cutaneous secukinumab in subjects of body weight 90 kg or higher with moderate to severe chronic plaque-type psoriasis; the Package Leaflet is updated accordingly. The RMP version 9.0 has also been submitted."

Request for Supplementary Information adopted on 24.06.2021.

Request for supplementary information adopted with a specific timetable.

See 9.1

---

**Dengvaxia - dengue tetravalent vaccine  
(live, attenuated) -  
EMA/H/C/004171/II/0016/G**

Sanofi Pasteur, Rapporteur: Christophe Focke, PRAC Rapporteur: Sonja Hrabcik, "Update of section 4.5 of the SmPC to include coadministration data on Gardasil/Cervarix/Adacel from CYD67, CYD71 and CYD66 final study reports respectively (final reports from 3 PAM MEA studies listed as category 3 studies in the RMP); these studies are dedicated to immunogenicity and safety of the concomitant administration; the Package Leaflet is updated accordingly. The RMP version 6.1. has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 10.06.2021, 11.02.2021.

Request for supplementary information adopted with a specific timetable.

---

**Gazyvaro - obinutuzumab -  
EMA/H/C/002799/II/0044/G, Orphan**

Request for supplementary information adopted with a specific timetable.

---

---

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Annika Folin, "C.I.4 Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to include the administration of obinutuzumab as a short duration infusion (SDI) of approximately 90 minutes in patients with Follicular Lymphoma (FL), based on the end of induction safety and efficacy data from the ongoing Phase IV study MO40597 (GAZELLE); the Package Leaflet is updated accordingly. The RMP version 8.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.

C.I.11.z

Update of RMP version 8.0 to:

- change the due date for the submission of the final CSR for Category 3 study BO21223 (GALLIUM);
- remove important identified risks as per the PRAC Assessment Report for the PSUR covering period 01Nov2018 to 30Oct2019 (Procedure no. EMEA/H/C/PSUSA/00010279/201910);
- correction of clinical cut-off dates and trial exposure data from previously conducted studies"

Request for Supplementary Information adopted on 24.06.2021.

---

**Herceptin - trastuzumab -  
EMA/H/C/000278/II/0168**

Roche Registration GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislowski, "Update of sections 4.2 and 4.4 of the SmPC (SC formulation) in order to modify the administration instructions by shortening observation time and including mild injection-related symptoms management based on final results from study SafeHER (MO28048) listed as a category 3 study in the RMP; this is a Phase III prospective, two Cohort nonrandomized, multicentre, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous Herceptin as adjuvant therapy in patients with operable HER2- positive early breast cancer. The Package Leaflet is updated accordingly. Additionally, the MAH took the opportunity to introduce minor editorial updates throughout the PI. The RMP version 21.1 has also been submitted."

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

Opinion adopted on 10.06.2021.  
Request for Supplementary Information adopted  
on 11.02.2021.

---

**Jakavi - ruxolitinib -**

**EMA/H/C/002464/II/0050**

Novartis Europharm Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin,  
"Update of sections 4.2 and 5.1 of the SmPC in order to update the posology and the method of administration as well as to include information on the A2201/EXPAND study CINC424A2201. The changes are based on final results of a Category 3 clinical study, phase Ib to fulfil an RMP post-approval commitment. This is a dose-finding study intended to establish the maximum safe starting dose (MSSD) of ruxolitinib tablets administered orally to patients with myelofibrosis (MF) in the previous unstudied population of patients who had baseline platelet counts between  $\geq 50 \times 10^9/L$  and  $< 100 \times 10^9/L$ . The Package Leaflet is updated accordingly. The RMP (final version 12.1) has also been submitted including, as well, the review of safety concerns in compliance with the Good Pharmacovigilance Practices Module V, Revision 2, as well as recent PRAC outcome on PSUR (Procedure no.: EMA/H/C/PSUSA/00010015/202002, CHMP Opinion dated 15-Oct-2020). The MAH also took the occasion to include some editorial changes in the text."

Opinion adopted on 24.06.2021.  
Request for Supplementary Information adopted  
on 28.01.2021.

Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Kadcyla - trastuzumab emtansine -**

**EMA/H/C/002389/II/0055**

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Anette Kirstine Stark,  
"Submission of a final Clinical Study Report of study MO28231 (KAMILLA) fulfil a Category 3 Additional Pharmacovigilance Activity in the Risk Management Plan to address the following safety concerns: Ventricular Dysfunction, Safety in Elderly Patients and the Use of a non-validated HER2 test. The Kadcyla EU RMP (version 13) has been updated to remove the commitment for this study and the safety concern "use of non-validated HER2 test"."  
Opinion adopted on 10.06.2021.

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Lorviqua - lorlatinib -  
EMA/H/C/004646/II/0013**

Pfizer Europe MA EEIG, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Nikica Mirošević Skvrce, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to include hypertension and hyperglycaemia as new adverse drug reactions (ADRs) with frequency common and very common respectively together with recommended dose modifications and warnings, based on data from Phase 3 study B7461006, comparing lorlatinib versus crizotinib for the first-line treatment of advanced ALK-positive NSCLC.

The Package Leaflet is updated accordingly. The RMP version 2.1 has also been submitted."

Opinion adopted on 24.06.2021.

Request for Supplementary Information adopted on 25.02.2021.

Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Mavenclad - cladribine -  
EMA/H/C/004230/II/0020**

Merck Europe B.V., Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, "C.I.4 Type II Update of sections 4.2 and 4.4 of the SmPC in order to change posology recommendations by adding an advice on preventive measures to avoid liver injury and to add a new warning on liver function and liver injury based on a review of post-approval data in MAH's safety database, non-clinical and clinical trial data and scientific literature (cladribine and liver injury and epidemiological data on hepatic injury in MS). The Package Leaflet is updated accordingly. The RMP version 1.6 has also been submitted." Request for Supplementary Information adopted on 10.06.2021.

Request for supplementary information adopted with a specific timetable.

---

**Natpar - parathyroid hormone -  
EMA/H/C/003861/II/0029, Orphan**

Shire Pharmaceuticals Ireland Limited, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Rhea Fitzgerald, "Submission of the final results of study SHP634-101: An Open-Label, Randomized, Crossover Study to Assess the Pharmacokinetic and Pharmacodynamic Profiles of Once-Daily and Twice-Daily Dose Regimens of recombinant human Parathyroid Hormone (rhPTH[1-84]) Administered Subcutaneously to Subjects with

Request for supplementary information adopted with a specific timetable.

See 9.1



---

Hypoparathyroidism. Further clinical evaluation of an alternative dosing regimen is no longer warranted, as outlined in the current specific obligation (study SHP634-403). The conditional marketing authorisation can therefore be converted into a standard marketing authorisation (no longer subject to a specific obligation) valid for 5 years.”

Request for Supplementary Information adopted on 24.06.2021.

---

**Nplate - romiplostim -  
EMA/H/C/000942/II/0079**

Amgen Europe B.V., Rapporteur: Maria Concepcion Prieto Yerro, PRAC Rapporteur: Eva A. Segovia, “Update of section 4.8 of the SmPC to add Anaphylactic reaction to the list of adverse drug reactions (ADRs) with frequency to be determined in the evaluation of the variation. The package leaflet has been amended accordingly.”

Opinion adopted on 24.06.2021.

Request for Supplementary Information adopted on 06.05.2021.

Negative Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Rinvoq - upadacitinib -  
EMA/H/C/004760/II/0009**

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, “C.I.4 - Update of sections 4.4 and 5.1 of the SmPC in order to amend the existing warning on vaccination based on the final results from vaccination substudy (within study M13-538) listed as a category 3 study in the RMP; this is an open-label extension to assess the impact of upadacitinib treatment with a stable background of methotrexate on immunological responses following administration of a pneumococcal vaccine in rheumatoid arthritis patients. The RMP version 5.0 has also been submitted.”

Request for Supplementary Information adopted on 24.06.2021, 25.03.2021.

Request for supplementary information adopted with a specific timetable.

---

**Rydapt - midostaurin -  
EMA/H/C/004095/II/0018/G, Orphan**

Novartis Europharm Limited, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Marcia Sofia Sanches de Castro Lopes Silva, “A.6 - Administrative change - Change in ATC Code/ATC Vet Code  
C.I.4, Update SmPC in section 4.5 in order to

Request for supplementary information adopted with a specific timetable.

---

add drug-drug interaction information with P-gp, BCRP, CYP2D6, substrates (digoxin, rosuvastatin, and dextromethorphan), based on final results from study CPKC412A2121, a Phase 1, open-label, drug-drug interaction study, listed as category 3 study in the RMP; section 5.2 of the SmPC and the Package Leaflet is updated accordingly. (MEA 005.3)

C.I.4, Update SmPC in section 4.5 in order to add drug-drug interaction information with CYP2B6, CYP2C8, CYP3A4 substrates, based on final results from study CPKC412A2122, a Phase 1, open-label, drug-drug interaction study, listed as category 3 study in the RMP; section 5.2 of the SmPC and the Package Leaflet is updated accordingly. (MEA 007.2)

C.I.4 Update SmPC in section 4.5 in order to add drug-drug interaction information with oral contraceptives, and section 4.6 to update information on pregnancy and contraception based on final results from study CPKC412A2123, a Phase 1, open-label, drug-drug interaction study, listed as category 3 study in the RMP; the Package Leaflet is updated accordingly. (MEA 008.2)

C.I.4 Update SmPC in section 5.2 in order to update pharmacokinetic information on OATP1B1 transporters based on final results from PBPK modelling study DMPK R2000528 listed as category 3 studies in the RMP (MEA 009);

C.I.4 Update SmPC in section 4.2 in order to amend posology instructions, section 4.4 to amend an existing warning and section 5.2 to update pharmacokinetic information for patients with severe hepatic impairment, based on final results from study CPKC412A2116 listed as category 3 study in the RMP. This is an open label, multiple dose study to evaluate the PK of midostaurin in subjects with mild, moderate and severe hepatic impairment compared to matched healthy subjects; (MEA010)

The RMP version 6.0 has also been submitted.

In addition, the MAH takes this opportunity to introduce minor changes to edit the wording related to the ethanol excipient in the Package Leaflet, according the Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668),

---

---

by rounding the volume of alcohol to the next integer number, i.e. from 16.9 to 17 ml.  
The requested group of variations proposed amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP)."  
Request for Supplementary Information adopted on 24.06.2021.

---

**Steglujan - ertugliflozin / sitagliptin - EMEA/H/C/004313/II/0015**

Merck Sharp & Dohme B.V., Rapporteur:  
Kristina Dunder, PRAC Rapporteur: Menno van der Elst, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC for Steglujan in order to update clinical information following final results from the VERTIS CV study (protocol 8835-004/B1521021) listed as a category 3 study in the RMP. This is a multi-centre, multi-national, randomised, double-blind, placebo-controlled study to evaluate the effect of ertugliflozin on cardiovascular risk in adult patients with type 2 diabetes and established atherosclerotic cardiovascular disease. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the MAH took the opportunity include an editorial change in section 4.1 of the SmPC."  
Request for Supplementary Information adopted on 24.06.2021, 25.02.2021.

Request for supplementary information adopted with a specific timetable.

---

**Tasigna - nilotinib - EMEA/H/C/000798/II/0109**

Novartis Europharm Limited, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Anette Kirstine Stark, "Update of SmPC sections 4.4, 4.8 and 5.1 based on the 5-year follow-up data from the study CAMN107A2203 in paediatric patients. Annex II D has been updated to reflect the fulfilment of the obligation to conduct the post-authorisation efficacy study (PAES). The package leaflet is updated accordingly. In addition, the Tasigna EU RMP version 24.0 has been updated to remove the corresponding additional pharmacovigilance activity and the missing information 'Long-term follow-up in paediatric patients'."  
Opinion adopted on 24.06.2021.  
Request for Supplementary Information adopted on 06.05.2021.

Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Tremfya - guselkumab -**

Request for supplementary information adopted

---

---

**EMA/H/C/004271/II/0028**

Janssen-Cilag International N.V., Rapporteur:

Agnes Gyurasics, PRAC Rapporteur: Brigitte

Keller-Stanislawski, "C.I.4

Update of sections 4.8 and 5.1 of the SmPC in order to update the EU product information with 5 years data from the final study reports of pivotal psoriasis studies PSO3001 and PSO3002 listed as additional PV activities (category 3 studies) in the RMP; in the long term extension part of these studies subjects received open-label guselkumab q8w, starting at Week 52 in PSO3001 and at Week 76 in PSO3002, with the last dose at Week 252 and the last safety follow-up visit at Week 264. The RMP version 8.1 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet." Request for Supplementary Information adopted on 10.06.2021.

with a specific timetable.

---

**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -****EMA/H/C/005675/II/0002**

AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC

Rapporteur: Jean-Michel Dogné, "Update of

sections 4.8, 5.1, 6.3 and 6.6 of the SmPC in order to update the safety profile and to add the adverse drug reactions: abdominal pain and urticaria with frequency uncommon; and pain in extremity and influenza-line illness with frequency common in section 4.8; based on the primary analysis (7th December data cut-off (post data-base lock) from the pooled pivotal studies (COV001, COV002, COV003 and COV005) that supported the conditional marketing authorisation and are listed as a specific obligation in the Annex II. The update on section 5.1 is editorial. The update in sections 6.3 and 6.6 relates to a rewording of the information of the shelf-life for opened vials for clarity purposes. The Package Leaflet and Labelling are updated accordingly. The MAH is taking the opportunity to update the product information in relation to the "genetically modified organisms" information. The RMP version 2.1 has also been submitted."

Opinion adopted on 24.06.2021.

Request for Supplementary Information adopted on 22.04.2021.

Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Xeljanz - tofacitinib -  
EMA/H/C/004214/II/0027**

Pfizer Europe MA EEIG, Rapporteur: Armando Genazzani, PRAC Rapporteur: Liana Gross-Martirosyan, "Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of Xeljanz 11 mg prolonged-release tablets SmPC in order to include the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug therapy; as an alternative to the immediate release film-coated tablets; section 4.2 of Xeljanz film-coated tablets is also updated to include switching with the prolonged-release tablet in the treatment of PsA. The Package Leaflet is updated accordingly. The RMP version 13.1 has also been submitted."

Opinion adopted on 24.06.2021.

Request for Supplementary Information adopted on 25.03.2021, 10.12.2020.

Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

See 9.1

---

**WS2069/G  
Edistride-EMA/H/C/004161/WS2069/  
0048/G  
Forxiga-EMA/H/C/002322/WS2069/  
0067/G**

AstraZeneca AB, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Annika Folin, "Grouped submission of final study reports of the DETERMINE studies D169EC00001 and D169EC00002, listed as category 3 PASS, assessing the risk of lower limb amputation. Both studies are international, Multicentre, parallel-group, randomised, double-blind, placebo-controlled, Phase III Study evaluating the effect of Dapagliflozin on Exercise capacity: Study D169EC00001 in patients with heart failure with preserved ejection fraction (HFpEF); Study D169EC00002 in patients with heart failure with reduced ejection fraction (HFrEF). The RMP version 25 was agreed during the procedure.

The studies are proposed to be removed from the Post-Authorisation Development Plan in the RMP for Forxiga and Edistride."

Opinion adopted on 10.06.2021.

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

#### B.5.4. PRAC assessed procedures

<p>PRAC Led</p> <p><b>Beovu - brolucizumab -</b> <b>EMA/H/C/004913/II/0008</b></p> <p>Novartis Europharm Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC in order to include the description of intraocular inflammation, based on final results from a non-interventional retrospective real-world evidence study conducted in patients with neovascular (wet) age-related macular degeneration (nAMD) to better understand the incidence of adverse events/safety signal after initiating treatment with brolucizumab for up to 6 months."</p> <p>Request for Supplementary Information adopted on 10.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>PRAC Led</p> <p><b>Cimzia - certolizumab pegol -</b> <b>EMA/H/C/001037/II/0099</b></p> <p>UCB Pharma S.A., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report from study (RA0020 - RABBIT) listed as a category 3 study in the RMP. This is a nationwide prospective observational cohort study in Germany on the long-term safety and effectiveness of bDMARDs in rheumatoid arthritis (RA). In addition, this submission includes a safety analysis across the 4 completed RA registries (ARTIS, NDB, BSRBR and RABBIT) as requested by EMA/PRAC in the final assessment report of Procedures EMA/H/C/001037/II/0072, EMA/H/C/001037/II/0081, and EMA/H/C/001037/II/0087. Based on this, revisions to the RMP summary of safety concerns and consequently the pharmacovigilance plan are proposed in line with GVP Module V Rev.2. An updated RMP version 19.1 is included."</p> <p>Opinion adopted on 10.06.2021.</p>	<p>Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>PRAC Led</p> <p><b>Dacogen - decitabine -</b> <b>EMA/H/C/002221/II/0044, Orphan</b></p> <p>Janssen-Cilag International N.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine</p>	<p>Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>

---

Vaillant, PRAC-CHMP liaison: Alexandre Moreau, "Update of section 4.6 of the SmPC in order to update information on fertility, pregnancy and lactation, following PSUR procedure PSUSA/00009118/202005; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives for Italy in the Package Leaflet and to include some editorial changes in the PI to align with standard English spelling." Opinion adopted on 10.06.2021.

---

PRAC Led  
**Faslodex - fulvestrant -  
EMA/H/C/000540/II/0073**

AstraZeneca AB, Rapporteur: Filip Josephson, PRAC Rapporteur: Annika Folin, PRAC-CHMP liaison: Filip Josephson, "Update of the RMP version 13 for fulvestrant to remove the additional risk minimisation measures for important identified risks and reclassify safety concerns based on Good Pharmacovigilance Practices (GVP) module V, risk management systems (revision 2) guidelines as requested by PRAC as a part of PRAC PSUR assessment report, procedure number EMA/H/C/PSUSA/00001489/202004 covering the period 26/04/2017 to 25/04/2020." Opinion adopted on 10.06.2021.

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

PRAC Led  
**HyQvia - human normal immunoglobulin -  
EMA/H/C/002491/II/0070/G**

Baxalta Innovations GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "C.I.4 (Type II) - Update of section 4.6 of the SmPC in order to update information on pregnancy and breast-feeding based on the final results from study 161301 listed as a category 3 study in the RMP; this is an observational study to collect long-term safety data from women treated with HyQvia. The package leaflet has been updated accordingly. RMP version 12.0 has also been submitted. In addition, the MAH took the opportunity to implement minor corrections and editorial changes to the SmPC. C.I.11.b (Type II) – Submission of an updated RMP version 12.0 to update the educational

Request for supplementary information adopted with a specific timetable.

---

material section Part V.2, additional Risk Minimisation Measures, for HyQvia. The change was requested by the PRAC in the outcome of the PSUSA procedure EMEA/H/C/PSUSA/00001633/202005." Request for Supplementary Information adopted on 10.06.2021.

---

PRAC Led

**InductOs - dibotermis alfa -  
EMA/H/C/000408/II/0100**

Medtronic BioPharma B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Pieter de Graeff, "C.I.11.b - Submission of an updated RMP version 2.1 in order to submit the final study report from study EUPAS32916 listed as category 3 study in the RMP. This is an observational study to evaluate the effectiveness of additional Risk Minimisation Measures for InductOs.

In addition, the MAH took the opportunity to submit study protocol for study EUPAS32916 that was agreed by PRAC."

Request for Supplementary Information adopted on 10.06.2021.

---

Request for supplementary information adopted with a specific timetable.

---

PRAC Led

**Kineret - anakinra -  
EMA/H/C/000363/II/0078**

Swedish Orphan Biovitrum AB (publ), Rapporteur: Kirstine Moll Harboe, PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Kirstine Moll Harboe, "Submission of the final report from study (Sobi-ANAKIN-201) listed as a category 3 study in the RMP. This is a non-interventional post-authorisation safety study to evaluate the safety of Kineret in the treatment of Cryopyrin Associated Periodic Syndromes (CAPS) in routine clinical care with regard to serious infections, malignancies, injection site reactions, allergic reactions and medication errors, including reuse of syringe. The RMP version 5.4 has been updated to reflect completion of this study.

In addition, the RMP is updated to include information about a completed paediatric study (Sobi.ANAKIN-301) assessed as per Article 46 of Reg No 1901/2006 (EMA/H/C/000363/P46/031). This was a randomised, double-blind, placebo-controlled,

---

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.



---

multicenter, phase 3 study which evaluated the efficacy, the safety, pharmacokinetics and immunogenicity of anakinra as compared to placebo in newly diagnosed Still's disease patients (including systemic juvenile idiopathic arthritis [SJIA] and adult-onset Still's disease [AOSD])."

Opinion adopted on 10.06.2021.

Request for Supplementary Information adopted on 11.02.2021.

---

PRAC Led

**Lojuxta - lomitapide -**

**EMA/H/C/002578/II/0047**

Amryt Pharmaceuticals DAC, Rapporteur:

Johann Lodewijk Hillege, PRAC Rapporteur:

Menno van der Elst, PRAC-CHMP liaison: Johann

Lodewijk Hillege, "To introduce an enhanced

pharmacovigilance system to evaluate the

occurrence and outcomes of pregnancy in

females of reproductive potential treated with

lomitapide who decide to continue the

pregnancy following advice from a

teratologist/clinician, replacing the currently

agreed Pregnancy Exposure Register (PER),

which is listed as part of the specific obligations

in the Annex II. The RMP version 6.5 has also

been submitted. In addition, the MAH took the

opportunity to introduce minor administrative

changes."

Request for Supplementary Information adopted on 10.06.2021.

Request for supplementary information adopted with a specific timetable.

---

PRAC Led

**Mavenclad - cladribine -**

**EMA/H/C/004230/II/0015**

Merck Europe B.V., Rapporteur: Kirstine Moll

Harboe, PRAC Rapporteur: Marcia Sofia Sanches

de Castro Lopes Silva, PRAC-CHMP liaison:

Bruno Sepodes, "Submission of an updated RMP

version 1.5.1 in order to align to the RMP

template Rev. 2. In addition, the MAH took the

opportunity to include long-term safety data

from the completed PREMIERE registry and

remove the completed study from the

pharmacovigilance plan, update of the status of

the post-approval safety studies CLARION and

CLEAR and update the RMP with the most recent

post-approval safety data from the PBRER."

Request for Supplementary Information adopted on 10.06.2021, 06.05.2021, 14.01.2021.

Request for supplementary information adopted with a specific timetable.

<p>PRAC Led</p> <p><b>Norvir - ritonavir -</b></p> <p><b>EMA/H/C/000127/II/0161</b></p> <p>AbbVie Deutschland GmbH &amp; Co. KG,</p> <p>Rapporteur: Johann Lodewijk Hillege, PRAC</p> <p>Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege,</p> <p>"Submission of an updated RMP version 7.1 in order to comply with revision 2 of the template. In addition, the MAH reviewed the information contained in the Norvir RMP and made the following updates:</p> <ul style="list-style-type: none"> <li>-Removal of important identified risk of toxicity of Norvir oral solution in preterm neonates</li> <li>-Removal of missing information regarding use of ritonavir in elderly patients</li> <li>-Analysis of the Antiretroviral Pregnancy Registry (APR) data will be provided with the ritonavir PSUR"</li> </ul> <p>Request for Supplementary Information adopted on 10.06.2021.</p>	<p>Request for supplementary information adopted with a specific timetable.</p>
<p>PRAC Led</p> <p><b>Orphacol - cholic acid -</b></p> <p><b>EMA/H/C/001250/II/0040, Orphan</b></p> <p>Laboratoires CTRS, Rapporteur: Konstantinos Markopoulos, PRAC Rapporteur: Sofia Trantza, PRAC-CHMP liaison: Konstantinos Markopoulos,</p> <p>"Submission of an updated RMP version 4.0 to bring it in line with the new RMP template. At the same time, the wording of the additional risk minimisation measures has been updated and the already approved protocol for the ongoing patient surveillance database study has been included in the RMP."</p> <p>Opinion adopted on 10.06.2021.</p>	<p>Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p>PRAC Led</p> <p><b>Pradaxa - dabigatran etexilate -</b></p> <p><b>EMA/H/C/000829/II/0126/G</b></p> <p>Boehringer Ingelheim International GmbH,</p> <p>Rapporteur: Kirstine Moll Harboe, PRAC</p> <p>Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Kirstine Moll Harboe, "C.I.13:</p> <p>Submission of the final report from drug utilisation study, 1160.129, GLORIA AF. This is a three-phase, international, multicenter, prospective, observational registry program in patients with newly diagnosed non-valvular atrial fibrillation (NV AF) at risk for stroke. The objective of the registry program is to</p>	<p>Request for supplementary information adopted with a specific timetable.</p>

---

investigate patient characteristics influencing the choice of antithrombotic treatment for the prevention of stroke in NV AF patients globally and to collect data from clinical practice settings on important outcome events of antithrombotic treatments for the prevention of stroke.

C.I.13: Submission of the final report from drug utilisation study, 1160.136, EU GLORIA AF listed as a category 3 study in the RMP. This is a three-phase, international, multicenter, prospective, observational registry program in patients with newly diagnosed non-valvular atrial fibrillation (NV AF) at risk for stroke. The objective of the registry program is to investigate patient characteristics influencing the choice of antithrombotic treatment for the prevention of stroke in NV AF patients from participating countries in EU/EEA Member States and to collect data from clinical practice settings on important outcome events of antithrombotic treatments for the prevention of stroke. The RMP version 39 has also been submitted.”  
Request for Supplementary Information adopted on 10.06.2021.

---

PRAC Led

**Revatio - sildenafil -**

**EMA/H/C/000638/II/0091**

Upjohn EESV, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk Hillege, “Submission of an updated RMP version 7.0 in order to update the summary of safety concerns in line with GVP module V rev 2 guidelines. Consequently, the educational programme for the risk of hypotension is proposed to be terminated and is being removed as an Annex II condition.”

Opinion adopted on 10.06.2021.

Request for Supplementary Information adopted on 06.05.2021, 14.01.2021.

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

PRAC Led

**Shingrix - herpes zoster vaccine (recombinant, adjuvanted) -**

**EMA/H/C/004336/II/0045**

GlaxoSmithKline Biologicals SA, Rapporteur: Christophe Focke, PRAC Rapporteur: Sonja Hrabcik, PRAC-CHMP liaison: Andrea Laslop, “Update of section 4.4 of the SmPC in order to add a new warning on an increased risk of

Request for supplementary information adopted with a specific timetable.

---

Guillain-Barré Syndrome (GBS) after vaccination with Shingrix observed in a post-marketing observational study in individuals aged 65 years or older. The RMP version 5.1 has also been submitted. In addition, the MAH took the opportunity to make some editorial changes to the SmPC and to update the list of local representatives in the Package Leaflet.”  
Request for Supplementary Information adopted on 10.06.2021.

---

PRAC Led  
**Zevalin - ibritumomab tiuxetan - EMEA/H/C/000547/II/0053**  
Ceft Biopharma s.r.o., Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Anette Kirstine Stark, PRAC-CHMP liaison: Sinan B. Sarac, “Update of the RMP in line with the new GVP module”  
Opinion adopted on 10.06.2021.  
Request for Supplementary Information adopted on 09.04.2021.

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

PRAC Led  
**WS1919**  
**Lyrica-EMEA/H/C/000546/WS1919/0109**  
**Pregabalin Pfizer-EMEA/H/C/003880/WS1919/0038**  
Upjohn EESV, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Johann Lodewijk Hillege, “Submission of an updated RMP (version 13.0) to include results from recently completed PASS studies, namely: 1) study A0081359: a population-based cohort study of pregabalin to characterize pregnancy outcomes; 2) study A0081106: a 12-month open-label study to evaluate the safety and tolerability of pregabalin as adjunctive therapy in paediatric subjects 1 month to 16 years of age with partial onset seizures and paediatric and adult subjects 5 to 65 years of age with primary generalized tonic-clonic seizures; 3) study A0081042: a double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of pregabalin as adjunctive therapy in children 1 month through <4 years of age with partial onset seizures; 4) study A0081105: a randomized, double-blind, placebo-controlled, parallel group, multicentre trial of pregabalin as adjunctive therapy in paediatric and adult subjects with primary

Request for supplementary information adopted with a specific timetable.

generalized tonic-clonic seizures. In addition, information on study A0081096: a prospective randomized 12-week controlled study of visual field change in subjects with partial seizures receiving pregabalin or placebo has been updated as well as study A0081365: a phase 4, randomised, double-blind, double-dummy, placebo- and active-controlled, single-dose, six-way crossover study to evaluate the potential for abuse with pregabalin (added as a new FDA-imposed PASS). The clinical study report (CSR) for study A0081359 is included in the submission."

Request for Supplementary Information adopted on 10.06.2021, 01.10.2020.

---

PRAC Led

**WS2043**

**OPDIVO-EMA/H/C/003985/WS2043/0102**

**Yervoy-EMA/H/C/002213/WS2043/0087**

Bristol-Myers Squibb Pharma EEIG, Lead PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "To provide an updated RMP to change the final due date for the PAES study CA2098Y8 (a Phase 3b, Randomized, Double-blind Study of Nivolumab Combined with Ipilimumab versus Nivolumab Monotherapy for Patients with Previously Untreated Advanced Renal Cell Carcinoma and Intermediate- or Poor-Risk Factors).

In addition, the marketing authorisation holder has taken the opportunity to include a minor editorial revision in the French translation of the PI as previously agreed with the Agency."

Opinion adopted on 10.06.2021.

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

PRAC Led

**WS2057**

**Aerius-EMA/H/C/000313/WS2057/0098**

**Azomyr-EMA/H/C/000310/WS2057/0102**

**Neoclarityn-EMA/H/C/000314/WS2057/0096**

Organon N.V., Duplicate, Duplicate of Allex (SRD), Azomyr, Opulis (SRD), Lead Rapporteur: Christophe Focke, Lead PRAC Rapporteur: Laurence de Fays, PRAC-CHMP liaison: Karin Janssen van Doorn, "Submission of an updated RMP version 2.1 in order to align with GVP Module V (rev 2) template which includes

Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

updates to the list of safety concerns and reflects the completion of a post-authorisation safety study listed as category 3 (A Nordic register-based study which studied the association between the use of desloratadine and risk of seizures, supraventricular tachycardia, and atrial fibrillation or flutter: EUPAS15038) assessed in EMEA/H/WS1655." Opinion adopted on 10.06.2021.

PRAC Led  
**WS2064**  
**Nuwiq-EMEA/H/C/002813/WS2064/0043**  
**Vihuma-**

Request for supplementary information adopted with a specific timetable.

**EMEA/H/C/004459/WS2064/0024**

Octapharma AB, Lead PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "To provide an updated RMP to remove the completed studies GENA-05 and GENA-15. As a consequence, in the section 'Missing Information' the following safety concerns have been removed: "Safety in previously untreated patients", "Children < 2 years" and "Immune tolerance induction". No new safety concerns were added. In addition, the RMP has been updated to GVP Module V Rev.2." Request for Supplementary Information adopted on 10.06.2021.

#### **B.5.5. CHMP-CAT assessed procedures**

**Zynteglo - betibeglogene autotemcel - EMEA/H/C/003691/II/0025, Orphan, ATMP**

Request for supplementary information adopted with a specific timetable.

bluebird bio (Netherlands) B.V, Rapporteur: Carla Herberts, CHMP Coordinator: Paula Boudewina van Hennik  
Request for Supplementary Information adopted on 18.06.2021.

#### **B.5.6. CHMP-PRAC-CAT assessed procedures**

#### **B.5.7. PRAC assessed ATMP procedures**

#### **B.5.8. Unclassified procedures and worksharing procedures of type I variations**

**WS1930**  
**Hexacima-EMEA/H/C/002702/WS1930/0107**

Positive Opinion adopted by consensus on 28.05.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP

<b>Hexaxim (SRD)-EMA/H/W/002495/WS1930/0112</b> <b>Hexyon-EMA/H/C/002796/WS1930/0111</b> Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 28.05.2021. Request for Supplementary Information adopted on 25.02.2021, 03.12.2020.	recommendation.
<b>WS2002</b> <b>Filgrastim Hexal-EMA/H/C/000918/WS2002/0061</b> <b>Zarzio-EMA/H/C/000917/WS2002/0062</b> Sandoz GmbH, Lead Rapporteur: Johann Lodewijk Hillegge Opinion adopted on 10.06.2021.	Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>WS2033</b> <b>Hexacima-EMA/H/C/002702/WS2033/0116</b> <b>Hexyon-EMA/H/C/002796/WS2033/0120</b> Sanofi Pasteur, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 24.06.2021. Request for Supplementary Information adopted on 29.04.2021.	Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>WS2042</b> <b>Ambirix-EMA/H/C/000426/WS2042/0115</b> <b>Fendrix-EMA/H/C/000550/WS2042/0075</b> <b>Infanrix hexa-EMA/H/C/000296/WS2042/0298</b> <b>Twinrix Adult-EMA/H/C/000112/WS2042/0150</b> <b>Twinrix Paediatric-EMA/H/C/000129/WS2042/0151</b> GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 10.06.2021.	Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>WS2053</b> <b>Infanrix hexa-EMA/H/C/000296/WS2053/0300</b> GlaxoSmithkline Biologicals SA, Lead Rapporteur: Christophe Focke Opinion adopted on 24.06.2021.	Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>WS2055</b> <b>Actraphane-EMA/H/C/000427/WS2055/</b>	Positive Opinion adopted by consensus on 28.05.2021. The Icelandic and Norwegian CHMP

<b>0089</b> <b>Actrapid-EMA/H/C/000424/WS2055/0083</b> <b>Insulatard-EMA/H/C/000441/WS2055/0087</b> <b>Mixtard-EMA/H/C/000428/WS2055/0090</b> <b>Protaphane-EMA/H/C/000442/WS2055/0086</b> Novo Nordisk A/S, Lead Rapporteur: Kirstine Moll Harboe Opinion adopted on 28.05.2021.	Members were in agreement with the CHMP recommendation.
<b>WS2056</b> <b>Fiasp-EMA/H/C/004046/WS2056/0029</b> <b>NovoMix-EMA/H/C/000308/WS2056/0108</b> <b>NovoRapid-EMA/H/C/000258/WS2056/0140</b> Novo Nordisk A/S, Lead Rapporteur: Kristina Dunder Opinion adopted on 10.06.2021.	Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>WS2060</b> <b>HyQvia-EMA/H/C/002491/WS2060/0071</b> <b>Kiovig-EMA/H/C/000628/WS2060/0109</b> Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus Request for Supplementary Information adopted on 10.06.2021.	Request for supplementary information adopted with a specific timetable.
<b>WS2061/G</b> <b>Rixathon-EMA/H/C/003903/WS2061/0048/G</b> <b>Riximyo-EMA/H/C/004729/WS2061/0048/G</b> Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus Opinion adopted on 03.06.2021.	Positive Opinion adopted by consensus on 03.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>WS2063</b> <b>Ryzodeg-EMA/H/C/002499/WS2063/0046</b> <b>Tresiba-EMA/H/C/002498/WS2063/0052</b> <b>Xultophy-EMA/H/C/002647/WS2063/0041</b> Novo Nordisk A/S, Lead Rapporteur: Kristina Dunder Opinion adopted on 10.06.2021.	Positive Opinion adopted by consensus on 10.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<b>WS2072</b> <b>Abseamed-EMA/H/C/000727/WS2072/0094</b>	Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP



<p><b>Binocrit-EMA/H/C/000725/WS2072/0093</b>  <b>Epoetin alfa Hexal-EMA/H/C/000726/WS2072/0093</b>  Sandoz GmbH, Lead Rapporteur: Alexandre Moreau  Opinion adopted on 24.06.2021.</p>	<p>recommendation.</p>
<p><b>WS2077</b>  <b>Kinzalkomb-EMA/H/C/000415/WS2077/0116</b>  <b>MicardisPlus-EMA/H/C/000413/WS2077/0119</b>  <b>PritorPlus-EMA/H/C/000414/WS2077/0126</b>  Boehringer Ingelheim International GmbH, Lead Rapporteur: Armando Genazzani, "To update sections 2 (Qualitative and quantitative composition) and 4.4 (Special warnings and precautions for use) of the SmPC and sections 2 (What you need to know before you &lt;take&gt; &lt;use&gt; X) and 6 (Contents of the pack and other information) of the PL to align the wording for the excipients lactose, sodium and sorbitol to the "Annex to the European Commission guideline on 'Excipients in the labelling and package leaflet of medicinal products for human use' (SANTE-2017-11668, Rev. 1)", published in Nov. 2019.  In addition, the marketing authorisation holder has taken the opportunity to:</p> <ul style="list-style-type: none"> <li>- implement minor editorial changes;</li> <li>- update the list of local representatives and align the PI for Kinzalkomb and PritorPlus to the QRD template v.10.1;</li> <li>- update the list of local representatives and align the PI for MicardiPlus to the latest QRD template v. 10.2;</li> <li>- ."</li> </ul> <p>Opinion adopted on 17.06.2021.</p>	<p>Positive Opinion adopted by consensus on 17.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p><b>WS2079/G</b>  <b>Fluenz Tetra-EMA/H/C/002617/WS2079/0108/G</b>  <b>Pandemic influenza vaccine H5N1</b>  <b>AstraZeneca-EMA/H/C/003963/WS2079/0041/G</b>  AstraZeneca AB, Lead Rapporteur: Christophe Focke  Opinion adopted on 24.06.2021.</p>	<p>Positive Opinion adopted by consensus on 24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</p>
<p><b>WS2084</b></p>	<p>Positive Opinion adopted by consensus on</p>

<b>Cegfila-EMA/H/C/005312/WS2084/0010</b> <b>Pelmeg-EMA/H/C/004700/WS2084/0014</b> Mundipharma Corporation (Ireland) Limited, Lead Rapporteur: Karin Janssen van Doorn Opinion adopted on 24.06.2021.	24.06.2021. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
---	--

### **B.5.9. Information on withdrawn type II variation / WS procedure**

### **B.5.10. Information on type II variation / WS procedure with revised timetable**

<b>Vaborem - meropenem / vaborbactam - EMA/H/C/004669/II/0010/G</b> Menarini International Operations Luxembourg S.A., Rapporteur: Filip Josephson, "A grouped application including 8 type II variations (C.I.4) and 1 type II variation (C.I.13): Update of section 4.5 of the SmPC based on the results of a series of non-clinical drug-drug interaction studies undertaken with vaborbactam or meropenem. The Package Leaflet has been updated accordingly. In addition, the MAH has submitted non-clinical data on the phototoxicity potential of meropenem from a 3T3 neutral red uptake phototoxicity test." Request for Supplementary Information adopted on 11.03.2021.	Request by the applicant dated 22 April 2021 for an extension to the clock stop to respond to the request for supplementary information adopted in March 2021.  The CHMP agreed to the request by the applicant.
--	--

## **B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION**

### **B.6.1. Start of procedure for New Applications: timetables for information**

**copanlisib - EMA/H/C/004334, Orphan**  
Bayer AG, treatment of adult patients with relapsed marginal zone lymphoma

**dimethyl fumarate - EMA/H/C/005956**  
treatment of multiple sclerosis

**dimethyl fumarate - EMA/H/C/005955**  
treatment of multiple sclerosis

<b>budesonide, micronised - EMA/H/C/005653, Orphan</b> Calliditas Therapeutics AB, treatment of primary immunoglobulin A (IgA) nephropathy	<b>Accelerated review</b>
---	---------------------------

---

**adalimumab - EMEA/H/C/005947**

treatment of rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis, paediatric uveitis

---

**maribavir - EMEA/H/C/005787, Orphan**

Shire Pharmaceuticals Ireland Limited, treatment of cytomegalovirus (CMV) infection

---

**opicapone - EMEA/H/C/005782**

treatment of Parkinson's disease and motor fluctuations

---

**tezepelumab - EMEA/H/C/005588**

add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma

---

**faricimab - EMEA/H/C/005642**

treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DME)

---

**B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information**

---

**Biktarvy - bicitgravir / emtricitabine / tenofovir alafenamide -****EMEA/H/C/004449/X/0040/G**

Gilead Sciences Ireland UC, Rapporteur: Jean-Michel Race, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Liana Gross-Martirosyan, "Extension application to introduce a new strength 30/120/15 mg. The extension application is grouped with a type II variation (C.I.6.a) to include paediatric indication: use in patients 2 years of age and older and weighing at least 14 kg. Sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC and the Package Leaflet are updated to support the extended indication. The RMP (version 3.1) is updated in accordance."

---

**Lyumjev - insulin lispro -****EMEA/H/C/005037/X/0010**

Eli Lilly Nederland B.V., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Annika Folin

---

**Sogroya - somapacitan -****EMEA/H/C/005030/X/0001/G, Orphan**

---

---

Novo Nordisk A/S, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Martin Huber  
"Extension application to add a new strength of 5 mg/1.5 mL (3.3 mg/mL) grouped with a Type II Quality variation and a Type IA variation. The RMP was updated (version 2.0) accordingly."

---

**Trydonis - beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium - EMEA/H/C/004702/X/0015**

Chiesi Farmaceutici S.p.A., Informed Consent of Trimbow, Rapporteur: Janet Koenig, PRAC Rapporteur: Jan Neuhauser, "Extension application to add a new pharmaceutical form (inhalation powder) associated with new strength (88µg / 5µg / 9µg). The RMP (version 7.1) is updated in accordance."

---

**Zejula - niraparib - EMEA/H/C/004249/X/0029, Orphan**

GlaxoSmithKline (Ireland) Limited, Rapporteur: Bjorg Bolstad, PRAC Rapporteur: Jan Neuhauser, "Extension application to introduce a new pharmaceutical form (100 mg film-coated tablet). The RMP (version 5.1) is updated in accordance."

---

**B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information**

---

**arachis hypogaea extract - EMEA/H/C/004810, Article 28**

treatment of peanut allergy  
List of Questions adopted on 25.02.2021.

---

**aducanumab - EMEA/H/C/005558**

Alzheimer's disease  
List of Questions adopted on 25.02.2021.

---

**artesunate - EMEA/H/C/005718, Orphan**

B And O Pharm, Treatment of severe malaria  
List of Questions adopted on 22.04.2021.

---

**adalimumab - EMEA/H/C/005548**

treatment of rheumatoid arthritis, psoriasis, hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis, uveitis, paediatric uveitis, juvenile idiopathic

---

---

arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis  
List of Questions adopted on 28.01.2021.

---

**Noxafil - posaconazole -**

**EMA/H/C/000610/X/0063/G**

Merck Sharp & Dohme B.V., Rapporteur:  
Alexandre Moreau, PRAC Rapporteur: Adrien Inoubli, "Extension application to introduce a new pharmaceutical form (gastro-resistant powder and solvent for oral suspension), grouped with a type II variation (C.I.6.a) to extend the approved indications for Noxafil to the paediatric population.  
As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC, as well as the package leaflet, are updated. The RMP (version 17.1) is updated in accordance."

List of Questions adopted on 25.03.2021.

---

**Paliperidone Janssen-Cilag International -  
paliperidone -**

**EMA/H/C/005486/X/0002/G**

Janssen-Cilag International N.V., Informed Consent of Xeplion, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "Extension application to introduce two new strengths of 700 mg and 1000 mg prolonged-release suspension for injection, grouped with the following variations:  
A.2.a - To change the (invented) name of the medicinal product from Paliperidone Janssen-Cilag International  
A.7 -  
6 x C.I.7.b. - To delete the 25 mg, 50 mg, 75 mg, 100 mg and 150 mg/100 mg strengths from the Paliperidone Janssen-Cilag marketing authorisation (EU/1/20/1453/001-006)."

List of Questions adopted on 22.04.2021.

---

**lasmiditan - EMA/H/C/005332**

acute treatment of migraine with or without aura in adults

List of Questions adopted on 25.03.2021.

---

**rivaroxaban - EMA/H/C/005600**

Treatment of deep vein thrombosis and pulmonary embolism and prevention of recurrent DVT and PE in adults. Prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery and treatment of deep vein thrombosis

---

---

and pulmonary embolism as well as prevention of recurrent DVT and PE in adults. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors.

List of Questions adopted on 28.01.2021.

---

**anifrolumab - EMEA/H/C/004975**

indicated as an add-on therapy for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), despite standard therapy

List of Questions adopted on 25.02.2021.

---

**sitagliptin fumarate - EMEA/H/C/005741**

treatment of type 2 diabetes mellitus

List of Questions adopted on 25.03.2021.

---

**avacopan - EMEA/H/C/005523, Orphan**

Vifor Fresenius Medical Care Renal Pharma France, Treatment of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)

List of Questions adopted on 25.02.2021.

---

**tecovirimat - EMEA/H/C/005248**

treatment of orthopoxvirus disease

List of Questions adopted on 25.02.2021.

---

**diroximel fumarate - EMEA/H/C/005437**

treatment of relapsing remitting multiple sclerosis

List of Questions adopted on 22.04.2021.

---

#### **B.6.4. Annual Re-assessments: timetables for adoption**

---

**DECTOVA - zanamivir -**

**EMEA/H/C/004102/S/0011**

GlaxoSmithKline Trading Services Limited,  
Rapporteur: Bjorg Bolstad, PRAC Rapporteur:  
Ulla Wändel Liminga

---

#### **B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed**

---

**Adcetris - brentuximab vedotin -**

**EMEA/H/C/002455/R/0090, Orphan**

Takeda Pharma A/S, Rapporteur: Paula  
Boudewina van Hennik, Co-Rapporteur: Jan  
Mueller-Berghaus, PRAC Rapporteur: Menno van

---

---

der Elst

---

**Daptomycin Hospira - daptomycin -**

**EMA/H/C/004310/R/0018**

Pfizer Europe MA EEIG, Generic, Generic of Cubicin, Rapporteur: Kolbeinn Gudmundsson, PRAC Rapporteur: Pernille Harg

---

**Jylamvo - methotrexate -**

**EMA/H/C/003756/R/0015**

Therakind (Europe) Limited, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Jan Neuhauser

---

**LEDAGA - chlormethine -**

**EMA/H/C/002826/R/0030, Orphan**

Helsinn Birex Pharmaceuticals Limited, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Tiphaine Vaillant

---

**NINLARO - ixazomib -**

**EMA/H/C/003844/R/0030, Orphan**

Takeda Pharma A/S, Rapporteur: Armando Genazzani, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Annika Folin

---

**Pregabalin Zentiva k.s. - pregabalin -**

**EMA/H/C/004277/R/0019**

Zentiva k.s., Generic, Generic of Lyrica, Rapporteur: Alar Irs, PRAC Rapporteur: Liana Gross-Martirosyan

---

**Rolufta Ellipta - umeclidinium -**

**EMA/H/C/004654/R/0019**

GlaxoSmithKline Trading Services Limited, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Jayne Crowe, PRAC Rapporteur: Ilaria Baldelli

---

**Tadalafil Lilly - tadalafil -**

**EMA/H/C/004666/R/0008**

Eli Lilly Nederland B.V., Informed Consent of Cialis, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Maria del Pilar Rayon

---

**Truxima - rituximab -**

**EMA/H/C/004112/R/0047**

Celltrion Healthcare Hungary Kft., Rapporteur: Sol Ruiz, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Anette Kirstine Stark

---

**Yargesa - miglustat -**

**EMA/H/C/004016/R/0011**

Piramal Critical Care B.V., Generic, Generic of Zavesca, Rapporteur: Daniela Philadelphia, PRAC

---

#### **B.6.6. VARIATIONS – START OF THE PROCEDURE**

**Timetables for adoption** provided that the validation has been completed.

#### **B.6.7. Type II Variations scope of the Variations: Extension of indication**

---

##### **COMIRNATY - covid-19 mRNA vaccine (nucleoside-modified) - EMA/H/C/005735/II/0030**

BioNTech Manufacturing GmbH, Rapporteur:  
Filip Josephson, Co-Rapporteur: Jean-Michel  
Race, PRAC Rapporteur: Menno van der Elst,  
"Extension of the existing indication from  
"individuals 16 years of age and older" to  
"individuals 12 years of age and older" for  
Comirnaty; as a consequence, sections 4.1, 4.2,  
4.8 and 5.1 of the SmPC are updated. The  
Package Leaflet is updated in accordance.  
Version 2.0 of the RMP has also been  
submitted."

---

##### **Spikevax - COVID-19 mRNA Vaccine (nucleoside-modified) - EMA/H/C/005791/II/0021**

Moderna Biotech Spain, S.L., Rapporteur: Jan  
Mueller-Berghaus, Co-Rapporteur: Andrea  
Laslop, "Extension of indication to include use in  
adolescents 12 to 17 years of age for COVID-19  
Vaccine Moderna; as a consequence, sections  
4.1, 4.2, 4.8 and 5.1 of the SmPC are updated.  
The Package Leaflet is updated in accordance."

---

##### **Tecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3- zeta chimeric antigen receptor and cultured - EMA/H/C/005102/II/0008/G, Orphan, ATMP**

Kite Pharma EU B.V., Rapporteur: Jan Mueller-  
Berghaus, CHMP Coordinator: Jan Mueller-  
Berghaus, PRAC Rapporteur: Menno van der  
Elst, "Group of variations including an extension  
of indication to include treatment of adult  
patients with relapsed or refractory (r/r) B-cell  
acute lymphoblastic leukemia (B-ALL) for  
Tecartus and a type IB variation . As a  
consequence, sections 2.2, 4.1, 4.2, 4.4, 4.8

---



---

and 5.1 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 1.1 of the RMP has also been submitted. Furthermore, the PI is brought in line with the latest QRD template.”

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

---

**TECFIDERA - dimethyl fumarate -**

**EMA/H/C/002601/II/0073**

Biogen Netherlands B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, “C.I.6 (Extension of indication) type II Art.29

Extension of indication to include treatment of relapsing remitting multiple sclerosis (RRMS) in paediatrics patients from 10 years of age and over; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.3 are updated. The Package Leaflet is updated in accordance.

The MAH is requesting an extension of the market protection of one additional year in line with the guidance on elements required to support the significant clinical benefit in comparison with existing therapies of a new therapeutic indication in accordance with Article 14(11) of Regulation (EC) 726/2004

Version 11.4 of the RMP has also been submitted to update the RMP (parts I-IV) based on study 109MS306 data supporting the request for a paediatric indication and the Applicant took the opportunity to update the RMP with the most updated data (Part II modules SIV, SV and SVII).”

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

---

**XALKORI - crizotinib -**

**EMA/H/C/002489/II/0072**

Pfizer Europe MA EEIG, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Tiphaine Vaillant, “Extension of indication to include treatment of paediatric patients (age  $\geq 6$  to  $< 18$  years) with relapsed or refractory systemic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) and with unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumour (IMT) for XALKORI based on the results from studies ADVL0912 and A8081013; as a

---

---

consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the ATC code for crizotinib. Moreover, the MAH took the opportunity to implement a minor change in the list of local representatives in the Package Leaflet.”

---

#### **B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects**

---

##### **Aimovig - erenumab -**

**EMA/H/C/004447/II/0016**

Novartis Europharm Limited, Rapporteur:  
Kristina Dunder

---

##### **Alprolix - eftrenonacog alfa -**

**EMA/H/C/004142/II/0036/G, Orphan**

Swedish Orphan Biovitrum AB (publ),  
Rapporteur: Andrea Laslop

---

##### **COMIRNATY - covid-19 mRNA vaccine (nucleoside-modified) -**

**EMA/H/C/005735/II/0039/G**

BioNTech Manufacturing GmbH, Rapporteur:  
Filip Josephson

---

See B.5.1

##### **COMIRNATY - covid-19 mRNA vaccine (nucleoside-modified) -**

**EMA/H/C/005735/II/0040/G**

BioNTech Manufacturing GmbH, Rapporteur:  
Filip Josephson

---

##### **COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) -**

**EMA/H/C/005735/II/0041/G**

BioNTech Manufacturing GmbH, Rapporteur:  
Filip Josephson

---

##### **COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) -**

**EMA/H/C/005735/II/0043**

BioNTech Manufacturing GmbH, Rapporteur:  
Filip Josephson

---

##### **COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) -**

**EMA/H/C/005735/II/0045/G**

BioNTech Manufacturing GmbH, Rapporteur:

---

---

Filip Josephson

---

**COVID-19 Vaccine Janssen - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein - EMEA/H/C/005737/II/0005** See B.5.1

Janssen-Cilag International N.V., Rapporteur:  
Christophe Focke

---

**Darzalex - daratumumab - EMEA/H/C/004077/II/0049/G, Orphan**

Janssen-Cilag International NV, Rapporteur:  
Sinan B. Sarac

---

**Fluad Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) - EMEA/H/C/004993/II/0017**

Seqirus Netherlands B.V., Rapporteur: Sol Ruiz

---

**Flucelvax Tetra - influenza vaccine surface antigen inactivated prepared in cell cultures - EMEA/H/C/004814/II/0021**

Seqirus Netherlands B.V., Rapporteur: Sol Ruiz

---

**Fluenz Tetra - influenza vaccine (live attenuated, nasal) - EMEA/H/C/002617/II/0109**

AstraZeneca AB, Rapporteur: Christophe Focke

---

**Hemlibra - emicizumab - EMEA/H/C/004406/II/0023/G**

Roche Registration GmbH, Rapporteur:  
Alexandre Moreau

---

**IKERVIS - ciclosporin - EMEA/H/C/002066/II/0026/G**

Santen Oy, Rapporteur: Peter Kiely

---

**Nepexto - etanercept - EMEA/H/C/004711/II/0010/G**

Mylan IRE Healthcare Limited, Rapporteur:  
Martina Weise

---

**SARCLISA - isatuximab - EMEA/H/C/004977/II/0009/G, Orphan**

sanofi-aventis groupe, Rapporteur: Paula  
Boudewina van Hennik

---

**Spectrila - asparaginase - EMEA/H/C/002661/II/0025**

medac Gesellschaft für klinische  
Spezialpräparate mbH, Rapporteur: Andrea  
Laslop

---

**Spikevax - COVID-19 mRNA Vaccine (nucleoside-modified) - EMEA/H/C/005791/II/0018/G** See B.5.1

---

---

Moderna Biotech Spain, S.L., Rapporteur: Jan  
Mueller-Berghaus

---

**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S** See B.5.1 and 9.1  
**[recombinant]) -**  
**EMA/H/C/005675/II/0020/G**  
AstraZeneca AB, Rapporteur: Sol Ruiz

---

**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S** See B.5.1 and 9.1  
**[recombinant]) -**  
**EMA/H/C/005675/II/0021/G**  
AstraZeneca AB, Rapporteur: Sol Ruiz

---

**VEYVONDI - vonicog alfa -**  
**EMA/H/C/004454/II/0017**  
Baxalta Innovations GmbH, Rapporteur: Jan  
Mueller-Berghaus

---

**WS2080/G**  
**Hexacima-EMA/H/C/002702/WS2080/**  
**0117/G**  
**Hexyon-EMA/H/C/002796/WS2080/**  
**0121/G**  
Sanofi Pasteur, Lead Rapporteur: Jan Mueller-  
Berghaus

---

**WS2095/G**  
**Blitzima-EMA/H/C/004723/WS2095/**  
**0043/G**  
**Truxima-EMA/H/C/004112/WS2095/**  
**0046/G**  
Celltrion Healthcare Hungary Kft., Lead  
Rapporteur: Sol Ruiz

---

#### **B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects**

---

**Alunbrig - brigatinib / brigatinib -**  
**EMA/H/C/004248/II/0033/G**  
Takeda Pharma A/S, Rapporteur: Sinan B.  
Sarac, "Update of section 4.5 of the SmPC in  
order to add drug-drug interaction information  
about the effect of brigatinib on the  
pharmacokinetics of a sensitive cytochrome  
P450 3A substrate (midazolam) in patients with  
ALK-positive or ROS1-positive solid tumours  
based on a clinical study report (Study 1001).  
Update of section 4.2 of the SmPC in order to  
clarify the existing renal impairment dosage  
adjustment recommendation based on results of  
previously submitted studies (clinical study  
AP26113-15-108, Study 108). Update of section

---

---

4.2 of the SmPC in order to clarify the existing hepatic impairment dosage adjustment recommendation based on results of previously submitted studies (clinical study AP26113-15-107, Study 107). Update of sections 4.4 and 4.5 of the SmPC in order to update drug-drug interaction information regarding concomitant treatment with moderate CYP3A inhibitors or inducers based on results of previously submitted studies (physiologically-based pharmacokinetic (PBPK) report and PBPK report addendum). Update section 5.1 of the SmPC in order to amend the ATC code; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement a statement regarding the sodium content of Alunbrig in section 4.4 of the SmPC and Package Leaflet. The MAH also took the opportunity to bring the Product Information in line with the latest QRD template (version 10.2 rev.1) and to update the list of local representatives in the Package Leaflet. Moreover, the MAH took the opportunity to introduce minor editorial changes in the PI in different languages.”

---

**Alunbrig - brigatinib / brigatinib -  
EMA/H/C/004248/II/0034**

Takeda Pharma A/S, Rapporteur: Sinan B. Sarac, “Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on photosensitivity based on a report of cumulative evidence for an association between exposure to brigatinib and subsequent development of photosensitivity reaction; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make a minor editorial change in section 4.8 of the SmPC.”

---

**COMIRNATY - COVID-19 mRNA vaccine  
(nucleoside-modified) -  
EMA/H/C/005735/II/0038/G**

BioNTech Manufacturing GmbH, Rapporteur: Filip Josephson, PRAC Rapporteur: Menno van der Elst, “To update section 4.4 of the SmPC to add a new warning on “vaccine stress-related responses” following signal detection and evaluation activity in the post-authorization setting, as a result of internal review of post-authorization cases; the Package Leaflet is updated accordingly.

---

---

To update section 4.8 of the SmPC to add "extensive swelling of the vaccinated limb" to the list of adverse drug reactions (ADRs) with frequency "Not known" agreed by the PRAC following the outcome of the of the Post Authorization Measure PAM MEA-002.3 (EMA/H/C/005735/MEA/002.3, dated 04. May 2021); the Package Leaflet is updated accordingly.

To update section 4.8 of the SmPC to add ("facial swelling") to the list of adverse drug reactions (ADRs) with frequency "Not known" agreed by the PRAC following the outcome of the Signal Assessment on localised swelling in patients with history of dermal filler injections with tozinameran (Comirnaty (COVID-19 mRNA vaccine), (EMA/H/C/005735/SDA/023 (EPITT ref. 19674); the Package Leaflet is updated accordingly."

---

**Feraccru - ferric maltol -  
EMA/H/C/002733/II/0033**

Norgine B.V., Rapporteur: Maria Concepcion Prieto Yerro, "to remove haemoglobin threshold from section 4.4 'Special warnings and precautions for use' of summary of product characteristics for Feraccru Capsules 30 mg, deleting the reference made that states "Feraccru is not recommended for use in patients with haemoglobin (Hb) <9.5 g/dl.""

---

**Kyprolis - carfilzomib -  
EMA/H/C/003790/II/0051/G, Orphan**

Amgen Europe B.V., Rapporteur: Blanca Garcia-Ochoa, "A.6 The ATC code of the product is updated

C.I.4, Update of section 4.2 of the SmPC in order to modify administration instructions of daratumumab when Kyprolis is dosed in combination with daratumumab and dexamethasone, based on results from efficacy and safety studies MMY2040 (ongoing phase 2), MMY1001 (completed phase 1b) and CANDOR (ongoing phase 3)."

---

**Phesgo - pertuzumab / trastuzumab -  
EMA/H/C/005386/II/0004**

Roche Registration GmbH, Rapporteur: Sinan B. Sarac, "Update in section 4.8, Undesirable Effects, to present the pooled data from Perjeta and Phesgo studies.

In addition to this, the MAH has taken the

---

---

opportunity to introduce minor updates in the SmPC and the Package leaflet:

- Update in section 9 of the SmPC to reflect the date of first authorisation
  - Editorial update in section 4 of the Package leaflet to add a space
  - Update in section 6 of the Package leaflet to adapt to the revised QRD Template v10.2"
- 

**Pradaxa - dabigatran etexilate -**

**EMA/H/C/000829/II/0128**

Boehringer Ingelheim International GmbH,  
Rapporteur: Kirstine Moll Harboe, "C.I.4,  
Update of section 4.2 of the SmPC in order to update the dosing information for Pradaxa coated granules and to introduce a new format of the dosing tables for all dosage forms of Pradaxa to avoid incorrect interpretation and possible mistakes.

In addition, a guidance related to the Schwartz formula is proposed to be included in section 4.2 of the SmPC. The Package Leaflet was updated accordingly. Furthermore, the MAH took the opportunity to request introduction of the link to a training video by scanning the QR code in Annex IIIA and IIIB and to include additional updates to Annex IIIA and mock-ups."

---

**Synflorix - pneumococcal polysaccharide conjugate vaccine (adsorbed) -**

**EMA/H/C/000973/II/0160**

GlaxoSmithKline Biologicals SA, Rapporteur:  
Kristina Dunder, "Update of section 5.1 Pharmacodynamic properties of the SmPC following submission of procedure EMA/H/C/000973/P46/070 to include results of the study 10PN-PD-DIT-082, a phase III, controlled, partially-blind study evaluating the interchangeability of Synflorix and 13-valent pneumococcal conjugate vaccine. Section 4.2 Posology and method of administration is updated to cross reference to section 5.1. In addition, the MAH took the opportunity to add in section 4.4 Special warnings and precautions of the SmPC a statement regarding the sodium content, in line with the guideline on "Excipients in the labelling and package leaflet of medicinal product for human use" and to update the list of local representatives in the Package Leaflet."

---

**Ultomiris - ravulizumab -**

---

---

**EMA/H/C/004954/II/0018**

Alexion Europe SAS, Rapporteur: Blanca Garcia-Ochoa, "To update section 4.2 Posology and method of administration of the SmPC regarding the inclusion of home infusion as an alternative infusion setting for Ultomiris for approved indications (paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS))."

---

**Vaxzevria - COVID 19 Vaccine (ChAdOx1 S [recombinant]) -****EMA/H/C/005675/II/0019**

AstraZeneca AB, Rapporteur: Sol Ruiz, "Submission of the interim and primary reports clinical study reports from Study D8111C00002, listed as a category 3 study in the RMP. This study is a Phase I/II randomised, double-blind, placebo-controlled, multicentre study in participants aged 18 years or older to determine the safety and immunogenicity of AZD1222, a nonreplicating ChAdOx1 Vector Vaccine, for the prevention of COVID-19. This submission fulfils the post-authorisation measures MEA 012 and MEA 012.1."

---

**Vectibix - panitumumab -****EMA/H/C/000741/II/0097**

Amgen Europe B.V., Rapporteur: Bjorg Bolstad, "Update of sections 4.4 and 4.8 of the SmPC in order to add the risk of corneal perforation to the risks of keratitis and ulcerative keratitis and to add corneal perforation (including keratorhexis, which also includes lowest level term corneal rupture) to the list of the adverse reactions, respectively following a safety evaluation.

The package leaflet has been updated accordingly. In addition, the applicant took the opportunity to remove frequency information due to variations in case frequency in section 4.8 of the SmPC and section 4 of the PL. Furthermore, the PI is being brought in line with the latest QRD template (version 10.2) and minor editorial changes was made in the PL."

---

**WS2070****Mekinist-EMA/H/C/002643/WS2070/0047****Tafinlar-EMA/H/C/002604/WS2070/0052**

Novartis Europharm Limited, Lead Rapporteur:

---



---

Paula Boudewina van Hennik, “  
Update of sections 4.2, 4.4 and 5.1 of the SmPC  
in order to modify administration instructions  
(pyrexia dose modification guidance in the  
Tafinlar and Mekinist SmpC); the Package  
Leaflet are updated accordingly. In addition, the  
WSA took the opportunity to update the list of  
local representatives for The Netherlands in the  
Package Leaflet and to include minor editorial  
changes”

---

#### **B.6.10. CHMP-PRAC assessed procedures**

---

##### **COMIRNATY - COVID-19 mRNA vaccine (nucleoside-modified) - EMA/H/C/005735/II/0036**

BioNTech Manufacturing GmbH, Rapporteur:  
Filip Josephson, PRAC Rapporteur: Menno van  
der Elst, “Update of sections 4.8 and 5.1 of the  
SmPC to include new information based on  
updated interim results from study C4591001.  
This was a phase 1/2/3, placebo-controlled,  
observer-blind, interventional, dose-finding,  
study to evaluate the safety, tolerability,  
immunogenicity and efficacy of SARS-CoV-2  
RNA vaccine candidates against COVID-19 in  
healthy individuals. The Package Leaflet is  
updated accordingly. The updated RMP (version  
2.1) has also been submitted.”

---

##### **Increlex - mecasermin - EMA/H/C/000704/II/0067**

Ipsen Pharma, Rapporteur: Outi Mäki-Ikola,  
PRAC Rapporteur: Kirsti Villikka, “Update of the  
conditions of the non-interventional PASS which  
is listed as a specific obligation in Annex II, by  
using different criteria of patient exposure and  
long-term follow up to assess the relevant  
safety data, with consequential amendment of  
the study completion date. The RMP version 13  
has also been submitted, also including an  
amended Global registry protocol (amendment  
8). The Package Leaflet is updated accordingly.  
In addition, the MAH took the opportunity to  
update the list of local representatives in the  
Package Leaflet, in line with the latest QRD  
template version 10.2 rev.1.”

---

##### **Qarziba - dinutuximab beta - EMA/H/C/003918/II/0027/G, Orphan**

---

---

EUSA Pharma (Netherlands) B.V., Rapporteur:  
Paula Boudewina van Hennik, PRAC Rapporteur:  
Brigitte Keller-Stanislawski, "

-A.6 - Type IA - ATC code change to L01XC16  
according to the WHO

-C.I.4: Type II- Update of section 4.8 of the  
SmPC in order to include changes to the overall  
incidence of reported adverse reactions based  
on post-marketing data. In addition, minor  
changes are introduced in the Summary of  
Product Characteristics, Package Leaflet and  
Labelling in order to harmonise the Product  
Information with other regulatory regions.

-C.I.11.b: Type II-Submission of RMP version  
10.00 in order to include an alignment to post-  
marketing data (PSUR6) and to introduce  
updates on the important identified risks and  
important potential risks.

In addition, some linguistic corrections are  
included on Swedish, Finnish, Italian, Spanish,  
and Portuguese EMA annexes."

---

**RAVICTI - glycerol phenylbutyrate -  
EMA/H/C/003822/II/0038/G, Orphan**

Immedica Pharma AB, Rapporteur: Kirstine Moll  
Harboe, PRAC Rapporteur: Ilaria Baldelli, "Group  
of variations consisting of:

- Submission of the final study report, HPN-100-  
014 non interventional registry study "Long-  
Term Registry of Patients with Urea Cycle  
Disorders (UCDs) conducted in the US".

- An update to the RMP (version 7) submitted to  
remove the important potential risks of  
carcinogenicity and PAA toxicity. The update to  
the RMP is based on the review of new and  
available data including the study report for  
HPN-100-014 and a new toxicological expert  
examination of pre-clinical carcinogenicity  
findings as well as a cumulative review of  
literature and post-marketing data. In  
accordance with the proposed changes to the  
RMP, an update of Annex II is requested to  
waive the imposed condition related to the non-  
interventional post authorisation safety study  
(PASS), "European Post-Authorization Registry  
for RAVICTI (glycerol phenylbutyrate) Oral  
Liquid in Partnership with the European Registry  
and Network for Intoxication Type Metabolic  
Diseases (E-IMD)". The SmPC and Package  
Leaflet have been updated to delete the  
information on additional monitoring (including

---

---

the black triangle)."

---

**REKAMBYS - rilpivirine -  
EMA/H/C/005060/II/0004**

Janssen-Cilag International N.V., Rapporteur:  
Johann Lodewijk Hillege, Co-Rapporteur: Bruno  
Sepodes, PRAC Rapporteur: Liana Gross-  
Martirosyan, "Update of section 4.2 (to change  
posology recommendations) and sections 4.8,  
5.1 and 5.2 of the SmPC (to update safety and  
efficacy information) based on week 124 results  
from the FLAIR study. This is a Phase III,  
randomized, open-label study to evaluate the  
efficacy, safety and tolerability of the combined  
treatment Cabotegravir and Rilpivirine. The  
Package Leaflet has been updated accordingly.  
Editorial changes and corrections have been  
carried out throughout the PI. The RMP version  
3.1 has also been submitted."

---

**Vaxzevria – COVID-19 Vaccine (ChAdOx1 S  
[recombinant]) -  
EMA/H/C/005675/II/0026**

AstraZeneca AB, Rapporteur: Sol Ruiz, PRAC  
Rapporteur: Jean-Michel Dogné, "Update of  
sections 4.4, 4.8 and 5.1 of the SmPC in order  
to include updated efficacy and safety  
information based on primary analysis from  
study D8110C00001 listed as a specific  
obligation in Annex II; this is a phase III  
randomised, double-blind, placebo-controlled,  
multicenter study in adults to determine the  
safety, efficacy and immunogenicity of  
Vaxzevria; the Package Leaflet and Annex II are  
updated accordingly. The updated RMP Version  
3 Succession 2 has also been submitted."

---

**Vocabria - cabotegravir -  
EMA/H/C/004976/II/0004**

ViiV Healthcare B.V., Rapporteur: Jean-Michel  
Race, Co-Rapporteur: Johann Lodewijk Hillege,  
PRAC Rapporteur: Martin Huber, "Update of  
section 4.2 (to change posology  
recommendations) and sections 4.4, 4.8, 5.1  
and 5.2 of the SmPC (to update safety and  
efficacy information) based on week 124 results  
from the FLAIR study. This is a Phase III,  
randomized, open-label study to evaluate the  
efficacy, safety and tolerability of the combined  
treatment Cabotegravir and Rilpivirine. The  
Package Leaflet has been updated accordingly.  
Editorial changes and corrections have been

---

---

carried out throughout the PI. The RMP version 2 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet to bring the PI in line with the latest QRD template version 10.2.”

---

#### **B.6.11. PRAC assessed procedures**

---

PRAC Led

**COVID-19 Vaccine Janssen - adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein -  
EMA/H/C/005737/II/0006/G**

Janssen-Cilag International N.V., Rapporteur: Christophe Focke, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, “

C.I.4-To update section 4.4 of the SmPC to add a warning for individuals who have experienced a previous cerebral venous sinus thrombosis (CVST) with thrombocytopenia or heparin-induced thrombocytopenia (HIT) to outweigh the potential risks before the administration of COVID-19 Vaccine Janssen; the Package Leaflet is updated accordingly. The updated RMP version 2.1 has also been submitted.

C.I.11.b- To update the EU-RMP for COVID-19 Vaccine Janssen to version 2.1 to include thrombosis with thrombocytopenia syndrome (TTS) in the list of the safety concerns as an important identified risk following the PRAC recommendation, dated 6 May 2021 in the outcome of the related signal of Embolic and Thrombotic events (procedure number SDA 018.1) with COVID-19 Vaccine Janssen (Ad26.COV2-S [recombinant]). In addition, the MAH took the opportunity to update in the EU-RMP the milestone date for the submission of the VAC31518COV4003 protocol; to propose a revised frequency of data mining from the EudraVigilance database and to correct the long-term follow-up time in the VAC31518COV4001 study.”

---

PRAC Led

**Spikevax - COVID-19 mRNA Vaccine (nucleoside-modified) -  
EMA/H/C/005791/II/0015/G**

---

---

Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Hans Christian Siersted, PRAC-CHMP liaison: Kirstine Moll Harboe, "Grouped variation to address PRAC requests raised in the 2nd and 3rd Moderna Monthly Safety Summary Report (MSSR) procedures (EMA/H/C/005791/MEA/011.1 and EMA/H/C/005791/MEA/011.2 respectively:

- C.I.3.b (Type II): Update of section 4.4 of the SmPC to provide additional safety information regarding hypersensitivity and anaphylaxis, as requested by the PRAC in the 2nd Monthly Safety Summary Report. The Package Leaflet is updated accordingly.
- C.I.3.b (Type II): Update of section 4.8 of the SmPC to include 'Delayed injection site reaction' as an adverse reaction, with the frequency 'Common', as requested by the PRAC in the 3rd Monthly Safety Summary Report. The Package Leaflet is updated accordingly.

In addition, the Marketing Authorisation Holder (MAH) submitted a justification for not adding diarrhoea to the PI as an adverse reaction, as requested by the PRAC in the 3rd Monthly Safety Summary Report, and took the opportunity to make minor editorial changes."

---

#### **B.6.12. CHMP-CAT assessed procedures**

---

##### **Zolgensma - onasemnogene abeparvovec - EMA/H/C/004750/II/0015, Orphan, ATMP**

Novartis Gene Therapies EU Limited, Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege, "Updates to sections 4.4, 4.8 and 5.1 of the SmPC to reflect the final study results study AVXS-101-CL-302; a Post-authorisation efficacy study intended to confirm the efficacy and safety and tolerability of a single dose of Zolgensma in patients younger than 6 months of age with SMA Type 1 with One or Two SMN2 Copies. The package leaflet has been updated accordingly and annex II has been updated to reflect completion of this Specific Obligation."

---

##### **WS2071**

**Tecartus-EMA/H/C/005102/WS2071/**

---

---

**0007**

**Yescarta-EMA/H/C/004480/WS2071/**

**0039**

Kite Pharma EU B.V., Lead Rapporteur: Jan  
Mueller-Berghaus, CHMP Coordinator: Jan  
Mueller-Berghaus

---

#### **B.6.13. CHMP-PRAC-CAT assessed procedures**

#### **B.6.14. PRAC assessed ATMP procedures**

#### **B.6.15. Unclassified procedures and worksharing procedures of type I variations**

---

**WS2076**

**Ambirix-EMA/H/C/000426/WS2076/**

**0116**

**Twinrix Adult-EMA/H/C/000112/**

**WS2076/0151**

**Twinrix Paediatric-EMA/H/C/000129/**

**WS2076/0152**

GlaxoSmithkline Biologicals SA, Lead  
Rapporteur: Christophe Focke

---

**WS2084**

**Cegfila-EMA/H/C/005312/WS2084/0010**

**Pelmeg-EMA/H/C/004700/WS2084/0014**

Mundipharma Corporation (Ireland) Limited,  
Lead Rapporteur: Karin Janssen van Doorn

---

**WS2087**

**Infanrix hexa-EMA/H/C/000296/**

**WS2087/0301**

GlaxoSmithkline Biologicals SA, Lead  
Rapporteur: Christophe Focke

---

**WS2100/G**

**Prezista-EMA/H/C/000707/WS2100/**

**0112/G**

**Rezolsta-EMA/H/C/002819/WS2100/**

**0043/G**

**Symtuza-EMA/H/C/004391/WS2100/**

**0036/G**

Janssen-Cilag International NV, Lead  
Rapporteur: Johann Lodewijk Hillege

---

## **B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY**

### **B.7.1. Yearly Line listing for Type I and II variations**

### **B.7.2. Monthly Line listing for Type I variations**

### **B.7.3. Opinion on Marketing Authorisation transfer (MMD only)**

### **B.7.4. Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)**

### **B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)**

### **B.7.6. Notifications of Type I Variations (MMD only)**

## **C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)**

## **D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)**

## **E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES**

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

### **E.1. PMF Certification Dossiers**

#### **E.1.1. Annual Update**

#### **E.1.2. Variations**

#### **E.1.3. Initial PMF Certification**

### **E.2. Time Tables – starting & ongoing procedures: For information**

---

PMF timetables starting and ongoing procedures    Tabled in MMD and sent by post mail (folder E).

---

## **F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver**

## **G. ANNEX G**

### **G.1. Final Scientific Advice (Reports and Scientific Advice letters):**

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

### **G.2. PRIME**

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

#### **G.2.1. List of procedures concluding at 21-24 June 2021 CHMP plenary:**

<b><i>Infectious Diseases</i></b>	
Treatment of chronic hepatitis B	The CHMP denied eligibility to PRIME and adopted the critical summary report.
<b><i>Cardiovascular Diseases</i></b>	
Treatment of acute ischemic stroke (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.
<b><i>Oncology</i></b>	
Treatment of myelofibrosis	The CHMP denied eligibility to PRIME and adopted the critical summary report.
<b><i>Neurology</i></b>	
Treatment of acute agitation associated with dementia (SME)	The CHMP denied eligibility to PRIME and adopted the critical summary report.

#### **G.2.2. List of procedures starting in June 2021 for July 2021 CHMP adoption of outcomes**

## **H. ANNEX H - Product Shared Mailboxes – e-mail address**